abcl-10q_20220630.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-22-028784.txt : 20220809 0001564590-22-028784.hdr.sgml : 20220809 20220809164207 ACCESSION NUMBER: 0001564590-22-028784 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbCellera Biologics Inc. CENTRAL INDEX KEY: 0001703057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39781 FILM NUMBER: 221149031 BUSINESS ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 BUSINESS PHONE: (604) 559-9005 MAIL ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 10-Q 1 abcl-10q_20220630.htm 10-Q abcl-10q_20220630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number: 001-39781

AbCellera Biologics Inc.

(Exact Name of Registrant as Specified in its Charter)

British Columbia	Not Applicable
( State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
2215 Yukon Street Vancouver, BC	V5Y 0A1
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (604) 559-9005

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common shares, no par value per share

ABCL

The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 4, 2022, the registrant had 285,138,643 common shares, no par value per share, outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	2
	Condensed Consolidated Statements of Stockholders’ Equity	3
	Condensed Consolidated Statements of Cash Flows	4
	Notes to Unaudited Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	60
Item 5.	Other Information	61
Item 6.	Exhibits	62
	Signatures	63

Summary of the Material and Other Risks Associated with Our Business

Our business is subject to numerous material and other risks and uncertainties. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report, including our financial statements and related notes hereto. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. The risks and uncertainties described below may change over time and other risks and uncertainties, including those that we do not currently consider material, may impair our business. These risks include, but are not limited to, the following:

•

We have incurred losses in certain years since inception and we may not be able to generate sufficient revenue to maintain profitability.

•

Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.

•

Our commercial success depends on the quality of our antibody discovery platform and technological capabilities and their acceptance by new and existing partners in our market.

•

If we cannot maintain and expand current partnerships and agreements and enter new partnership agreements that generate discovery programs for antibodies, our business could be adversely affected.

•

In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.

•

Development of a biologic molecule is inherently uncertain, and it is possible that none of the drug candidates discovered using our antibody discovery platform that are further developed by our partners will receive marketing approval or become viable commercial products, on a timely basis or at all.

•

The failure of our partners to meet their contractual obligations to us could adversely affect our business.

•

We may be unable to manage our current and future growth effectively, which could make it difficult to execute on our business strategy.

•

We have invested, and expect to continue to invest, in research and development efforts that further enhance our antibody discovery platform. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.

•

Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs with the antibodies that we have discovered, and the price of our common shares may decline as a result of announcements of unexpected results or developments.

•

Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common shares to decline.

•

The life sciences and biotech platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability.

•

Our business has been and may continue to be adversely affected by the COVID-19 pandemic.

•

The ongoing military action between Russia and Ukraine and related sanctions could adversely affect our business, financial condition, and patent administration.

•

Our success depends on our ability to protect our intellectual property.

•

If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.

•

Sales of a substantial number of our common shares in the public market could cause our share price to fall significantly, even if our business is doing well.

Investing in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties contained in Part II, Item 1A, Risk Factors, together with all other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as our other filings with the Securities and Exchange Commission, or the SEC, before investing in our common stock. Any of the risk factors we describe below under Part II, Item 1A, Risk Factors, could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common shares. Additional risks that are currently unknown to us or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See “Forward-Looking Information” in this Quarterly Report on Form 10-Q.

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheets

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

(Unaudited)

	December 31, 2021		June 30, 2022
Assets
Current assets:
Cash and cash equivalents	$	476,142	$	790,615
Marketable securities		246,835		231,652
Total cash, cash equivalents, and marketable securities		722,977		1,022,267
Accounts and accrued receivable		160,576		52,797
Restricted cash		25,000		25,000
Other current assets		21,247		43,891
Total current assets		929,800		1,143,955
Long-term assets:
Property and equipment, net		111,616		149,178
Intangible assets, net		148,392		143,179
Goodwill		47,806		47,806
Investments in and loans to equity accounted investees		50,313		65,824
Other long-term assets		30,642		43,842
Total long-term assets		388,769		449,829
Total assets	$	1,318,569	$	1,593,784
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other liabilities	$	32,017	$	24,390
Current portion of contingent consideration payable		22,934		34,252
Income taxes payable		35,683		107,322
Accrued royalties payable		22,506		50,555
Deferred revenue		7,536		4,621
Total current liabilities		120,676		221,140
Long-term liabilities:
Operating lease liability		36,413		32,759
Deferred revenue and grant funding		60,758		64,800
Contingent consideration payable		35,886		24,629
Deferred tax liability		37,370		34,616
Other long-term liabilities		1,733		2,984
Total long-term liabilities		172,160		159,788
Total liabilities		292,836		380,928
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2021 and June 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at December 31, 2021 and June 30, 2022, respectively		722,430		726,825
Additional paid-in capital		35,357		56,001
Accumulated other comprehensive income		280		576
Accumulated earnings		267,666		429,454
Total shareholders' equity		1,025,733		1,212,856
Total liabilities and shareholders' equity	$	1,318,569	$	1,593,784
Subsequent events

The accompanying notes are an integral part of these condensed consolidated financial statements.

AbCellera Biologics Inc.

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2021			2022			2021			2022
Revenue:
Research fees	$	5,215		$	12,538		$	9,201		$	21,871
Licensing revenue		263			147			20,522			377
Milestone payments		1,000			-			8,000			-
Royalty revenue		21,165			33,232			192,661			340,249
Total revenue		27,643			45,917			230,384			362,497
Operating expenses:
Royalty fees		3,610			5,210			23,622			49,847
Research and development⁽¹⁾		15,046			26,685			27,403			53,052
Sales and marketing⁽¹⁾		1,295			3,120			3,869			5,490
General and administrative⁽¹⁾		11,203			14,412			17,688			28,680
Depreciation and amortization		3,522			4,886			6,827			8,875
Total operating expenses		34,676			54,313			79,409			145,944
Income (loss) from operations		(7,033	)		(8,396	)		150,975			216,553
Other (income) expense
Other (income) expense		(314	)		25			(645	)		(641	)
Grants and incentives		(4,646	)		(1,535	)		(7,794	)		(6,730	)
Total other (income)		(4,960	)		(1,510	)		(8,439	)		(7,371	)
Net earnings (loss) before income tax		(2,073	)		(6,886	)		159,414			223,924
Income tax (recovery) expense		250			(101	)		44,516			62,136
Net earnings (loss)	$	(2,323	)	$	(6,785	)	$	114,898		$	161,788
Foreign currency translation adjustment		2,152			(211	)		2,152			296
Comprehensive income (loss)	$	(171	)	$	(6,996	)	$	117,050		$	162,084

Net earnings (loss) per share attributable to common shareholders
Basic	$	(0.01	)	$	(0.02	)	$	0.42		$	0.57
Diluted	$	(0.01	)	$	(0.02	)	$	0.36		$	0.52
Weighted-average common shares outstanding
Basic		272,196,107			284,686,542			270,953,541			284,292,312
Diluted		272,196,107			284,686,542			321,555,443			313,361,183

The accompanying notes are an integral part of these condensed consolidated financial statements.

¹Exclusive of depreciation and amortization

AbCellera Biologics Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

(Unaudited)

	Common Shares				Additional Paid-in			Accumulated			Accumulated Other Comprehensive			Total Shareholders'
	Shares		Amount		Capital			Earnings			Income			Equity
Balances as of December 31, 2021		283,257,104	$	722,430	$	35,357		$	267,666		$	280		$	1,025,733
Shares issued and restricted stock units ("RSUs") vested under stock option plan		1,264,077		3,325		(2,922	)		-			-			403
Stock-based compensation expense		-		-		12,291			-			-			12,291
Foreign currency translation adjustment		-		-		-			-			507			507
Net earnings		-		-		-			168,573			-			168,573
Balances as of March 31, 2022		284,521,181	$	725,755	$	44,726		$	436,239		$	787		$	1,207,507
Shares issued and restricted stock units ("RSUs") vested under stock option plan		531,121		1,070		(838	)		-			-			232
Stock-based compensation expense		-		-		12,113			-			-			12,113
Foreign currency translation adjustment		-		-		-			-			(211	)		(211	)
Net loss		-		-		-			(6,785	)		-			(6,785	)
Balances as of June 30, 2022		285,052,302	$	726,825	$	56,001		$	429,454		$	576		$	1,212,856

	Common Shares				Additional Paid-in			Accumulated			Accumulated Other Comprehensive		Total Shareholders'
	Shares		Amount		Capital			Earnings			Income		Equity
Balances as of December 31, 2020		269,497,768	$	710,387	$	5,919		$	114,202		$	-	$	830,508
Shares issued under stock option plan		1,428,162		752		(579	)		-			-		173
Stock-based compensation expense		-		-		4,021			-			-		4,021
Reclassification of liability classified options		-		-		5,201			-			-		5,201
Net earnings		-		-		-			117,221			-		117,221
Balances as of March 31, 2021		270,925,930	$	711,139	$	14,562		$	231,423		$	-	$	957,124
Shares issued under stock option plan		6,056,748		3,619		(1,840	)		-			-		1,779
Share-based compensation expense		-		-		8,473			-			-		8,473
Reclassification of liability classified options		-		-		474			-			-		474
Foreign currency translation adjustment		-		-		-			-			2,152		2,152
Net loss		-		-		-			(2,323	)		-		(2,323	)
Balances as of June 30, 2021		276,982,678	$	714,758	$	21,669		$	229,100		$	2,152	$	967,679

The accompanying notes are an integral part of these condensed consolidated financial statements.

AbCellera Biologics Inc.

Condensed Consolidated Statements of Cash Flows

(Expressed in thousands of U.S. dollars)

(Unaudited)

	Six months ended June 30,
	2021			2022
Cash flows from operating activities:
Net income	$	114,898		$	161,788
Cash flows from operating activities:
Depreciation of property and equipment		1,897			3,681
Amortization of intangible assets		4,930			5,213
Amortization of operating lease right-of-use assets		1,354			2,120
Stock-based compensation		13,900			24,404
Other		337			(298	)
Changes in operating assets and liabilities:
Accounts and accrued research fees receivable		(28,339	)		(6,963	)
Accrued royalties receivable		172,768			106,583
Income taxes payable		(30,330	)		52,251
Accounts payable and accrued liabilities		(3,640	)		(1,882	)
Deferred revenue		4,848			(2,979	)
Accrued royalties payable		(3,623	)		28,049
Deferred grant revenue		22,349			5,406
Other assets		(4,121	)		(4,139	)
Net cash provided by operating activities		267,228			373,234
Cash flows from investing activities:
Purchases of property and equipment		(40,448	)		(45,817	)
Purchase of marketable securities		-			(134,306	)
Proceeds from marketable securities		-			145,808
Receipt of grant funding		4,520			8,098
Long-term investments and other assets		(5,034	)		(11,657	)
Investment in and loans to equity accounted investees		(20,510	)		(15,694	)
Net cash used in investing activities		(61,472	)		(53,568	)
Cash flows from financing activities:
Repayment of long-term debt and contingent consideration		(4,373	)		(73	)
Proceeds from debt and exercise of stock options		2,755			2,175
Payment of liability for in-licensing agreement		(5,000	)		(4,060	)
Net cash used in financing activities		(6,618	)		(1,958	)
Effect of exchange rate changes on cash and cash equivalents		(683	)		(1,411	)
Increase in cash and cash equivalents		198,455			316,297
Cash and cash equivalents and restricted cash, beginning of period		594,116			501,142
Cash and cash equivalents and restricted cash, end of period	$	792,571		$	817,439
Restricted cash included in other assets		-			(1,824	)
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$	792,571		$	815,615
Supplemental disclosure of non-cash investing and financing activities
Property plant and equipment in accounts payable		-			2,146
Right-of-use assets obtained in exchange for operating lease obligation		29,573			(796	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

AbCellera Biologics Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

(Unaudited)

1. Nature of operations

AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. The Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies.

2. Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2021.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2021 and 2022 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021.

All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

3. Significant accounting policies

Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

COVID-19 Pandemic

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the

carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s condensed consolidated financial statements.

Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.

4. Net earnings (loss) per share

Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:

	Three months ended June 30,						Six months ended June 30,
	2021			2022			2021		2022
Basic earnings (loss) per share
Net earnings (loss) attributable to common shareholders - basic	$	(2,323	)	$	(6,785	)	$	114,898	$	161,788
Weighted-average common shares outstanding - basic		272,196,107			284,686,542			270,953,541		284,292,312
Net earnings (loss) per share attributable to common shareholders - basic	$	(0.01	)	$	(0.02	)	$	0.42	$	0.57

Diluted earnings (loss) per share
Net earnings (loss) attributable to common shareholders - diluted	$	(2,323	)	$	(6,785	)	$	114,898	$	161,788
Weighted-average common shares outstanding - basic		272,196,107			284,686,542			270,953,541		284,292,312
Stock options and RSUs		-			-			50,601,902		29,068,871
Weighted-average common shares outstanding - diluted		272,196,107			284,686,542			321,555,443		313,361,183
Net earnings (loss) per share attributable to common shareholders - diluted	$	(0.01	)	$	(0.02	)	$	0.36	$	0.52

The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three months ended June 30, 2021 and June 30, 2022, as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended June 30, 2021 and June 30, 2022 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.

The Company excluded 47,221,295 and nil potential common shares for the three and six months ended June 30, 2021, respectively, and 48,678,673 and 11,937,411 potential common shares for the three and six months ended June 30, 2022, respectively, from the computation of diluted net earnings (loss) per share attributable to common shareholders because including them would have had an anti-dilutive effect.

5. Property and equipment, net

Property and equipment, net consisted of the following:

	December 31, 2021			June 30, 2022
Computers	$	7,843		$	7,961
Land		33,044			53,405
Laboratory equipment		18,805			32,407
Leasehold improvements		23,962			32,160
Operating lease right-of-use assets		37,788			36,464
Property and equipment		121,442			162,397
Less accumulated depreciation		(9,826	)		(13,219	)
Property and equipment, net	$	111,616		$	149,178

As of December 31, 2021 and June 30, 2022, leasehold improvements include tenant improvements in progress that have not commenced depreciation in the amount of $19.8 million and $7.7 million, respectively. Depreciation expense on property and equipment for the three and six months ended June 30, 2021 was $1.1 million and $1.9 million, respectively, and $2.3 million and $3.7 million, for the three and six months ended June 30, 2022, respectively.

6. Intangible assets

Intangible assets consisted of the following:

	June 30, 2022
	Gross carrying amount		Accumulated amortization		Net book value
License	$	35,873	$	13,889	$	21,984
Technology		52,700		3,905		48,795
IPR&D		72,400		-		72,400
	$	160,973	$	17,794	$	143,179

Amortization expense on intangible assets is estimated to be as follows for each of the next five years ended June 30:

	Amortization Expense
2023	$	10,425
2024		8,803
2025		4,041
2026		4,041
2027		4,041
	$	31,351

7. Investments in and loans to equity accounted investees

The Company has entered into two joint ventures as part of the construction of future office and laboratory headquarters. During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). As of June 30, 2022, the equity investment balance of $19.8 million represents the contributions made since inception. In March, 2021, the Company entered into the Beedie joint venture (Beedie JV). To date, the equity investment balance of $15.2 million represents contributions made since inception into the Beedie JV. To date, the Company has recorded immaterial amounts of its proportionate income or loss with respect to both ventures.

In March, 2021, the Company made a commitment of up to CAD $82.7 million ($61.5 million) to the Dayhu JV to fund the construction at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the joint venture. As of December 31, 2021, and June 30, 2022, the outstanding related party loan balance was $18.0 million and $30.8 million, respectively, to the joint venture.

In June 2022, the Company made a commitment to Beedie for a land loan of up to CAD $7.5 million ($5.8 million) plus a construction loan for up to 80% of Beedie’s share of construction costs. The commitment is at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement of the construction loan and five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the joint venture.

Subsequent to June 30, 2022, the Company entered into an agreement of up to CAD $46.0 million ($35.7 million) with Dayhu to replace the outstanding construction loan balance as at January 1, 2023, at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement. The agreement has a maturity of December 31, 2025, with a call provision, callable by the Company after September 30, 2023, including customary make whole provisions. The loan is secured by the underlying land and existing and future assets of the joint venture.

8. Accounts payable and other liabilities

Accounts payable and other liabilities consisted of the following:

	December 31, 2021		June 30, 2022
Accounts payable and accrued liabilities	$	14,924	$	10,313
Liability for in-licensing agreement		4,933		-
Operating lease liability		3,652		4,023
Payroll liabilities		4,035		4,282
Current portion of deferred grant funding		4,473		5,772
Total accounts payable and other liabilities	$	32,017	$	24,390

9. Shareholders’ equity

Sixth Amended and Restated Stock Option Plan:

The Company maintains the AbCellera Biologics Inc. Sixth Amended and Restated Stock Option Plan and our Pre-IPO Plan. Any awards granted under the Pre-IPO Plan will remain subject to the terms of our Pre-IPO Plan and applicable award agreements.

2020 Share Option and Incentive Plan:

Our 2020 Share Option and Incentive Plan, or 2020 Plan, was approved by our board of directors on November 18, 2020, and approved by our shareholders on December 1, 2020.

As of June 30, 2022, the number of shares available for issuance under the 2020 Plan was 24,415,404, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.

The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2021:

	Number of Shares			Weighted- Average Exercise Price
Outstanding as of December 31, 2021		39,206,307		$	0.86
Granted		-			-
Exercised		(1,734,149	)		0.37
Forfeited		(451,917	)		0.27
Outstanding as of June 30, 2022		37,020,241		$	0.89
Options exercisable as of June 30, 2022		20,705,504			0.61

The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2021:

	Number of Shares			Weighted- Average Exercise Price
Outstanding as of December 31, 2021		5,284,347		$	19.19
Granted		3,583,848			10.88
Exercised		-			-
Forfeited		(327,546	)		15.90
Outstanding as of June 30, 2022		8,540,649		$	15.83
Options exercisable as of June 30, 2022		584,306			26.07

As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and are subject to annual vesting. The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2021:

	Number of Shares			Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2021		1,080,413		$	23.62
Granted		2,289,954			10.88
Vested and settled		(61,178	)		45.52
Forfeited		(192,481	)		15.87
Outstanding as of June 30, 2022		3,116,708		$	14.31

Stock-based compensation:

Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:

	Three months ended June 30,				Six months ended June 30,
	2021		2022		2021		2022
Research and development	$	3,720	$	6,264	$	6,877	$	12,201
Sales and marketing		161		475		1,116		1,469
General and administrative		4,592		5,374		5,907		10,734
	$	8,473	$	12,113	$	13,900	$	24,404

10. Revenue

The disaggregated revenue categories are presented on the face of the condensed consolidated statements of income (loss) and comprehensive income (loss).

Deferred revenue

Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.

Deferred revenue outstanding in each respective period is as follows:

		December 31, 2020				June 30, 2021				December 31, 2021				June 30, 2022
Deferred revenue		$	26,321			$	31,232			$	34,954			$	32,004

During the three and six months ended June 30, 2021, the Company recognized $1.8 million and $3.4 million, respectively, and $6.3 million and $7.7 million during the three and six months ended June 30, 2022, respectively, of revenue that had been included in deferred revenue in the previous year.

In March of 2020, the Company entered into a research collaboration and license agreement with Eli Lilly pursuant to which the Company will perform discovery research for several targets for Eli Lilly to develop and commercialize. Under the agreement, the Company is entitled to receive an aggregate of up to $29.0 million of milestone payments as well as royalties in the low single digits based on net sales for non-COVID-19 targets and in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million.

The agreement resulted in an initial upfront payment of $26.7 million, of which $21.9 million was included in deferred revenue at December 31, 2020. In the year ended December 31, 2021, the Company received an additional $1.7 million in payments, for total payments received in respect of this agreement of $28.4 million. In the six months ended June 30, 2022, the Company received $0.6 million in additional payments. The Company recognized $3.8 million and $4.3 million of revenue in the three and six months ended June 30, 2022, respectively. The Company expects to recognize approximately $1.4 million in revenue in the next 12 months related to these payments under the agreement.

Of the remaining deferred revenue balance of $15.2 million, which is related to various other agreements, approximately $3.2 million is expected to be recognized in revenue in the next 12 months.

11. Financial instruments

Fair Value Measurements

The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.

The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans to equity accounted investees, accounts payable and accrued liabilities and royalties payable, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, royalties payable, and loans to equity accounted investees approximate their fair values.

Contingent Consideration

Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition.

The following table presents the changes in fair value of the liability for contingent consideration:

Six months ended June 30, 2022

Liability at

beginning of

the period

Increase (decrease) in fair

value of liability for contingent

consideration

Liability at

end of the

period

Trianni (i)

22,934

574

23,508

TetraGenetics (ii)

35,886

(513

)

35,373


i)	The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.
ii)	The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 8%, the rate that measures the risks inherent in the future cash flows.

Marketable Securities

As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations.

Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.

The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:

	Fair Value Measurements at June 30, 2022:
	Level 1		Level 2		Level 3		Total
Marketable securities
U.S. government agencies	$	17,358	$	-	$	-	$	17,358
Certificate of deposit		-		20,875		-		20,875
Commercial paper		-		34,711		-		34,711
Corporate bonds		-		142,392		-		142,392
Asset backed securities		-		16,316		-		16,316
	$	17,358	$	214,294	$	-	$	231,652

12. Commitments and contingencies

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.

The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.

Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three and six months ended June 30, 2022, the Company has expensed approximately $5.2 million and $49.8 million, respectively, related to such obligations, of which $50.6 million is included in current liabilities.

Since inception, the Company has incurred expenditures of $44.9 million and $26.3 million under phase 1 and 2, respectively, under the Canadian government’s Strategic Innovation Fund, or SIF. Spending under phase 1 of the agreement and such amounts are not repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of June 30, 2022, no amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable as of June 30, 2022.

13. Related Party Transaction

In addition to the loans to the equity accounted investees disclosed in Note 7, the Company had the following related party transactions:

During the second quarter, the Company engaged advisory services with a firm co-founded by a director of the Company in the amount of up to $0.3 million, of which $0.1 million was paid and included in other assets at June 30, 2022.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Forward-looking statements can often be identified by the use of terminology such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but are not limited to:

•

our expectations regarding the rate and degree of market acceptance of our antibody discovery platform;

•

companies and technologies in our industry that compete with our business;

•

our ability to manage and grow our business by introducing our antibody discovery platform to new partners and expanding our relationships with existing partners;

•

our partners ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties to us, in the expected timelines or at all;

•

our ability to provide our partners with a full solution from target to investigational new drug, or IND, submission;

•

our partners ability to develop a molecule discovered by us into a viable commercial product, on a timely basis or at all;

•

our expectations regarding the completion of our good manufacturing practices, or GMP, facility and our manufacturing capabilities;

•

our ability to establish and maintain intellectual property protection for our technologies and workflows and avoid or defend against claims of patent infringement;

•

our ability to attract, hire and retain key personnel and to manage our future growth effectively;

•

our ability to obtain additional financing in future offerings;

•

the volatility of the trading price of our common shares;

•

business disruptions affecting our operations and the development of our platform due to the global COVID-19 pandemic;

•

the global economic impact of the ongoing conflict between Russia and Ukraine and related sanctions and market volatility;

•

our ability to avoid material weaknesses or significant deficiencies in our internal control over financial reporting in the future;

•

our expectations regarding our Passive Foreign Investment Company, or PFIC, status for our taxable year ended December 31, 2022, or any future taxable year;

•

our expectations regarding our recent business acquisitions and our ability to realize the intended benefits of such transactions;

•

our expectations regarding the use of our cash resources;

•

the ability of our partners to deliver royalty bearing products to the market;

•

our expectations about market trends; and

•

our ability to predict and adapt to government regulation.

We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements. We have included important factors in the cautionary statements included in this Quarterly Report, particularly in “Summary of the Material and Other Risks Associated with Our Business” above and “Risk Factors” below, that we believe could cause actual results or events to differ materially from our forward-looking statements. We operate in a competitive and rapidly changing environment and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter.

Additionally, inflation generally affects us by increasing our employee-related costs and certain other expenses. Our financial condition and results of operations may also be impacted by other factors we may not be able to control, such as global supply chain disruptions, uncertain global economic conditions, global trade disputes or political instability as further discussed in the section “Risk Factors” in this Quarterly Report.

You should read this Quarterly Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may differ materially from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

This Quarterly Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All market data used in this Quarterly Report involves assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

We express all amounts in this Quarterly Report on Form 10-Q in U.S. dollars, except where otherwise indicated. References to “$” and “US$” are to U.S. dollars and references to “C$” and “CAD$” are to Canadian dollars.

Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to “AbCellera,” the “Company,” “we,” “us” and “our” refer to AbCellera Biologics Inc. and its consolidated subsidiaries.

Impact of COVID-19

Since the start of the COVID-19 pandemic, we have taken and continue to take steps to protect our employees, business partners, vendors, and contractors. To address the multiple dimensions of the pandemic, we have been continuously monitoring the global situation, executing mitigation activities whenever and wherever required, following guidance from provincial and federal health authorities, and implementing a hybrid return to our facilities for those employees who have been working remotely.

We continue to take the following actions to address the evolving COVID-19 pandemic:

•

We implemented comprehensive COVID-19 guidelines that are shared via our internal communication platform to provide real-time updates company-wide relying on directives from local health authorities. As information is gathered, we adapt accordingly, including work from home requirements.

•

We implemented protocols for employees necessary to carry out Company functions in the office and laboratory facilities including physical distancing, personal protective equipment, signage, erecting barriers between desks and lab benches, and implementing space restrictions for different areas of the facilities.

•

We have not been required to stop research activities due to the COVID-19 pandemic. We will continue to adapt and apply new measures as required and as directed by local health authorities.

Overview

We believe that the surest path to a better future is through technological advancement and that the new frontier of technology lies at the interface of computation, engineering and biology. Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. We aim to become the centralized operating system for next generation antibody discovery.

Our full-stack, artificial intelligence, or AI, powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. We believe our technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. We forge partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. We empower them to move quickly, reduce cost and tackle the toughest problems in drug development. As of June 30, 2022, we had 164 discovery programs that are either completed, in progress or under contract with 38 partners. As a recent example, in a collaboration with Eli Lilly and Company, or Lilly, we applied our technology stack to co-develop two antibody therapies to treat and prevent COVID-19. Starting from a single blood sample obtained from a convalescent patient, we and our partners identified a viable antibody drug candidate within three weeks that advanced into clinical testing 90 days after initiation of the program. Lilly progressed into these clinical trials at a greatly accelerated pace as a result of the Coronavirus Treatment Acceleration Program, which is a special emergency program for possible coronavirus therapies created by the FDA in 2020 to expedite the development of potentially safe and effective life-saving treatments to combat the COVID-19 pandemic. With respect to other or future product candidates, there is no assurance that any of our partners or collaborators will be able to advance a product candidate into clinical development on this timeframe again in the future, or at all. We initiated our partnering program in 2015 and have only had two AbCellera discovery programs and two Trianni programs result in milestone or royalty payments to us to date, and we have not yet had a program receive clinical marketing approval.

We structure our agreements in a way that is designed to align our partners’ economic interests with our own. We forge partnerships with large cap pharmaceutical companies, biotechnology companies of all sizes and non-profit and government organizations. Our partners select a target and define the antibody properties needed for therapeutic development. We provide discovery solutions to partners that have a range of discovery capabilities, from the highly enabled to the less enabled. We enable discovery against targets that have traditionally been intractable, and we accelerate programs against less difficult targets.

Our deals emphasize participation in the success and upside of future antibody therapeutics. Our partnership agreements include near-term payments for technology access, research and intellectual property rights, and downstream payments in the form of clinical and commercial milestones, and royalties on net sales. We also participate in alternative investment opportunities including equity in our business partners and various rights for deeper involvement in moving molecules forward. Longer-term we are eligible to receive additional payments upon satisfaction of clinical and commercial milestones, which we refer to as milestone payments, as well as royalties on sales of products derived from antibodies that we discover for our partners. Our discovery partnerships generally include royalty payments on net sales in the single digit to low-double digit range.

We generated revenue of $27.6 million and $230.4 million for the three and six months ended June 30, 2021, respectively, and $45.9 million and $362.5 million for the three and six months ended June 30, 2022, respectively. We have also grown the number of programs that we have under contract with our partners, as illustrated by the following charts.

We incurred sales and marketing expenses of $1.3 million and $3.9 million for the three and six months ended June 30, 2021, respectively, and $3.1 million and $5.5 million for the three and six months ended June 30, 2022, respectively. We are continuing to invest into our business development team and into marketing our solutions to new and existing partners.

We focus a substantial portion of our resources on research and development efforts towards deepening our technology and expertise along our technology stack, and we expect to continue to make significant investments in this area for the foreseeable future. We incurred research and development expenses of $15.0 million and $27.4 million for the three and six months ended June 30, 2021, respectively, and $26.7 million and 53.1 million for the three and six months ended June 30, 2022, respectively. We incurred general and administrative expenses of $11.2 million and $17.7 million for the three and six months ended June 30, 2021, respectively, and $14.4 million and $28.7 million of the three and six months ended June 30, 2022, respectively. We expect to continue to incur significant expenses, and we expect such expenses to increase substantially in connection with our ongoing activities, including as we:

•

invest in research and development activities to improve our technology stack and platform;

•

market and sell our solutions to existing and new partners;

•

expand and enhance operations to deliver programs, including investments in manufacturing;

•

acquire businesses or technologies to support the growth of our business;

•

attract, hire and retain qualified personnel;

•

continue to establish, protect and defend our intellectual property and patent portfolio, including our ongoing litigation; and

•

operate as a public company.

To date, we have financed our operations primarily from revenue from our antibody discovery partnerships in the form of revenue, government funding from grants, external borrowings, and from the issuance and sale of convertible preferred shares and notes, and common shares.

Our net loss for the three months ended June 30, 2021, was $2.3 million and our net earnings for the six months ended June 30, 2021 was $114.9 million. Our net loss for the three months ended June 30, 2022 was $6.8 million and our net earnings for the six

months ended June 30, 2022 was $161.8 million. As of June 30, 2022, we had accumulated earnings of $429.5 million and we had cash, cash equivalents and marketable securities totaling $1,022.3 million.

Recent Developments

In February 2022, we announced that bebtelovimab (LY-CoV1404), the second antibody developed through our collaboration with Lilly, received an Emergency Use Authorization, or EUA, from the FDA for the treatment of mild-to-moderate COVID-19. Lilly announced in February 2022 that it entered into a purchase agreement with the U.S. government to supply up to 600,000 doses of bebtelovimab no later than March 31, 2022, with an option of 500,000 additional doses no later than July 31, 2022, for at least $720 million.

In June 2022, we announced that Eli Lilly modified its purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for consideration of approximately $275 million. Eli Lilly shipped and we recognized royalty revenue on approximately half of these doses in the quarter ended June 30, 2022. The option to purchase the remaining 350,000 doses no later than September 14, 2022, remains in the agreement.

Key Factors Affecting Our Results of Operations and Future Performance

We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part II, Item 1A of this report, captioned “Risk Factors”.

•

Securing additional programs under contract. Our potential to grow revenue, in both the near and long term, is dependent on our ability to secure additional programs under contract from new and existing partners. For existing partners, we seek to expand our relationships with them to cover multi-year, multi-target programs. Since our first commercial partnership in 2015, as of June 30, 2022, we had 164 discovery programs that are either completed, in progress or under contract with 38 partners. We are building our business development team across the major biotechnology geographic hubs in order to bring in new partners and new programs under contract, and we believe that we have a significant opportunity to continue to increase the number of partners who have programs based on our platform. Our ability to continue to grow our number of programs under contract is dependent upon our ability to educate the market and support the business through investment in our sales and marketing efforts and through further research and development to enhance our technological differentiation.

•

Our partners successfully developing and commercializing the antibodies that we discover. We estimate that, based on the terms of our existing contracts and estimates of historical rates of success of antibody drug development, the vast majority of the potential value for each program under contract is represented by potential future milestone payments and royalties rather than research fees. As a result, we believe our business and our future results of operations will be highly reliant on the degree to which our partners successfully develop and commercialize the antibodies that we discover based on contracts with our partners. As our partners continue to advance development of the antibodies that we have discovered, we expect to start receiving additional milestone payments and royalties if any partners commence commercial sales of such antibodies.

•

Rate and timing of selecting and initiating discovery projects by our partners. Once programs are secured under contract, partners must select targets and agree on a detailed statement of work before we commence discovery research on any antibodies. The rate and timing of such selection and initiation differs from partner to partner. Research fees that we recognize under our partnerships depend on our delivery of antibodies for development by our partners and delays by our partners in selecting targets and agreeing on statements of work will impact revenue recognition.

•

Investing in enhancements to our technology stack. Our ability to maintain and expand our partnerships is dependent on the advantages our technology stack delivers to our partners. We intend to maintain our leading position through research and development investments to refine and add capabilities in areas such as computation, protein engineering, immunization technologies, genetically engineered rodents and cell line selection. We have successfully closed and will continue to look for strategic technology acquisitions to improve, broaden and deepen our capabilities and expertise in antibody discovery and development, or those that offer opportunities to expand our partnership business into adjacent therapeutic modalities. We intend to devote substantial resources to continue to improve our technological differentiation which will impact our financial performance.

•

Scaling our operations to execute on discovery programs. As we secure additional programs under contract and as our partners initiate discovery programs, our operational capacity to execute such research activities may become strained. We are making significant investments in capital and time to increase our ability to address future growth, including building new headquarters through our Dayhu and Beedie joint ventures, building a new small-scale manufacturing plant, investing in research and development and continuing to hire talented personnel across functions. We have new facilities under development scheduled to take occupancy in early 2023 that are intended to materially expand capacity. As we expand our workforce, we expect a significant increase in our operating expenses, including stock-based compensation.

Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

Cumulative Metrics	June 30, 2021		June 30, 2022		Change %
Number of discovery partners		33		38		15	%
Programs under contract		138		164		19	%
Program starts		60		88		47	%
Molecules in the clinic		4		6		50	%

The table below outlines the details of molecules in the clinic as at June 30, 2022:

Molecule	Most advanced stage	Partner	Therapy areas	Program type
Bamlanivimab (LY-CoV555)	Marketed, EUA	Eli Lilly and Company	Infectious disease – COVID-19	Discovery partnership
Bebtelovimab (LY-CoV1404)	Marketed, EUA	Eli Lilly and Company	Infectious disease – COVID-19	Discovery partnership
NBL-012	Phase 1 completed	NovaRock Biotherapeutics Inc.	Dermatology, gastrointestinal, immunology	Trianni license
NBL-015	IND/CTA authorized	NovaRock Biotherapeutics Inc.	Oncology	Trianni license
Undisclosed	IND/CTA authorized	Undisclosed	Undisclosed	Trianni license
IVX-01	Clinical field study	Invetx	Animal health	Discovery partnership

Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract from existing customers through repeat business opportunities.

Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Molecules in the clinic represent the count of unique molecules for which an IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using

licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

Summary partnership agreements with pharmaceutical and biotechnology companies that include downstream participation from 2016 to June 30, 2022:

Partner	# of Targets & Duration	Therapeutic Indication or Modality	Date Announced
Atlas' stealth stage company	Up to 3 targets, multi-year	Undisclosed	August 3, 2022
Undisclosed biotech	Up to 3 targets, multi-year	Undisclosed	June 29, 2022	*
Empirico	2 additional targets	Undisclosed	May 3, 2022
Everest Medicines	Up to 10 targets, multi-year	Oncology and undisclosed	September 22, 2021
Moderna	Up to 6 targets, multi-year	RNA-encoded antibodies	September 15, 2021
EQRx	Multi-target, multi-year	Oncology and immunology (initially)	August 4, 2021
Tachyon	Single target	Oncology	August 3, 2021
Undisclosed biotech	Up to 4 targets, multi-year	Undisclosed	June 30, 2021	*
Angios	Multi-target, multi-year	Ophthalmology	May 6, 2021
Undisclosed biotech	Multi-target, multi-year	Oncology	May 6, 2021	*
Empirico	5 targets, multi-year	Undisclosed	April 14, 2021
Gilead Sciences	8 targets, multi-year	Undisclosed	April 1, 2021
Abdera Therapeutics	9 targets, multi-year	Oncology	January 14, 2021
Invetx	Multi-target, multi-year	Animal Health	November 19, 2020
Kodiak Sciences	Multi-target, multi-year	Ophthalmology	October 29, 2020
IGM Biosciences	Multi-target, multi-year	Oncology and immunology	September 24, 2020
Undisclosed	Single target	Bispecific	June 3, 2020	*
Eli Lilly	Up to 9 targets, multi-year	COVID-19 program and additional indications	May 22, 2020	*
Regeneron Pharmaceuticals	Multi-target, multi-year	Multiple undisclosed	March 16, 2020	*
Invetx	Multi-target, multi-year	Animal health	February 23, 2020
Undisclosed	Multi-target, multi-year	Cell therapy	September 25, 2019	*
Gilead Sciences	Single target	Infectious disease	June 13, 2019
Denali Therapeutics	8 targets, multi-year	Neurological diseases	February 28, 2019
Novartis	Up to 10 targets, multi-year	Undisclosed	February 14, 2019
Autolus Therapeutics	Single target	Cell therapy (CAR-T)	November 29, 2018
Denali Therapeutics	Single target	Neurological diseases	June 12, 2018
Undisclosed mid-cap biopharma	Undisclosed	Undisclosed	January 25, 2018
Teva Pharmaceutical Industries	Single target	Membrane protein	June 13, 2017
Pfizer	Multi-target, multi-year	Membrane protein	January 5, 2017
Undisclosed global biotech	Multi-target, multi-year	Undisclosed	November 4, 2016
Kodiak Sciences	Single target	Ophthalmology	August 24, 2016
Teva Pharmaceutical Industries	Undisclosed	Undisclosed	February 2, 2016
* Effective date of agreement

Results of operations

Comparison of the three and six months ended June 30, 2021 and 2022

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

The following table summarizes our unaudited results of operations data for the three and six months ended June 30, 2021 and 2022:

	Three months ended June 30,						Six months ended June 30,
	2021			2022			2021			2022
Revenue:
Research fees	$	5,215		$	12,538		$	9,201		$	21,871
Licensing revenue		263			147			20,522			377
Milestone payments		1,000			-			8,000			-
Royalty revenue		21,165			33,232			192,661			340,249
Total revenue		27,643			45,917			230,384			362,497
Operating expenses:
Royalty fees		3,610			5,210			23,622			49,847
Research and development(1)		15,046			26,685			27,403			53,052
Sales and marketing(1)		1,295			3,120			3,869			5,490
General and administrative(1)		11,203			14,412			17,688			28,680
Depreciation and amortization		3,522			4,886			6,827			8,875
Total operating expenses		34,676			54,313			79,409			145,944
Income (loss) from operations		(7,033	)		(8,396	)		150,975			216,553
Other (income) expense
Other (income) expense		(314	)		25			(645	)		(641	)
Grants and incentives		(4,646	)		(1,535	)		(7,794	)		(6,730	)
Total other (income)		(4,960	)		(1,510	)		(8,439	)		(7,371	)
Net earnings (loss) before income tax		(2,073	)		(6,886	)		159,414			223,924
Income tax (recovery) expense		250			(101	)		44,516			62,136
Net earnings (loss)	$	(2,323	)	$	(6,785	)	$	114,898		$	161,788
Foreign currency translation adjustment		2,152			(211	)		2,152			296
Comprehensive income (loss)	$	(171	)	$	(6,996	)	$	117,050		$	162,084
Net earnings (loss) per share attributable to common shareholders
Basic	$	(0.01	)	$	(0.02	)	$	0.42		$	0.57
Diluted	$	(0.01	)	$	(0.02	)	$	0.36		$	0.52
Weighted-average common shares outstanding
Basic		272,196,107			284,686,542			270,953,541			284,292,312
Diluted		272,196,107			284,686,542			321,555,443			313,361,183

(1)	Amounts are exclusive of depreciation and amortization. Amounts include stock-based compensation as follows:

	Three months ended June 30,				Six months ended June 30,
	2021		2022		2021		2022
Research and development	$	3,720	$	6,264	$	6,877	$	12,201
Sales and marketing		161		475		1,116		1,469
General and administrative		4,592		5,374		5,907		10,734
	$	8,473	$	12,113	$	13,900	$	24,404

Revenue

	Three months ended June 30,				Change						Six months ended June 30,				Change
	2021		2022		Amount			%			2021		2022		Amount			%
Revenue
Research fees	$	5,215	$	12,538	$	7,323			140	%	$	9,201	$	21,871	$	12,670			138	%
Licensing revenue		263		147		(116	)		(44	)%		20,522		377		(20,145	)		(98	)%
Milestone payments		1,000		-		(1,000	)		(100	)%		8,000		-		(8,000	)		(100	)%
Royalty revenue		21,165		33,232		12,067			57	%		192,661		340,249		147,588			77	%
Total revenue	$	27,643	$	45,917	$	18,274			66	%	$	230,384	$	362,497	$	132,113			57	%

Revenue increased by $18.3 million from the three months ended June 30, 2021 compared to the three months ended June 30, 2022. The increase was driven primarily by a $12.1 million increase in royalty revenue that is directly associated with the specified percentage of proceeds that Lilly received from the sales of bebtelovimab in addition to a $7.3 million increase in research fees attributable to the increase in programs under contract. The increase in revenue was partially offset by a decrease of $1.0 million with no new milestone achievements within the period.

Revenue increased by $132.1 million from the six months ended June 30, 2021 compared to the six months ended June 30, 2022. The increase was driven primarily by a $147.6 million increase in royalty revenue that is directly associated with the specified percentage of proceeds that Lilly received from the sales of bebtelovimab in addition to a $12.7 million increase in research fees attributable to the increase in programs under contract. The increase in revenue was partially offset by a decrease of $20.1 million in licensing revenue related to the Trianni platform and no new milestone achievements within the period.

Operating Expenses

Royalty Fees

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Royalty fees

3,610

5,210

1,600

23,622

49,847

26,225

111

Royalty fees for the three and six months ended June 30, 2021 were $3.6 million and $23.6 million, respectively, and $5.2 million and $49.8 million for the three and six months ended June 30, 2022, respectively. Royalty fees were attributable to the royalty revenues received by the Company from sales of bamlanivimab and bebtelovimab by Eli Lilly due to AbCellera’s collaborations in pandemic response.

Research and Development

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Research and development

15,046

26,685

11,639

27,403

53,052

25,649

Research and development expenses increased by $11.6 million, or 77%, from the three months ended June 30, 2021 compared to the three months ended June 30, 2022, reflecting continuing strong investments in the capacity and capabilities of AbCellera’s discovery and development platform. Of this increase, $5.6 million is due to the increase in compensation expense consistent with the increase in headcount. $5.9 million of the increase is attributed to an increase in research materials, facilities, supplies and services consistent with the overall increase in research and development activities.

Research and development expenses increased by $25.6 million, or 94%, from the six months ended June 30, 2021 compared to the six months ended June 30, 2022, reflecting continuing strong investments in the capacity and capabilities of AbCellera’s discovery and development platform. Of this increase, $14.7 million is due to the increase in compensation expense consistent with the increase in headcount. $11.4 million of the increase is attributed to an increase in research materials, facilities, supplies and services consistent with the overall increase in research and development activities, offset by a decrease of $0.7 million in legal fees.

Sales and Marketing

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Sales and marketing

1,295

3,120

1,825

141

3,869

5,490

1,621

Sales and marketing expenses increased by $1.8 million, or 141%, from the three months ended June 30, 2021 compared to the three months ended June 30, 2022. The increase was attributable to business development activity and compensation costs of $1.8 million.

Sales and marketing expenses increased by $1.6 million, or 42%, from the six months ended June 30, 2021 compared to the six months ended June 30, 2022. The increase in compensation costs of $2.5 million was offset by a decrease of $0.8 million for a donation to Surrey Hospital made in the first quarter of 2021.

General and Administrative

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

General and administrative

11,203

14,412

3,209

17,688

28,680

10,992

General and administrative expenses increased by $3.2 million, or 29%, from the three months ended June 30, 2021 compared to the three months ended June 30, 2022. $0.8 million of the increase in general and administrative expense is related to the increased impact of non-cash stock-based compensation expense. $2.4 million of the increase in general and administrative expense is attributed to software and licensing expenditures, compensation expense exclusive of stock-based compensation, and general office and facilities expenses to support the growth of the Company.

General and administrative expenses increased by $11.0 million, or 62%, from the six months ended June 30, 2021 compared to the six months ended June 30, 2022. $4.8 million of the increase in general and administrative expense is related to the increased impact of non-cash stock-based compensation expense. $6.8 million of the increase in general and administrative expense is attributed to software and licensing expenditures, compensation expense exclusive of stock-based compensation, and general office and facilities expenses to support the growth of the Company. The overall increase was offset by a $0.7 million reduction in legal and accounting fees and other corporate matters in the period.

Depreciation and Amortization

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Depreciation and amortization

3,522

4,886

1,364

6,827

8,875

2,048

Depreciation and amortization expenses increased by $1.4 million, or 39%, from the three months ended June 30, 2021 compared to the three months ended June 30, 2022. Depreciation expense increased by $1.2 million due to the depreciation of equipment and facilities related to capital equipment purchases.

Depreciation and amortization expenses increased by $2.0 million, or 30%, from the six months ended June 30, 2021 compared to the six months ended June 30, 2022. Amortization expense increased by $0.3 million due to the amortization of acquired intangible assets over their respective useful lives. Depreciation expense increased by $1.8 million due to the depreciation of equipment and facilities related to capital equipment purchases.

Other (Income) Expense

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Other (income) expense

(314

)

339

(108

(645

)

(641

)

Other (income) expense decreased by $0.3 million, or 108%, from the three months ended June 30, 2021 compared to the three months ended June 30, 2022 and remained relatively unchanged for the six months ended June 30, 2021 and June 30, 2022. Interest income earned in both periods was offset by adjustments in foreign exchange, contingent consideration, and other expenses.

Grants and Incentives

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Grants and incentives

(4,646

)

(1,535

)

3,111

(67

(7,794

)

(6,730

)

1,064

(14

Grants and incentives decreased by $3.1 million, or 67%, from the three months ended June 30, 2021 compared to the three months ended June 30, 2022, and decreased $1.1 million, or 14%, for the six months ended June 30, 2021 compared to the six months ended June 30, 2022. This decrease was primarily driven by a decrease in activity relating to research and development expenditures that are eligible for the SIF project for the period.

Income Tax (Recovery) Expense

Three months ended

June 30,

Change

Six months ended

June 30,

Change

2021

2022

Amount

2021

2022

Amount

Income tax (recovery) expense

250

(101

)

(351

)

(140

44,516

62,136

17,620

Income tax recovery increased $0.4 million in the three months ended June 30, 2022, primarily driven by a change in effective income tax rates, partially offset by net earnings in the period. For the six months ended June 30, 2022, the $17.6 million increase in provision for income taxes is due to current net earnings.

Liquidity and Capital Resources

As of June 30, 2022, we had $1,022.3 million of cash, cash equivalents and marketable securities, comprising $790.6 million in cash and cash equivalents and $231.7 million in marketable securities. The increase of $299.3 million since December 31, 2021, was primarily from cash flow from operations and driven by the receipt of accounts receivable relating to royalties from bamlanivimab and bebtelovimab in the six months ended June 30, 2022.

We have generated positive operating cash flow cumulatively since our inception in 2012 and in every year since 2018. We intend to significantly invest in our business, and as a result may incur operating losses in future periods. We will continue to invest in research and development efforts towards expanding our capabilities and expertise along our technology stack, the building of our business development team and marketing our solutions to new and existing partners, and the expansion of our future office headquarters, and related infrastructure, including execution of long-term office-lease arrangements. Based on our current business plan, we believe that our existing cash, cash equivalents, and anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs and do not anticipate the need of external funding over at least the next 36 months following the date of this report.

Cash Flows

The following table summarizes our cash flows for the periods presented:

	Six months ended June 30,
	2021			2022
Net cash provided by (used in):
Operating activities	$	267,228		$	373,234
Investing activities		(61,472	)		(53,568	)
Financing activities		(6,618	)		(1,958	)
Effect of exchange rate fluctuations on cash and cash equivalents		(683	)		(1,411	)
Net increase in cash and cash equivalents	$	198,455		$	316,297

Operating activities

Net cash provided by operating activities increased from $267.2 million in the six months ended June 30, 2021 to $373.2 million in the six months ended June 30, 2022. The increase resulted primarily from increased royalty revenues from our partnership with Eli Lilly and an increase in discovery research activities, partially offset by an increase in expenditures that reflect AbCellera’s investment in research and development activities and growth of the company.

Investing activities

Net cash used by investing activities decreased from $61.5 million in the six months ended June 30, 2021 to $53.6 million in the six months ended June 30, 2022. Investing activities during the six months ended June 30, 2021 were attributed to the purchase of property and equipment and investments in and loans to equity accounted investees. For the six months ended June 30, 2022, investing activities included the purchase of property and equipment, long-term investments, and investments in and loans to equity accounted investees, partly offset by proceeds from marketable securities.

Financing activities

Net cash used by financing activities was $6.6 million for the six months ended June 30, 2021 due to the repayment of long-term debt and intangible asset obligation, partly offset by proceeds from exercise of options for common stock. Net cash used by financing activities was $2.0 million for the six months ended June 30, 2022 due to final payment of an in-licensing agreement partly offset by proceeds from long-term debt.

Critical Accounting Policies and Significant Judgements and Estimates

Detailed information about our critical accounting policies and estimates is set forth in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no significant changes to these policies during the six months ended June 30, 2022.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Our exposure to market risk is described in Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our annual report on Form 10-K for the year ended December 31, 2021. We believe our exposure to market risk has not changed materially since then.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are designed to ensure that information required to be disclosed is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, to allow timely decisions regarding required disclosure. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of June 30, 2022 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

There have been no material changes to legal proceedings as set forth in our annual report on Form 10-K for the period ended December 31, 2021.

Item 1A. Risk Factors.

Risks Related to Our Business and Strategy

We have incurred losses in certain years since inception and we may not be able to generate sufficient revenue to maintain profitability.

We expect to invest heavily in our business. We expect to experience fluctuations in revenue and expenses which makes it difficult to evaluate our business. We may incur losses that are materially larger than what we have previously incurred. We have incurred losses in certain years since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. Our net loss for the three months ended June 30, 2021 was $2.3 million and our net earnings for the six months ended June 30, 2021 was $114.9. Our net loss for the three months ended June 30, 2022 was $6.8 million and our net earnings for the six months ended June 30, 2022 was $161.8 million. As of June 30, 2022, we had accumulated earnings of $429.5 million. We expect that our operating expenses will continue to increase significantly, including as we:

•

invest in research and development activities to improve our technology and platform;

•

market our solutions to existing and new partners;

•

acquire businesses or technologies to support our business;

•

attract, hire and retain qualified personnel;

•

maintain, expand, enforce, protect and defend our intellectual property portfolio;

•

prosecute and defend our ongoing and any future patent litigation;

•

build our new GMP manufacturing facility;

•

create additional infrastructure to support our operations, including expanding our sales and marketing organization;

•

add operational, financial and management information systems and personnel to support our operations as a public company; and

•

experience any delays or encounter issues with any of the above.

Our expenses could increase beyond expectations for a variety of reasons, including our growth strategy and the increase in our operations. Since our inception, we have financed our operations primarily from revenue from upfront payments generated through our receipt of technology access fees and discovery research fees through the performance of service contracts with our partners, payments from partners upon the satisfaction of clinical milestones, government funding and one off government grants, the incurrence of indebtedness, and from private placements of our common and convertible preferred shares. Given our strategy and plans to invest in enhancing and scaling our business, we will need to generate significant additional revenue to achieve and sustain future profitability. Even though we have achieved profitability, we cannot be sure that we will remain profitable for any sustained period of time. We may not be able to generate sufficient revenue to sustain profitability and our recent and historical growth should not be considered indicative of our future performance.

Our revenue has fluctuated from period to period, and our revenue for any historical period may not be indicative of results that may be expected for any future period.

During the years ended December 31, 2020 and 2021, we received payments from our partnership contracts generated upon the satisfaction of clinical milestones, as well as royalty payments for the first time. During the six months ended June 30, 2022, we continued to receive royalty payments primarily on sales of bebtelovimab. Upfront technology access fees are generated upon execution of our partnership agreements. Research and discovery fees are generated by research activities that we perform for our partners, the timing and nature of which are dictated by the commencement of antibody discovery campaigns selected by our partners. Clinical milestone payments are generated upon the achievement of development milestones by our partners with respect to the antibodies that we deliver. We are also eligible to receive royalty payments upon net sales of antibodies that we have discovered for our partners. In 2020, 2021, and six months ended June 30, 2022, these royalty payments related to our partnership with Eli Lilly upon

sales of bamlanivimab and bebtelovimab, antibodies designed to treat and prevent COVID-19. Therefore, significant amount of royalty payments that we have received in recent periods are derived from a compound developed in a single partnership, and there can be no assurance that the revenues we have generated in such periods will be replicated in future periods. As we continue to see new and emerging variants, we would expect the use of bamlanivimab used alone or administered with another therapy, or bebtelovimab, to be subject to future distribution, use pauses or limitations, and withdrawals of authorization as we have seen in the past. This would correspondingly pause any royalty revenue we earn on the sales of bamlanivimab or bebtelovimab. We currently do not generate significant recurring revenue and, until such time as we establish significant recurring revenue, if at all, we will be prone to regular fluctuations in our revenue dependent on the timing of our entry into partnership agreements, our partners initiating discovery programs, and our partners achieving development milestones or commercial sales with respect to drug candidates utilizing antibodies discovered using our platform. We do not expect to generate significant recurring revenue unless and until such time as we secure additional programs under contract that, in the aggregate, result in regular and continuous execution of new partnership contracts, research discovery activities, achievement of development milestones or commencement of commercial sales. However, we are unable to predict whether and the extent to which the minimum annual payments under our partnership agreements will be exceeded, or the timing of the achievement of any milestones under these agreements, if they are achieved at all. In some cases, the timing and likelihood of payments to us under these agreements is dependent on our partners’ successful utilization of the antibodies discovered using our platform, which is outside of our control. Because of these factors, our operating results could vary materially from quarter to quarter from our forecasts.

Our quarterly and annual operating results have fluctuated in the past and may fluctuate in the future, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

•

the level of demand for our antibody discovery platform and solutions, which may vary significantly;

•

the timing and cost of, and level of investment in, research, development and commercialization activities relating to our platform and technology, which may change from time to time;

•

the start and completion of programs in which our platform is utilized;

•

the relative reliability and robustness of our platform, including the data generation and computational tools within our technology stack;

•

the introduction of new technologies, platform features or software, by us or others in our industry;

•

expenditures that we may incur to acquire, develop or commercialize additional technologies;

•

expenditures involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including costs related to our intellectual property litigation with Berkeley Lights, and the outcome of this and any other future patent litigation we may be involved in;

•

the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;

•

natural disasters, outbreaks of disease or public health crises, such as the COVID-19 pandemic;

•

the timing and nature of any future acquisitions or strategic partnerships;

•

future accounting pronouncements or changes in our accounting policies; and

•

general social, political and economic conditions and other factors, including inflationary pressures and factors unrelated to our operating performance or the operating performance of our competitors.

For example, 2020 was the first year in which we received payments from a partner beyond upfront fees. The antibody, bamlanivimab developed by Eli Lilly and Company, has undergone clinical testing and has received EUA from the FDA, and we have received associated milestone payments and royalties on net sales in 2020 and 2021. Eli Lilly progressed into these clinical trials at a greatly accelerated pace as a result of the Coronavirus Treatment Acceleration Program, which is a special emergency program for possible coronavirus therapies created by the FDA in 2020 to expedite the development of potentially safe and effective life-saving treatments to combat the COVID-19 pandemic. With respect to other or future product candidates, there is no assurance that any of our partners or collaborators will be able to advance a product candidate through clinical development on this timeframe again in the future, or at all. We initiated our partnering program in 2015 and have only had two AbCellera discovery programs and two Trianni programs result in milestone or royalty payments to us to date, and we have not yet had a program receive clinical marketing approval.

There is no guarantee that we will continue to generate the levels of revenue, particularly milestone and royalty revenues, from our partnerships as we have experienced in recent periods. As we continue to see new and emerging variants, we would expect the use of bamlanivimab used alone or administered with another therapy, or bebtelovimab, to be subject to future distribution, use pauses or limitations, and withdrawals of authorization as we have seen in the past. This would correspondingly pause any royalty revenue we earn on the sales of bamlanivimab or bebtelovimab. In addition, we have only recently begun to generate licensing revenue from our Trianni humanized rodent platform. There can be no assurance that we will continue to generate or expand our licensing revenue from this product offering in future periods.

The effect of one of the factors discussed above, or the cumulative effects of a combination of factors discussed above, could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

We may need to raise additional capital to fund our existing operations, improve our platform or expand our operations. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition.

Based on our current business plan, we believe our existing cash and cash equivalents and anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs over at least the next 36 months following the date of this report. If our available cash resources together with our anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our antibody discovery platform, or the realization of other risks described in this annual report, we may be required to raise additional capital prior to such time through issuances of equity or convertible debt securities, entrance into a credit facility or another form of third party funding or seek other debt financing. Such additional financing may not be available on terms acceptable to us or at all.

In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. For example, this may include reasons such as to:

•

increase our sales and marketing efforts to drive market recognition of our platform and address competitive developments;

•

fund development and marketing efforts of our current and future programs;

•

expand the capabilities of our platform into adjacent therapeutic modalities, including vaccine development and cell therapy;

•

acquire, license or invest in technologies;

•

acquire or invest in complementary businesses or assets; and

•

finance capital expenditures and general and administrative expenses.

Our present and future funding requirements will depend on many factors, including:

•

our ability to achieve revenue growth;

•

the cost of expanding our operations, including our sales and marketing efforts;

•

our rate of progress in selling access to our platform and marketing activities associated therewith;

•

our rate of progress in, and cost of research and development activities associated with, antibody discovery;

•

the effect of competing technological and market developments;

•

the continued impact of the ongoing COVID-19 pandemic on global social, political and economic conditions;

•

the economic and geopolitical impact of the ongoing conflict in the Ukraine;

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including costs related to our intellectual property litigation with Berkeley Lights, and the outcome of this and any other future patent litigation we may be involved in; and

•

costs related to any domestic and international expansion.

The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders would result. Any preferred equity securities issued also would likely provide for rights, preferences or privileges senior to those of holders of our common shares. If we raise funds by issuing debt securities, those debt securities would have rights,

preferences and privileges senior to those of holders of our common shares. Debt financing and preferred equity financing, if available, may also involve agreements that include covenants restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures, or declaring dividends. For example, our agreement with the Strategic Innovation Fund, or SIF requires us to obtain consent in the event that an individual or company (or two or more of them acting in concert) acquires the direct or indirect beneficial ownership of 20% or more of our voting securities. In the event consent is not obtained, the agreement may be terminated and we will be obligated to repay all or a portion of the contribution amounts from SIF.

If we are unable to obtain adequate financing or financing on terms satisfactory to us, if we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could have a material adverse effect on our business, financial condition, results of operations and prospects.

Our commercial success depends on the quality of our antibody discovery platform and technological capabilities and their acceptance by new and existing partners in our market.

We utilize our antibody discovery platform to identify antibodies for further development and potential commercialization by our partners. As a result, the quality and sophistication of our platform and technology is critical to our ability to conduct our research discovery activities and to deliver more promising molecules and to accelerate and lower the costs of discovery as compared to traditional methods for our partnerships. In particular, our business depends, among other things, on:

•

our platform’s ability to successfully identify therapeutic antibodies on the desired timeframes that can ultimately be used to prevent and treat diseases;

•

our ability to execute on our strategy to enter into new partnerships with new or existing partners and establish a robust internal pipeline of antibody discovery programs;

•

our ability to increase awareness of the capabilities of our technology and solutions;

•

our partners’ and potential partners’ willingness to adopt new technologies;

•

whether our platform reliably provides advantages over legacy and other alternative technologies and is perceived by customers to be cost effective;

•

the rate of adoption of our solutions by pharmaceutical companies, biotechnology companies of all sizes, government organizations and non-profit organizations and others;

•

prices we charge for our data packages and the discoveries that we make;

•

the relative reliability and robustness of our platform;

•

our ability to develop new solutions for partners;

•

if competitors develop a platform that performs functional testing of cells at a greater throughput than us;

•

the timing and scope of any approval that may be required by the U.S. Food and Drug Administration, or FDA, or any other regulatory body for drugs that are developed based on antibodies discovered by us;

•

the impact of our investments in innovation and commercial growth;

•

negative publicity regarding our or our competitors’ technologies resulting from defects or errors; and

•

our ability to further validate our technology through research and accompanying publications.

There can be no assurance that we will successfully address any of these or other factors that may affect the market acceptance of our platform or our technology. If we are unsuccessful in achieving and maintaining market acceptance of our platform, our business, financial condition, results of operations and prospects could be adversely affected.

If we cannot maintain and expand current partnerships and agreements and enter new partnership agreements that generate discovery programs for antibodies, our business could be adversely affected.

Our primary focus is on the discovery of antibodies for targets that are selected by our partners. Our partners then use the data packages provided by us to develop their own drug candidates without our involvement. As a result, our success depends on our ability to expand the number and scope of our partnerships. Many factors may impact the success of these partnerships, including our ability to perform our obligations, our partners’ satisfaction with our data packages, our partners’ ability to successfully develop, secure regulatory approval for and commercialize drug candidates using antibodies discovered using our platform, our partners’

internal priorities (including fluctuations in research and developments budgets), our partners’ resource allocation decisions and competitive opportunities, disagreements with partners, the costs required of either party to the partnerships and related financing needs, and operating, legal and other risks in any relevant jurisdiction.

In our partnership programs, we maintain rights to large unique data sets that connect information at the level of single-cell measurements, DNA sequence and protein function. We use this data to create an accelerating flywheel of learning: data generation from our partnership business provides the basis for AI modules that lead to expanded capabilities and faster data generation which supports our partnership business. As a result, in addition to reducing our revenue or delaying the development of our future solutions, the loss of one or more of these relationships may reduce our exposure to such information, thus hindering our efforts to further our technological differentiation and improve our platform. In certain of our partnership programs, we may elect to make additional investments in certain partnership agreements at progressive stages of pre-clinical development, clinical development, and commercialization in exchange for an increased share of product sales. Because of the inherent uncertainties in drug development described elsewhere in these Risk Factors, there can be no assurance that any additional investments we may elect to make would yield meaningful return, if at all.

We engage in conversations with companies regarding potential partnerships on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, including due to our inability to discover any usable antibodies for the selected targets or the antibodies that we do discover may not be successfully developed or commercialized by our partners. In such circumstances, we would not generate any substantial revenues from such a collaboration in the form of discovery research fees, milestone payments, royalties or otherwise. Speculation in the industry about our existing or potential partnerships can be a catalyst for adverse speculation about us, or our data packages, which can adversely affect our reputation and our business.

In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.

In recent periods, a limited number of partnerships accounted for a significant portion of our revenues. For the year ended December 31, 2020, three of our partners accounted for 35%, 25% and 14% of our research fees revenue and eight partners accounted for the remaining 26% of research fees revenue. For the year ended December 31, 2020 we recognized our first milestone and royalty revenue streams, totaling $213.3 million, exclusively from our partnership with Lilly. For the year ended December 31, 2021, four partners accounted for 29%, 17%, 11% and 10% of our research fees revenue and twelve partners accounted for the remaining 33% of research fees revenue. For the year ended December 31, 2021, we recognized licensing revenue of $7.0 million and royalty revenue of $327.3 million exclusively from our partnership with Lilly. Because a significant portion of our revenue in 2020 and 2021 was derived from sales of bamlanivimab, the reduction in sales of this compound that we have experienced in recent periods have reduced our royalty revenues attributed to sales of this compound. If these reductions are not offset by increases in other sources of revenue, our results of operations for future periods may be materially and adversely affected. As we continue to see new and emerging variants, we would expect the use of bamlanivimab used alone or administered with another therapy, or bebtelovimab, to be subject to future distribution, use pauses or limitations, and withdrawals of authorization as we have seen in the past. This would correspondingly pause any royalty revenue we earn on the sales of bamlanivimab or bebtelovimab.

Our existing partnerships cover a large number of current programs under contract, and therefore represent a large portion of potential downstream value. In addition, our partnership agreements are typically terminable at will with 90 days’ notice prior to identification of a target, after which point they may only be terminated for cause. As a result, if we fail to maintain our relationships with our partners or if any of our partners discontinue their programs, our future results of operations could be materially and adversely affected.

Development of a biological molecule is inherently uncertain, and it is possible that none of the drug candidates discovered using our antibody discovery platform that are further developed by our partners will receive marketing approval or become viable commercial products, on a timely basis or at all.

We use our platform to offer antibodies to partners who are engaged in antibody discovery and development. These partners include large cap pharmaceutical companies, biotechnology companies of all sizes and non-profit and government organizations. While we receive upfront payments generated through our receipt of technology access fees and discovery research fees for performing research activities for our partners, we estimate that the vast majority of the economic value of the contracts that we enter into with our partners is in the downstream payments that are payable if certain milestones are met or approved products are sold. As a result, our future growth is dependent on the ability of our partnerships to successfully develop and commercialize therapies based on antibodies discovered using our platform. Due to our reliance on our partners, the risks relating to product development, regulatory clearance, authorization or approval and commercialization apply to us derivatively through the activities of our partners. While we believe our platform is capable of identifying high quality antibodies, there can be no assurance that our partnerships will successfully

develop, secure marketing approvals for and commercialize any drug candidates based on the antibodies that we discover. As a result, we may not realize the intended benefits of our partnerships. We initiated our partnering program in 2015 and have only had two AbCellera discovery programs and two Trianni programs result in milestone or royalty payments to us to date, and we have not yet had a program receive clinical marketing approval.

Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, there may not be successful development of any drug candidates with the antibodies that we discover, or we and our partners may choose to discontinue the development of these drug candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, commercialization potential, production limitations or prioritization of their resources. It is possible that none of these drug candidates will ever receive regulatory approval and, even if approved, such drug candidates may never be successfully commercialized. For example, under our research agreement with Eli Lilly, we are eligible to receive and have received payments upon the achievement of certain development milestones and are eligible to receive royalties resulting from sales of both COVID-19 and non-COVID-19 products that incorporate antibodies we discovered. While we have received milestone and royalty payments from this collaboration, there can be no assurance that we will receive additional milestone payments or any royalties in the future. Furthermore, there can be no assurance that Eli Lilly will be successful in its further development of bamlanivimab or bebtelovimab. As we continue to see new and emerging variants, we would expect the use of bamlanivimab used alone or administered with another therapy, or bebtelovimab, to be subject to future distribution, use pauses or limitations, and withdrawals of authorization as we have seen in the past. This would correspondingly pause any royalty revenue we earn on the sales of bamlanivimab or bebtelovimab.

In addition, even if these drug candidates receive regulatory approval in the United States, the drug candidates may never obtain approval or commercialize such drugs outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. Furthermore, approved drugs may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Likewise, we or our partners have to make decisions about which clinical stage and pre-clinical drug candidates to develop and advance, and we or our partners may not have the resources to invest in all of the drug candidates that contain antibodies discovered using our platform, or clinical data and other development considerations may not support the advancement of one or more drug candidates. Decision-making about which drug candidates to prioritize involves inherent uncertainty, and our partners’ development program decision-making and resource prioritization decisions, which are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one more of our partners is involved in a business combination, the partner might deemphasize or terminate the development or commercialization of any drug candidate that utilizes an antibody that we have discovered. If one of our strategic partners terminates its agreement with us, we may find it more difficult to attract new partners.

We are also subject to industry-wide FDA and other regulatory risk. The number of new drug applications, or NDAs, and biologics license applications, or BLAs, approved by the FDA varies significantly over time and if there were to be an extended reduction in the number of NDAs and BLAs approved by the FDA, the industry would contract and our business would be materially harmed.

The failure to effectively advance, market and sell suitable drug candidates with the antibodies that we discover could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common shares to decline. In addition to the inherent uncertainty in drug development addresses above, our ability to forecast our future revenues may be limited.

The failure of our partners to meet their contractual obligations to us could adversely affect our business.

Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us to our standards, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of products using our antibodies or result in litigation or arbitration.

In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations.

Moreover, some of our partners are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, and are often subject to country-specific privacy and data security risk as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us, which may have a material adverse effect on our business, financial condition and results of operations.

We may be unable to manage our current and future growth effectively, which could make it difficult to execute on our business strategy.

Since our inception in 2012, we have experienced rapid growth and anticipate further growth in our business operations. This growth requires managing complexities across all aspects of our business, including complexities associated with increased headcount, integration of acquisitions, expansion of international operations, expansion of facilities, including our new GMP facility, execution on new lines of business and implementations of appropriate systems and controls to grow the business. Our growth has required significant time and attention from our management, and placed strains on our operational systems and processes, financial systems and internal controls and other aspects of our business.

We expect to continue to increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, engineers, laboratory personnel, client and account services personnel and sales and marketing staff and improve and maintain our technology to properly manage our growth. We may also need to hire, train and manage individuals with expertise that is separate, supplemental or different from expertise that we currently have, and accordingly we may not be successful in hiring, training and managing such individuals. For example, if our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees, or if we are not successful in retaining our existing employees, our business may be harmed. Improving our technology and processes have required us to hire and retain additional scientific, engineering, sales and marketing, software, manufacturing, distribution and quality assurance personnel. As a result, we have experienced rapid headcount growth, resulting in approximately 450 employees as of June 30, 2022. We currently serve partners around the world and plan to continue to expand to new international jurisdictions as part of our growth strategy, which will lead to increased dispersion of our employees. Moreover, we expect that we will need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company. As a public company, our management and other personnel need to devote a substantial amount of time towards maintaining compliance with these requirements. A risk associated with maintaining this rate of growth, for example, is that we may face challenges integrating, developing and motivating our rapidly growing and increasingly dispersed employee base.

We may not be able to maintain the quality, reliability or robustness of our platform, or the expected turnaround times of our solutions and support, or to satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. If we are unable to manage our growth properly, we may experience future weaknesses in our internal controls, which we may not successfully remediate on a timely basis or at all. To effectively manage our growth, we must continue to improve our operational and manufacturing systems and processes, our financial systems and internal controls and other aspects of our business and continue to effectively expand, train and manage our personnel. The time and resources required to improve our existing systems and procedures, implement new systems and procedures and to adequately staff such existing and new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could adversely affect our operations and negatively impact our business and financial results.

We use our technology stack for the discovery of antibodies and, since our inception, we have dedicated a substantial portion of our resources on the development of our platform and the technology that it incorporates to further enhance our antibody discovery platform. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect operating results and that such investments may not generate sufficient technological advantage relative to alternatives in the market which would, in turn, impact revenues to offset liabilities assumed and expenses associated with these new investments. The industry in which we operate changes rapidly as a result of technological and drug developments, which may render our solutions less desirable. We believe that we must continue to invest a significant amount of time and resources in our platform and technology to maintain and improve our competitive position. If we do not achieve the benefits anticipated from these investments, if the achievement of these benefits is delayed, or if our technology stack is not able to accelerate the process of antibody discovery as quickly as we anticipate, our revenue and operating results may be adversely affected.

Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs, and the price of our common shares may decline as a result of announcements of unexpected results or developments.

Our partners have significant discretion in determining when and whether to make announcements about the status of our partnerships, including about preclinical and clinical developments and timelines for advancing antibodies discovered using our platform. We do not plan to disclose the development status and progress of individual drug candidates of our partners, unless and until those partners do so first. Our partners may wish to report such information more or less frequently than we intend to or may not

wish to report such information at all, in which case we would not report that information either. In addition, if partners choose to announce a collaboration with us, there is no guarantee that we will recognize research discovery fees in that quarter or even the following quarter, as such fees are not payable to us until our partner begins discovery activities. The price of our common shares may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information.

From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Certain of our partners have also made public statements regarding their expectations for the development of programs under partnership with us and they and other partners may in the future make additional statements about their goals and expectations for partnerships with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners’ antibody discovery and development programs, the amount of time, effort, and resources committed by us and our current and future partners, and the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that our partners’ current and future programs will advance or be completed in the time frames we or they expect. If our partners fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected and the price of our common shares could decline.

We face significant competition in the life sciences technology market. Our technologies address antibody therapeutic discovery challenges that are addressed by other platform technologies controlled by companies that have a variety of business models, including the development of internal pipelines of therapeutics, technology licensing, and the sale of instruments and devices. Examples of technical competition at different steps of our technology stack include:

•

In the field of single-cell screening, companies that provide access to similar technologies such as Berkeley Lights, HiFiBio Inc., Ligand Pharmaceuticals Inc., and Sphere Fluidics Ltd.

•

In antibody RepSeq, companies that provide access to similar technologies such as 10X Genomics Inc., Adaptive Biotechnologies Corp., Atreca Inc. and Distributed Bio Inc. (acquired by Charles River Laboratories in 2021)

•

In bispecific antibody engineering, from companies that provide access to similar technologies such as Abbvie Inc., Genmab A/S, Merus N.V. and Zymeworks Inc.

•

In discovery using genetically engineered rodents, companies that provide access to similar technologies such as Ablexis LLC, Crescendo Biologics Ltd., Harbour Antibodies BV, Kymab Ltd., Ligand Pharmaceuticals Inc. and RenBio Inc.

We also face direct business competition from companies that provide antibody discovery services using technologies such as hybridoma and display. Companies with discovery business models that include downstream payments include Adimab LLC, Distributed Bio Inc. (acquired by Charles River Laboratories in 2021) and WuXi Biologics Inc. In addition, we compete with a variety of fee-for-service contract research organizations that provide services, in most cases using legacy technologies, that compete with one or more steps in our technology stack. In addition, our partners may also elect to develop their workflows on legacy systems rather than rely on our platform.

Our competitors and potential competitors may enjoy a number of competitive advantages over us. For example, these may include:

•

longer operating histories;

•

larger customer bases;

•

greater brand recognition and market penetration;

•

greater financial resources;

•

greater technological and research and development resources;

•

better system reliability and robustness;

•

greater selling and marketing capabilities; and

•

better established, larger scale and lower cost manufacturing capabilities.

As a result, our competitors and potential competitors may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their platforms or instruments than we can or sell their platforms or instruments, or offer solutions competitive with our platform and solutions at prices designed to win significant levels of market share. In addition, we may encounter challenges in marketing our solutions with our pricing model, which is structured to capture the potential downstream revenues associated with drug candidates that were discovered using our platform. Our partners and potential partners may prefer one or more pricing models employed by our competitors that involve upfront payments rather than downstream revenues. We may not be able to compete effectively against these organizations.

In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to technology and platform development than we can. If we are unable to compete successfully against current and future competitors, we may be unable to increase market adoption and sales of our platform, which could prevent us from increasing our revenue or sustaining profitability.

Our antibody discovery platform technology may not meet the expectations of our partners, which means our business, financial condition, results of operations and prospects could suffer.

Our success depends on, among other things, the market’s confidence that our platform is capable of substantially shortening the amount of time necessary to perform certain research activities as compared to the use of legacy and other alternative technologies, and will enable more efficient or improved pharmaceutical and biotechnology product development. For example, while we have in the past been able to identify a potential drug candidate for human testing within 90 days, there is no assurance that we will be able to do so on this timeframe again in the future, or at all. To date, we have only had one program result in clinical milestone and two programs result in royalty payments to us. While our partnership with Eli Lilly has produced bamlanivimab, an antibody for which Eli Lilly was granted two EUAs by the FDA, for administration alone and together with etesevimab, and a similar authorization by Health Canada for bamlanivimab alone. This partnership has also produced bebtelovimab, a second antibody that was granted an EUA by the FDA. Despite these authorizations, we have not yet had a program receive full marketing approval. As we continue to see new and emerging variants, we would expect the use of bamlanivimab used alone or administered with another therapy, or bebtelovimab, to be subject to future distribution, use pauses or limitations, and withdrawals of authorization as we have seen in the past. This would correspondingly pause any royalty revenue we earn on the sales of bamlanivimab or bebtelovimab. We also believe that pharmaceutical and biotechnology companies are likely to be particularly sensitive to defects and errors in the use of our platform, including if our platform fails to deliver meaningful acceleration of certain research timelines accompanied by results at least as good as the results generated using legacy or other alternative technologies. There can be no guarantee that our platform will meet the expectations of pharmaceutical and biotechnology companies.

If we are unable to support demand for our antibody discovery platform, including ensuring that we have adequate teams and facilities to meet increased demand, or if we are unable to successfully manage our anticipated growth, our business could suffer.

We have experienced significant growth in the number of programs under contract in recent periods for which we are conducting research discovery activities. As we secure additional programs under contract and as our partners initiate discovery programs, our operational capacity to execute such research activities may become strained. We are also planning to devote significant resources to vertical integration into our platform. As a result, our strategy requires us to successfully scale our teams and facilities to meet future demand for our solutions. Our ability to grow our capacity will depend on our ability to expand our workforce and our facilities, and increase efficiency through automation and software solutions. We may also need to purchase additional equipment, some of which can take several months or more to procure and set up. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities or process enhancements will be successfully implemented and in a timely manner. For example, we are currently expanding our facilities in Vancouver and internationally. Such facilities require purpose-built buildings often with rezoning requirements. Such projects are typically long in duration and subject to delays. Failure to manage this growth could result in delays, higher costs, declining quality, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our data packages and could damage our reputation and the prospects for our business.

Our management uses certain key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions and such metrics may not accurately reflect all of the aspects of our business needed to make such evaluations and decisions, in particular as our business continues to grow.

In addition to our consolidated financial results, our management regularly reviews a number of operating and financial metrics, including number of programs under contract, the trend of potential downstream revenue terms (milestones and royalties) of the portfolio, the performance of the portfolio in probability of success in achieving clinical milestones as compared to historical averages and the performance of the portfolio in the time taken to achieve clinical milestones, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that these metrics are representative of our current business; however, these metrics may not accurately reflect all aspects of our business and we anticipate that these metrics may change or may be substituted for additional or different metrics as our business grows and as we introduce new solutions. If our management fails to review other relevant information or change or substitute the key business metrics they review as our business grows, their ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted.

The sizes of the markets and forecasts of market growth for the demand of our antibody discovery platform and other of our key performance indicators are based on a number of complex assumptions and estimates and may be inaccurate.

We estimate annual total addressable markets and forecasts of market growth for our platform, data packages and technologies. We have also developed a standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third party estimates and other business data, including assumptions and estimates relating to our ability to generate revenue from the development of new workflows. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. As a result, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from technology access fees, discovery research fees, milestone payments or royalties may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our platform is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and prospects.

We must adapt to rapid and significant technological change and respond to introductions of new products and technologies by competitors to remain competitive.

We provide our antibody discovery solution and capabilities in industries that are characterized by significant enhancements and evolving industry standards. As a result, our partners’ needs are rapidly evolving. If we do not appropriately innovate and invest in new technologies, our platform may become less desirable in the markets we serve, and our partners could move to new technologies offered by our competitors or engage in antibody discovery themselves. Though we believe partners in our markets display a significant amount of loyalty to their supplier of research or a particular product or service, we also believe that because of the initial time investment required by many of our partners to reach a decision about whether to partner with us, it may be difficult to regain that customer once the customer enters into a partnership or collaboration agreement with a competitor. Without the timely introduction of new solutions and technological enhancements, our offerings will likely become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new technologies and markets to further broaden and deepen our capabilities and expertise in antibody discovery and development. For example, to the extent we fail to timely introduce new and innovative technologies or solutions, adequately predict our partners’ needs or fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affected.

We depend on our information technology systems, and any failure of these systems could harm our business.

We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting, our platform, our advanced automation systems, and advanced application software. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. These implementations were expensive and required a significant effort in terms of both time and effort. In addition to the aforementioned business systems, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our

technical systems. These information technology and telecommunications systems support a variety of functions, including manufacturing operations, laboratory operations, data analysis, quality control, customer service and support, billing, research and development activities, scientific and general administrative activities. A significant risk in implementing these systems, for example, is the integration and communication between separate IT systems.

Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious software, bugs or viruses, human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future.

Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or protected health information or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

In the ordinary course of our business, we collect and store petabytes of sensitive data, including legally protected health information, personally identifiable information, intellectual property and proprietary business information owned or controlled by ourselves or our strategic partners. We manage and maintain our applications and data by utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face four primary risks relative to protecting this critical information: loss of access risk, inappropriate disclosure risk, inappropriate modification risk and the risk of being unable to adequately monitor our controls over the first three risks.

Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure and that of any third-party provider we may utilize, may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and regulatory penalties. Although we have implemented security measures and a formal enterprise security program to prevent unauthorized access to sensitive data, there is no guarantee that we can protect our systems from breach. Unauthorized access, loss or dissemination could also disrupt our operations (including our ability to conduct our analyses, pay providers, conduct research and development activities, collect, process and prepare company financial information, provide information about any future products, and manage the administrative aspects of our business) and damage our reputation, any of which could adversely affect our business.

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and its implementing regulations, impose certain requirements relating to the privacy, security, transmission and breach reporting of individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them that involve individually identifiable health information. Mandatory penalties for HIPAA violations can be significant, and criminal and monetary penalties, as well as injunctive relief, may be imposed for HIPAA violations. Although drug manufacturers are not directly subject to HIPAA, prosecutors are increasingly using HIPAA-related theories of liability against drug manufacturers and their agents and we also could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

Furthermore, in the event of a breach as defined by HIPAA, HIPAA regulations impose specific reporting requirements to regulators, individuals impacted by the breach and the media. Issuing such notifications can be costly, time and resource intensive, and can generate significant negative publicity. Breaches of HIPAA may also constitute contractual violations that could lead to contractual damages or terminations. In addition, U.S. states have enacted and are considering enacting laws relating to the protection of patient health and other data, which may be more rigorous than, or impose additional requirements beyond those required by, HIPAA. For example, the California Consumer Privacy Act (“CCPA”), which became effective on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations as well as a limited private right of action for data breaches, which may increase the volume of data breach litigation. While limited CCPA exemptions may apply to portions of our business, the recency of the CCPA’s implementing regulations and the California Attorney General’s enforcement activity means our obligations under the CCPA could evolve in the future, which may increase our compliance costs and potential liability.

Further, a new California privacy law, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022). Additionally, some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, on March 2, 2021, Virginia enacted the Consumer Data Protection Act (the “CDPA”) and, on July 8, 2021, Colorado’s governor signed the Colorado Privacy Act (“CPA”), into law. The CDPA and the CPA will both become effective January 1, 2023. While the CDPA and CPA incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.

A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.

We may also become subject to laws and regulations in non-U.S. countries covering data privacy and the protection of health-related and other personal information. In particular, the European Economic Area (“EEA”) has adopted data protection laws and regulations that impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure, processing and security of personal information that identifies or may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations, and have generally become more stringent over time.

The General Data Protection Regulation 2016/679 (“GDPR”) applies to the processing of personal data in the EEA. The GDPR imposes many requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded) data and additional obligations when contracting third-party processors in connection with the processing of the personal data. The GDPR allows EEA countries to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of EEA countries may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties; we may also be liable should any individual who has suffered financial or non-financial damage arising from our infringement of the GDPR exercise their right to receive compensation against us. Furthermore, adverse publicity relating to our failure to comply with the GDPR could cause a loss of goodwill, which could have an adverse effect on our reputation, brand, business and financial condition. In addition, further to the UK’s exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK’s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK’s data protection regime, which is independent from but aligned to the EU’s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to £17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU’s GDPR, the European Commission (“EC”) has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.

To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC’s new standard contractual clauses but has published a draft version of a UK-specific transfer mechanism, which, once finalized, will enable transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.

The interpretation and application of consumer, health-related and data protection laws in the United States, the EEA, and elsewhere are often uncertain, contradictory and in flux. Any failure or perceived failure to comply with federal, state or foreign laws or regulations, contractual or other legal obligations related to data privacy or data protection may result in claims, warnings, communications, requests or investigations from individuals, supervisory authorities or other legal or regulatory authorities in relation to our processing of personal data. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition, these privacy regulations vary between states, may differ from country to country, and may vary based on whether testing is performed in the United States or in the local country. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business.

Furthermore, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business.

In addition, as a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities

Our marketing department is expanding, and if we are unable to continue this growth and effectively execute on our marketing strategy, our business may be adversely affected.

We continue to expand our commercial organization in order to effectively market our solutions to existing and new partners. Competition for employees capable of negotiating and entering into partnerships with pharmaceutical and biotechnology companies is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our platform and limit our revenue growth and potential profitability. In addition, the time and cost of establishing a specialized sales, marketing and service force for a particular service may be difficult to justify in light of the revenue generated or projected.

Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to successfully sell our programs and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality.

The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, engineers and salespeople could adversely affect our business.

Our success depends on the skills, experience and performance of key members of our senior management team. The individual and collective efforts of these employees will be important as we continue to develop our platform and our technology, and as we expand our commercial activities. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. While certain of our executive officers are party to employment contracts with us, we cannot guarantee their retention for any period of time beyond the applicable notice period.

Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and engineers. We may not be able to attract or retain qualified scientists and engineers in the future due to the competition for qualified personnel among life science businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific and engineering personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. A key risk in this area, for example, is that certain of our employees are at-will, which means that either we or the employee may terminate their employment at any time.

We have made technology acquisitions and expect to acquire businesses or assets or make investments in other companies or technologies that could negatively affect our operating results, dilute our shareholders’ ownership, increase our debt or cause us to incur significant expense.

We have made technology acquisitions and expect to pursue acquisitions of businesses and assets in the future. We also may pursue strategic alliances and joint ventures that leverage our technologies and industry experience to expand our offerings or distribution. Although we have acquired other businesses or assets in the past, we may not be able to find suitable partners or

acquisition or asset purchase candidates in the future, and we may not be able to complete such transactions on favorable terms, if at all. The competition for partners or acquisition candidates may be intense, and the negotiation process will be time-consuming and complex. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, these acquisitions may not strengthen our competitive position, the transactions may be viewed negatively by partners or investors, we may be unable to retain key employees of any acquired business, relationships with key suppliers, manufacturers or partners of any acquired business may be impaired due to changes in management and ownership, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. We cannot guarantee that we will be able to fully recover the costs of any acquisition. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture. We also may experience losses related to investments in other companies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Acquisitions may also expose us to a variety of international and business related risks, including intellectual property, regulatory laws, local laws, tax and accounting.

To finance any acquisitions or asset purchase, we may choose to issue securities as consideration, which would dilute the ownership of our shareholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common shares is low or volatile, we may not be able to acquire companies or assets using our securities as consideration.

Our business could become subject to government regulation and the regulatory approval and maintenance process may be expensive, time-consuming and uncertain both in timing and in outcome.

Our data packages are currently not subject to approval by the FDA. However, our business could in the future become subject to regulation by the FDA, or comparable international agencies. For example, in May 2020, we announced that we received a commitment from the Government of Canada under Innovation, Science and Economic Development’s, or ISED, Strategic Innovation Fund, or SIF, of up to CAD $175.6 million ($125.6 million), the proceeds of which we plan to use to build a GMP facility in Vancouver, British Columbia, which will house our manufacturing and manufacturing support infrastructure. This facility, once completed, will become subject to various regulations, which could include regular inspections, certifications and audits. Such regulatory approval processes or clearances may be expensive, time-consuming and uncertain, and our failure to obtain or comply with such approvals and clearances could have an adverse effect on our business, financial condition and operating results. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, including regulation of our data packages, could arise at any time, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our data packages or future products, if required.

Our billing and collections processing activities are time-consuming, and any delay in transmitting invoices or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue.

Billing for our data packages can be time-consuming, as many of our partners are large pharmaceutical or biotechnology companies and engage various models for their accounts payable matters, including outsourcing to third parties. We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, which could require to write-off significant accounts receivable and recognize bad debt expenses, which could adversely affect our business, financial condition, results of operations and prospects.

If our operating facilities become damaged or inoperable or we are required to vacate a facility, our ability to conduct and pursue our research and development efforts may be jeopardized.

We currently derive the majority of our revenue based upon scientific and engineering research and development and testing conducted in Vancouver, British Columbia. Our facilities and equipment could be harmed or rendered inoperable or inaccessible by natural or man-made disasters or other circumstances beyond our control, including fire, earthquake, power loss, communications failure, war or terrorism, or another catastrophic event, such as a pandemic or similar outbreak or public health crisis, which may render it difficult or impossible for us to support our partners and develop updates, upgrades and other improvements to our technology and platform, advanced automation systems, and advanced application and workflow software for some period of time. The inability to address system issues could develop if our facilities are inoperable or suffers a loss of utilization for even a short period of time, may result in the loss of partners or harm to our reputation, and we may be unable to regain those partners or repair our reputation in the future. Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify new facilities or license or transfer our proprietary technology to a third - party. Even in the event we are able to find a third - party to assist in research and development efforts, we may be unable to negotiate commercially reasonable terms to engage with the third - party.

We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.

Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella and directors’ and officers’ insurance.

Any additional insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. A successful liability claim, or series of claims, in which judgments exceed our insurance coverage could adversely affect our business, financial condition, results of operations and prospects, including preventing or limiting the use of our platform to discover antibodies.

Operating as a public company makes it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage, seek alternative insurance options or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects.

Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

In the ordinary course of our business, we generate and store sensitive data, including research data, intellectual property and proprietary business information owned or controlled by ourselves or our employees, partners and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, accidental exposure, unauthorized access, inappropriate modification and the risk of our being unable to adequately monitor and audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf. Further, to the extent our employees are working at home during the COVID-19 pandemic, additional risks may arise as a result of depending on the networking and security put into place by the employees. The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use or disclosure, no security measures can be perfect and our information technology and infrastructure may be vulnerable to attacks by hackers or infections by viruses or other malware or breached due to employee erroneous actions or inactions by our employees or contractors, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, any of which could adversely affect our business.

International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of Canada and the United States.

We currently have operations in Canada, the United States, Australia and the United Kingdom and our business strategy incorporates future international expansion. Doing business internationally involves a number of risks including:

•

multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, tariffs, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses;

•

failure by us or our distributors to obtain approvals to conduct our business in various countries;

•

differing intellectual property rights;

•

complexities and difficulties in obtaining intellectual property protection, enforcing our intellectual property and defending against third party intellectual property claims;

•

difficulties in staffing and managing foreign operations;

•

logistics and regulations associated with shipping systems and parts and components for systems, consumables and reagent kits, as well as transportation delays;

•

travel restrictions that limit the ability of marketing, presales, sales, services and support teams to service partners;

•

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our data packages, and exposure to foreign currency exchange rate fluctuations;

•

international trade disputes that could result in tariffs and other protective measures;

•

natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and

•

regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ activities that may fall within the purview of the Canadian Corruption of Foreign Public Officials Act, or CFPOA, or U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions.

Any of these factors could significantly harm our future international expansion and operations and, consequently, our business, financial condition, results of operations and prospects. In addition, certain international markets are subject to significant political and economic uncertainty, including for example the effect of the withdrawal of the United Kingdom from the European Union. Significant political and economic developments in international markets for which we intend to operate, or the perception that any of them could occur, creates further challenges for operating in these markets in addition to creating instability in global economic conditions.

Our business activities are subject to the FCPA and other anti-bribery and anti-corruption laws of the United States and other countries in which we operate, as well as U.S. and certain foreign export controls and trade sanctions. Violations of such legal requirements could subject us to liability.

We are subject to the FCPA, which among other things prohibits companies and their third-party intermediaries from offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Companies in the biotechnology and biopharmaceutical field are highly regulated and therefore involve interactions with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. We are also subject to the Canadian equivalent to the FCPA, the CFPOA. These laws are complex and far-reaching in nature, and, as a result, there is no certainty that all of our employees, agents or contractors will comply with such laws and regulations. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, financial condition, results of operations and prospects. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.

In addition, our data packages may be subject to U.S. and foreign export controls and trade sanctions. Compliance with applicable regulatory requirements regarding the export of our data packages may create delays in us providing our data packages in international markets or, in some cases, prevent the export thereof to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our data packages by, or in our decreased ability to export our data packages to, existing or potential customers with international operations. Any decreased use of our data packages or limitation on our ability to export or sell our data packages would likely adversely affect our business.

We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.

We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, provincial, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We are subject to periodic inspections by Canadian provincial and federal authorities to ensure compliance with applicable laws. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.

In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. In the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.

Once completed, our manufacturing operations will be dependent upon third party suppliers, including single source suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.

We are building a GMP facility in Vancouver, British Columbia, to house our manufacturing and manufacturing support infrastructure. We anticipate that some of the suppliers of critical components or materials for our processes may be single or sole source suppliers and the replacement of these suppliers or the identification and qualification of suitable second sources may require significant time, effort and expense, and could result in delays in production, which could negatively impact our business operations and revenue. There can be no assurance that our supply of components necessary for the operation of this facility will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In addition, loss of any critical component provided by a single source supplier could require us to change the design of our manufacturing process based on the functions, limitations, features and specifications of the replacement components.

In addition, several other non-critical components and materials that comprise our systems are currently manufactured by a single supplier or a limited number of suppliers. In many of these cases, we have not yet qualified alternate suppliers and rely upon purchase orders, rather than long-term supply agreements. A supply interruption or an increase in demand beyond our current suppliers’ capabilities could harm our ability to manufacture our systems unless and until new sources of supply are identified and qualified. Our reliance on these suppliers subjects us to a number of risks that could harm our business, including:

•

interruption of supply resulting from modifications to or discontinuation of a supplier’s operations;

•

delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier’s variation in a component;

•

a lack of long-term supply arrangements for key components with our suppliers;

•

inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;

•

difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;

•

a modification or change in a manufacturing process or part that unknowingly or unintentionally negatively impacts the operation of our systems;

•

production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications;

•

delay in delivery due to our suppliers prioritizing other customer orders over ours;

•

damage to our brand reputation caused by defective components produced by our suppliers;

•

increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers; and

•

fluctuation in delivery by our suppliers due to changes in demand from us or their other partners.

Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our partners, which would have an adverse effect on our business.

Although we expect our recent business acquisitions will result in synergies and other benefits to us, we may not realize those benefits because of difficulties related to integration.

In November 2020, we consummated the Trianni acquisition. In September 2021, we consummated the TetraGenetics acquisition. We expect that the integration process will require significant time and resources, and we may not be able to manage the process successfully. If we are not able to successfully integrate the businesses with ours, the anticipated benefits of the acquisitions may not be realized fully or may take longer than expected to be realized. We may also incur higher than expected costs as a result of the acquisitions or experience an overall post-completion process that takes longer than originally anticipated. In addition, at times the attention of certain members of our management and resources may be focused on integration of the businesses of the companies and diverted from day-to-day business operations, which may disrupt our ongoing business and the business of the combined company. We expect to incur non-recurring costs in connection with both acquisitions and integrating to our operations. Management cannot ensure that the elimination of duplicative costs or the realization of other efficiencies will offset the transaction and integration costs in the near term or at all. Furthermore, uncertainty about the effect of the acquisitions on our business, employees, customers, third parties with whom we have relationships may have an adverse effect on our business, financial condition, results of operations and prospects. In addition, such challenges in integrating our acquisitions may be magnified by the ongoing COVID-19 pandemic.

Other potential difficulties we may encounter as part of the integration process include (i) the challenge of integrating complex systems, operating procedures, regulatory compliance programs, technology, networks and other assets of the acquisitions in a seamless manner that minimizes any adverse impact on our employees, patients, suppliers and other business partners; and (ii) potential unknown liabilities, liabilities that are significantly larger than we currently anticipate and unforeseen increased expenses or delays associated with the acquisitions, including costs to integrate the businesses that may exceed the costs that we currently anticipate. As part of our ongoing research and development we may make changes in our planned use of in process research and development which could result in a future impairment of the corresponding intangible asset.

For instance, in connection with the acquisition, we acquired a suite of transgenic humanized rodent lines currently being validated and available for discovery projects in the near future. There can be no assurance that these rodent lines will ever be validated or available for use by us or our partners. Further, it is possible that we will experience disruption of either company’s or both companies’ ongoing businesses, including as we continue to service Trianni’s existing contracts for the foreseeable future. In addition, we have only recently begun to generate licensing revenue from our Trianni humanized rodent platform. There can be no assurance that we will continue to generate or expand our licensing revenue from this product offering in future periods. Accordingly, the contemplated benefits of the Trianni acquisition may not be realized fully, or at all, or may take longer to realize than expected.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain sufficient intellectual property protection for our technology, including our platform and Celium, our proprietary antibody visualization software, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our data packages may be impaired.

We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict the use of our intellectual property.

To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors’ products and services, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive.

Our success depends in large part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States, Canada and in other countries with respect to our platform, our software and our technologies, without infringing the intellectual property rights of others.

We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our platform and related technologies and uses thereof, as we deem appropriate. Our patents and patent applications in the United States, Canada and certain foreign jurisdictions relate to our technology. However, obtaining and enforcing patents in our industry is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that issues as a patent), will exclude others from making, using or

selling our technology or technology that is substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

As of June 30, 2022, we owned or exclusively licensed over 70 issued or allowed patents and over 70 pending patent applications worldwide. We own registered trademarks and trademark applications for AbCellera, AbCellera Australia Pty. Ltd. (formerly Channel Bio), Celium, Trianni, the Trianni Mouse, and TetraGenetics in the U.S., Canada, Australia and Europe. It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our technology.

It is possible that in the future some of our patents, licensed patents and patent applications may be challenged at the United States Patent and Trademark Office, or USPTO, or in proceedings before the patent offices of other jurisdictions. We may not be successful in defending any such challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in loss of exclusivity or freedom to operate, patent claims being narrowed, the unenforceability or invalidity of such patents, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, limit the duration of the patent protection of our technology, and increased competition to our business. We may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.

Any changes we make to our technology, including changes that may be required for commercialization or that cause them to have what we view as more advantageous properties may not be covered by our existing patent portfolio, and we may be required to file new applications and/or seek other forms of protection for any such alterations to our technology. There can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to our technology.

The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies’ patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries.

Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technology.

Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary platforms, methods and technologies that are patentable.

Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 16, 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third-party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our technology or (ii) invent any of the inventions claimed in our or our licensor’s patents or patent applications.

The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third - party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third - party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our and our licensors’ ability to obtain new patents or to enforce existing patents and may facilitate third-party challenges to any owned or licensed patents.

Issued patents covering our platform and technology could be found invalid or unenforceable if challenged.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that they no longer cover our platform and our technology, which may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products.

We may not be aware of all third party intellectual property rights potentially relating to our platform or technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application.

To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.

We rely on in-licenses from third parties. If we lose these rights, our business may be materially adversely affected, our ability to develop improvements to our technology stack and antibody discovery platform may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements.

We are party to a royalty-bearing license agreement with the University of British Columbia that grants us exclusive rights to exploit certain patent rights that are related to our systems. Through our acquisition of Lineage, we obtained an exclusive license from Stanford University to patents and patent applications directed toward immune repertoire sequencing. We may need to obtain

additional licenses from others to advance our research, development and commercialization activities. Some of our license agreements impose, and we expect that any future exclusive in-license agreements will impose, various development, diligence, commercialization and other obligations on us. We may enter into engagements in the future, with other licensors under which we obtain certain intellectual property rights relating to our platform and technology. These engagements take the form of exclusive license or of actual ownership of intellectual property rights or technology from third parties. Our rights to use the technology we license are subject to the continuation of and compliance with the terms of those agreements. In some cases, we may not control the prosecution, maintenance or filing of the patents to which we hold licenses, or the enforcement of those patents against third parties.

Moreover, disputes may arise with respect to our licensing or other upstream agreements, including:

•

the scope of rights granted under the agreements and other interpretation-related issues;

•

the extent to which our systems and consumables, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

•

the sublicensing of patent and other rights under our collaborative development relationships;

•

our diligence obligations under the license agreements and what activities satisfy those diligence obligations;

•

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

•

the priority of invention of patented technology.

In spite of our efforts to comply with our obligations under our in-license agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such in-license is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. In addition, absent the rights granted to us under such license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our development and commercialization activities which are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which may not be ultimately successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, our rights to certain components of our technology stack are licensed to us on a non-exclusive basis. The owners of these non-exclusively licensed technologies are therefore free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor’s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the counterparty, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us.

If we cannot acquire or license rights to use technologies on reasonable terms or if we fail to comply with our obligations under such agreements, we may not be able to commercialize new technologies or services in the future and our business could be harmed.

In the future, we may identify third party intellectual property and technology we may need to license in order to engage in our business, including to develop or commercialize new technologies or services, and the growth of our business may depend in part on our ability to acquire, in-license or use this technology. However, such licenses may not be available to us on acceptable terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if such licenses are available, we may be required to pay the licensor in return for the use of such licensor’s technology, lump-sum payments, payments based on certain milestones such as sales volumes, or royalties based on sales of our platform. In addition, such licenses may be non-exclusive, which could give our competitors access to the same intellectual property licensed to us. We may also need to acquire or negotiate licenses to patents or patent applications before or after introducing a new service. The acquisition and licensing of third-party patent rights is a competitive area, and other companies may also be

pursuing strategies to acquire or license third party patent rights that we may consider attractive. We may not be able to acquire or obtain necessary licenses to patents or patent applications. Even if we are able to obtain a license to patent rights of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us.

In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize technology covered by these license agreements. If these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Additionally, termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more technologies that rely on such agreements.

While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.

In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to further commercialize our technology may be materially harmed.

Further, we may not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.

Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

Our business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other rights are found to be invalid or unenforceable. Moreover, we could encounter delays in the introduction of services while we attempt to develop alternatives. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing products, which could harm our business, financial condition, results of operations and prospects.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our platform, software, systems, workflows and processes in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States and Canada can be less extensive than those in the United States and Canada. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States and Canada, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. Further, we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States and Canada, or from selling or importing products made using our inventions in and into the United States, Canada or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own platform or technologies and may also sell their products or services to territories where we have patent protection, but enforcement is not as strong as that in the United States and Canada. These platforms and technologies may compete with ours. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents

against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, or that are initiated against us, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and Canada and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

•

others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future;

•

we, or our current or future collaborators, might not have been the first to make the inventions covered by the issued patents and pending patent applications that we license or may own in the future;

•

we, or our current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;

•

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;

•

it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents;

•

issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;

•

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

•

we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;

•

we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;

•

we cannot ensure that we will be able to further commercialize our technology on a substantial scale, if approved, before the relevant patents that we own or license expire;

•

we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our technology;

•

we may not develop additional proprietary technologies that are patentable;

•

the patents or intellectual property rights of others may harm our business; and

•

we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.

We rely heavily on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our technology platform, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction.

Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States and Canada may be less willing, or unwilling, to protect trade secrets.

We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We have employed and expect to employ individuals who were previously employed at universities or other companies. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, advisors, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential technologies and solutions, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects.

We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position.

The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly

leading to market confusion. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such rights, we may not be able to use these trademarks to develop brand recognition of our technologies or platform. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business.

We have not yet registered certain of our trademarks in all of our potential markets, although we have registered AbCellera in the United States and Canada as well as certain of our trademarks outside of the United States and Canada. If we apply to register these trademarks in other countries, and/or other trademarks in the United States, Canada and other countries, our applications may not be allowed for registration in a timely fashion or at all; and further, our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may in the future be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third party rights, we may not be able to use these trademarks to market our technologies in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could harm our business, financial condition, results of operations and prospects. And, over the long-term, if we are unable to establish name recognition based on our trademarks, then our marketing abilities may be materially adversely impacted.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, partners or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems, including our software, workflows, consumables and reagent kits. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

We are and in the future may be involved in litigation and other proceedings related to intellectual property, which could be time-intensive and costly and may adversely affect our business, financial condition, results of operations and prospects.

In recent years, there has been significant litigation in the United States and other jurisdictions involving intellectual property rights. We are and may in the future be involved with litigation or actions at the USPTO or the patent offices of other jurisdictions with various third parties that claim we or our partners using our solutions have misappropriated, misused or infringed other parties’ intellectual property rights. We expect that the number of such claims may increase as our business and the level of competition in our industry segments grow. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management’s time and attention from the development of the business, requiring the payment of monetary damages (including treble damages, attorneys’ fees, costs and expenses) or royalty payments, or result in potential or existing partners delaying purchases of our data packages or entering into engagements with us pending resolution of the dispute.

As we move into new markets and applications for our platform, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success may depend in part upon our ability to develop, manufacture, market and sell any products and services that we may develop and use without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties, or the invalidity of such patents or proprietary rights.

Our research, development and commercialization activities may in the future be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation and other patent challenges, both within and outside the United States and Canada, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and inter partes review proceedings before the USPTO, and corresponding foreign patent offices. Third parties may initiate legal proceedings against us or our licensor,

and we or our licensor may initiate legal proceedings against third parties. The outcome of such proceedings would be uncertain and could have a material adverse effect on the success of our business. Numerous U.S., Canadian and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our platform and technology. As the biotechnology industry expands and more patents are issued, the risk increases that our technologies may be subject to claims of infringement of the patent rights of third parties.

Additionally, the risks of being involved in such litigation and proceedings may increase if our technology nears commercialization. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and one or more third parties may assert that our technologies infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets.

The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. An unfavorable outcome in any such proceeding could require us to cease using the related technology or developing or commercializing our technology, or to attempt to license rights to it from the prevailing party, which may not be available on commercially reasonable terms, or at all.

Third parties may assert that we are employing their proprietary technology without authorization. We are also aware of issued U.S. patents and patent applications with subject matter related to our platform, systems, workflows and processes, and there may be other related third party patents or patent applications of which we are not aware.

It is possible that we are or may become aware of patents or pending patent applications that we think do not relate to our technology or that we believe are invalid or unenforceable, but that may nevertheless be interpreted to encompass our technology and to be valid and enforceable. Thus, we do not know with certainty that our technology, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party’s intellectual property.

In addition, we may receive in the future, correspondence from third parties referring to the relevance of such third parties’ intellectual property to our technology, our workflows or our advanced automated systems, and we are currently engaged in litigation with one such third party, Berkeley Lights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future programs or technologies may infringe. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our platform, or the systems, workflows, consumables and reagent kits that comprise our platform, infringes these patents. As to pending third party applications, we cannot predict with any certainty which claims will issue, if any, or the scope of such issued claims. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platforms, including our systems, workflows, consumables and reagent kits. Under the applicable law of certain jurisdictions, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our technologies. We may incorrectly determine that our technologies are not covered by a third party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our technologies.

There can be no assurance that we will prevail in any suit initiated against us by third parties, successfully settle or otherwise resolve patent infringement claims. A court of competent jurisdiction could hold that third party patents are valid, enforceable and infringed, which could materially and adversely affect our ability and the ability of our licensor to commercialize any technology we may develop and any other technologies covered by the asserted third-party patents. Third parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell data packages, and could result in the award of substantial damages against us, including treble damages, attorney’s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors and other third parties gaining access to the same intellectual property. In addition, we could encounter delays and incur significant costs in service introductions while we attempt to develop alternative processes, technologies or services, or redesign our technologies or services, to avoid infringing third party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses or to develop a workaround could prevent us from commercializing products or services, and the prohibition of sale or the threat of the prohibition of sale of any of our data packages could materially affect our business and our ability to gain market acceptance for our technologies. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.

In addition, our agreements with some of our partners, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects.

Any uncertainties resulting from the initiation and continuation of any litigation or administrative proceeding could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

The outcome of our litigation with Berkeley Lights may adversely affect our business, financial condition, results of operations and prospects.

In July 2020, we filed a complaint against Berkeley Lights, in the United States District Court for the District of Delaware, alleging that Berkeley Lights infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by the Company, including U.S. Patent Nos. 10,107,812; 10,274,494; 10,466,241; 10,578,618; 10,697,962; 10,087,408; 10,421,936 and 10,704,018, by making, using, offering for sale, selling and/or importing Berkeley Lights’ Beacon Optofluidic System. In August 2020, we filed an additional related complaint against Berkeley Lights in the United States District Court for the District of Delaware, alleging that Berkeley Lights infringed and continues to infringe, directly and indirectly, U.S. Patent Nos. 10,718,768; 10,738,270; 10,746,737 and 10,753,933. In September 2020, we filed another complaint against Berkeley Lights in the United States District Court for the District of Delaware, alleging that Berkeley Lights infringed and continues to infringe, directly and indirectly, U.S. Patent Nos. 10,775,376; 10,775,377 and 10,775,378. On December 3, 2020, the judge assigned to these three lawsuits ordered that they be transferred to the U.S. District Court for the Northern District of California. In these lawsuits, we are seeking, among other things, a judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement). In February 2021, these lawsuits were consolidated and assigned to the Honorable Judge Lucy Koh. In February 2021, Berkeley Lights filed a motion seeking leave to amend its counterclaims to add the allegations of unfair competition (as plead in the case described below) against AbCellera only. In July 2021, the Court allowed Berkeley to amend its counterclaims to add the unfair competition claims subject to our right to seek dismissal with prejudice should the counterclaims not overcome objections previously presented by us to the court. The Company is continuing to oppose the unfounded counterclaim and we intend to seek dismissal with prejudice. In March 2021, the court set this matter down for a jury trial with a December 12, 2022 start date. In July 2021, Berkeley Lights filed a Petition for Inter-Partes Review of U.S. Patent No. 10,087,408 that we exclusively license from the University of British Columbia. In July 2021, Berkeley Lights filed a second Petition for Inter-Partes Review of U.S. Patent No. 10,421,936 that we exclusively license from the University of British Columbia. In August 2021, Berkeley Lights filed a third Petition for Inter-Partes Review of U.S. Patent No. 10,738,270 that we exclusively license from the University of British Columbia. In August 2021, the court stayed the patent litigation against Berkeley Lights in view of the Petitions for Inter-Partes Review filed by Berkeley Lights. In January 2022, the PTAB denied one petition and instituted one petition. In February 2022, the PTAB denied the final petition. Trial on the instituted petition is scheduled for November 2022.

In August 2020, Berkeley Lights filed a complaint in the Northern District of California against us and our wholly-owned subsidiary Lineage Inc. The complaint includes two counts of unfair competition and one count of non-infringement of a U.S. patent: Patent No. 10,058,839 (the “’839 patent”). Berkeley Lights is seeking, among other things, damages and a declaratory judgment of non-infringement of the ’839 patent. We filed a motion to dismiss the action for lack of jurisdiction and failure to state a claim upon which relief can be granted pursuant to Federal Rules of Civil Procedure 12(b) 1, 2, and 6. In January 2021, the Court determined that there was no jurisdiction over AbCellera or Lineage and dismissed the unfair competition claims but ordered jurisdictional discovery on a limited basis with respect to AbCellera only regarding Berkeley Lights’ request for declaratory judgment on the ‘839 patent. In July 2021, Berkeley Lights voluntarily dismissed this lawsuit.

In the event that Berkeley Lights were to prevail in the litigation against us, as a result of which Berkeley Lights could continue to sell its products, it could reduce our competitive advantage and differentiation in the market place, impairing our ability to bring in new business. Furthermore, Berkeley Lights may seek to invalidate the asserted patents during the litigation. If Berkeley Lights succeeds in invalidating the asserted patents, the strength of our intellectual property portfolio could be adversely affected and our ability to protect our technology, business and reputation or to generate licensing revenue from our intellectual property would be adversely impacted.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Litigation or other legal proceedings relating to intellectual property claims, even if resolved in our favor, may cause us to incur substantial costs and divert the attention of our management and technical personnel from their normal responsibilities in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Such litigation or proceedings could substantially increase our operating costs and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property proceedings could harm our ability to compete in the marketplace. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Any of the foregoing could harm our business, financial condition, results of operations and prospects.

We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have a material adverse effect on the success of our business.

Third parties, including our competitors, could be infringing, misappropriating or otherwise violating our intellectual property rights. Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors’ products and services, and may in the future seek to enforce our rights against potential infringement, misappropriation or violation of our intellectual property. However, the steps we have taken to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our data packages.

Litigation may be necessary for us to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. We are currently engaged in a lawsuit with Berkeley Lights based upon our allegations of its infringement of our intellectual property rights and we may become involved in additional lawsuits in the future. If we do not prevail in such legal proceedings, we may be required to pay damages, we may lose significant intellectual property protection for our technologies, such that competitors could copy our technologies and we could be forced to cease selling certain of our data packages. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, financial condition, results of operations and prospects. In any lawsuit we bring to enforce our intellectual property rights, a court may refuse to stop the other party from using the technology at issue on grounds that our intellectual property rights do not cover the technology in question. Further, in such proceedings, the defendant could counterclaim that our intellectual property is invalid or unenforceable and the court may agree, in which case we could lose valuable intellectual property rights. The outcome in any such lawsuits are unpredictable. Even if we do prevail in any future litigation related to intellectual property rights, the cost and time requirements of the litigation could negatively impact our financial results.

Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on issued United States and most foreign patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications in order to maintain such patents and patent applications. We have systems in place to remind us to pay these fees, and we engage an outside service and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, if we or our licensors fail to maintain the patents and patent applications covering our products and technology our competitors may be able to enter the market with similar or identical products or technology without infringing our patents and this circumstance would have a material adverse effect on our business.

Patent terms may be inadequate to protect our competitive position on our technology for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our platform or technology are obtained, once the patent life has expired, we may be open to competition from others. If our platform or technologies require extended development and/or regulatory review, patents protecting our platform or technologies might expire before or shortly after we are able to successfully commercialize them. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing processes or technologies similar or identical to ours.

Our use of open source software could compromise our ability to offer our data packages and subject us to possible litigation.

We use open source software in connection with our technology and computational engine of our platform, Celium. Companies that incorporate open source software into their technologies and services have, from time to time, faced claims challenging their use of open source software and compliance with open source license terms. As a result, we could be subject to lawsuits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to the licensee’s software that incorporates, links or uses such open source software, and make available to third parties for no cost, any derivative works of the open source code created by the licensee, which could include the licensee’s own valuable proprietary code. While we monitor our use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, or could be claimed to have occurred, in part because open source license terms are often ambiguous. There is little legal precedent in this area and any actual or claimed requirement to disclose our proprietary source code or pay damages for breach of contract could harm our business and could help third parties, including our competitors, develop technologies that are similar to or better than ours. Any of the foregoing could harm our business, financial condition, results of operations and prospects.

Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.

Some of our intellectual property rights may have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our technology pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as “march-in rights”). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. To date, only our work in helping develop bamlanivimab may be subject to government funding or “march-in” rights. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.

Risks Related to Ownership of Our Common Shares

If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.

Ensuring that we have effective internal financial and accounting controls and procedures in place so that we can produce financial statements that are, in all material respects, in conformity with accounting principles generally accepted in the United States

of America, on a timely basis is a costly and time-consuming effort that needs to be re-evaluated annually. We are also subject to the reporting and compliance requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, which require annual management assessment of the effectiveness of our internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles.

Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In our efforts to maintain proper and effective internal control over financial reporting, we may discover significant deficiencies or material weaknesses in our internal control over financial reporting, which we may not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we identify one or more material weaknesses in the future, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements, which may harm the market price of our shares.

Future sales and issuances of our common shares or rights to purchase common shares, including pursuant to our Employee Share Option and Incentive Plan, or EIP, could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations, including expanded research and development activities, and costs associated with operating as a public company. To raise capital, we may sell common shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common shares, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing shareholders, and new investors could gain rights, preferences, and privileges senior to the holders of our common shares, including common shares sold in our IPO.

Pursuant to our incentive plan, that we adopted in connection with our IPO, our management is authorized to grant equity incentive awards to our employees, directors and consultants.

Initially, the aggregate number of our common shares that may be issued pursuant to share awards under the EIP was 21,280,000 shares. The number of common shares reserved for issuance under the EIP shall be cumulatively increased on January 1, 2022 and each January 1 thereafter by 5% of the total number of common shares outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our shareholders may experience additional dilution, which could cause our share price to fall.

Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies.

We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses on terms unfavorable to us.

We do not intend to pay dividends on our common shares, so any returns will be limited to the value of our common shares.

We currently anticipate that we will retain future earnings for the development, operation, expansion and continued investment into our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our common shares. Any return to shareholders will therefore be limited to the appreciation of their common shares, which may never occur.

Our principal shareholders and management own a significant percentage of our shares and will be able to exert significant influence over matters subject to shareholder approval.

Our executive officers, directors, and 5% shareholders beneficially currently own over twenty percent of our common shares in the aggregate, based on ownership information filed by such holders. Therefore, these shareholders have the ability to influence us through this ownership position. These shareholders may be able to determine all matters requiring shareholder approval. For example, these shareholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common shares that you may feel are in your best interest as one of our shareholders.

Sales of a substantial number of our common shares in the public market could cause our share price to fall significantly, even if our business is doing well.

Sales of a substantial number of our common shares in the public market could occur at any time. If our shareholders sell, or the market perceived that our shareholders intend to sell, substantial amounts of our common shares in the public market, the market price of our common shares could decline significantly.

We have filed registration statements on Form S-3 and on Form S-8 to register our common shares that are issuable pursuant to our equity incentive plans. Shares registered under Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options.

Additionally, certain holders of our common shares have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common shares could decline.

We are governed by the corporate laws of Canada which in some cases have a different effect on shareholders than the corporate laws of the United States.

We are governed by the Business Corporations Act (British Columbia), or BCBCA, and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction, and may, together with our charter documents, have the effect of delaying, deferring or discouraging another party from acquiring control of our company by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance. The material differences between the BCBCA and Delaware General Corporation Law, or DGCL, that may have the greatest such effect include, but are not limited to, the following: (i) for certain corporate transactions (such as mergers and amalgamations or amendments to our articles) the BCBCA generally requires the voting threshold to be a special resolution approved by 66 2/3% of shareholders, or as set out in the articles, as applicable, whereas DGCL generally only requires a majority vote; and (ii) under the BCBCA a holder of 5% or more of our common shares can requisition a special meeting of shareholders, whereas such right does not exist under the DGCL. We cannot predict whether investors will find our company and our common shares less attractive because we are governed by foreign laws.

Our articles and certain Canadian legislation contain provisions that may have the effect of delaying, preventing or making undesirable an acquisition of all or a significant portion of our shares or assets or preventing a change in control.

Certain provisions of our articles and certain provisions under the BCBCA, together or separately, could discourage, delay or prevent a merger, acquisition or other change in control of us that shareholders may consider favorable, including transactions in which they might otherwise receive a premium for their common shares. These provisions include the establishment of a staggered board of directors, which divides the board into three groups, with directors in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or remove incumbent members of our board of directors. As such, these provisions could also limit the price that investors might be willing to pay in the future for our common shares, thereby depressing the market price of our common shares. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace members of our board of directors. Among other things, these provisions include the following:

•

shareholders cannot amend our articles unless such amendment is approved by shareholders holding at least 66 2/3% of the shares entitled to vote on such approval;

•

our board of directors may, without shareholder approval, issue preferred shares in one or more series having any terms, conditions, rights, preferences and privileges as the board of directors may determine; and

•

shareholders must give advance notice to nominate directors or to submit proposals for consideration at shareholders’ meetings.

A non-Canadian must file an application for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a “Canadian business” within the meaning of the Investment Canada Act, where prescribed financial thresholds are exceeded. A reviewable acquisition may not proceed unless the Minister is satisfied that the investment is likely to be of net benefit to Canada. If the applicable financial thresholds were exceeded such that a net benefit to Canada review would be required, this could prevent or delay a change of control and may eliminate or limit strategic opportunities for shareholders to sell their common shares. Furthermore, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation has a pre-merger notification regime and mandatory waiting period that applies to certain types of transactions that meet specified financial thresholds, and permits the Commissioner of Competition to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us.

Our articles designate specific courts in Canada and the United States as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us.

Pursuant to our articles, unless we consent in writing to the selection of an alternative forum, the courts of the Province of British Columbia and the appellate courts therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of ours to us; (c) any action or proceeding asserting a claim arising out of any provision of the BCBCA or our articles (as either may be amended from time to time); or (d) any action or proceeding asserting a claim or otherwise related to our affairs, or the Canadian Forum Provision. The Canadian Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. In addition, our articles further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving any complaint filed in the United States asserting a cause of action arising under the Securities Act, or the U.S. Federal Forum Provision. In addition, our articles provide that any person or entity purchasing or otherwise acquiring any interest in our common shares is deemed to have notice of and consented to the Canadian Forum Provision and the U.S. Federal Forum Provision; provided, however, that shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.

The Canadian Forum Provision and the U.S. Federal Forum Provision in our articles may impose additional litigation costs on shareholders in pursuing any such claims. Additionally, the forum selection clauses in our amended articles may limit our shareholders’ ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are “facially valid” under Delaware law, there is uncertainty as to whether other courts, including courts in Canada and other courts within the U.S., will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The U.S. Federal Forum Provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The courts of the Province of British Columbia and the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.

Because we are a Canadian company, it may be difficult to serve legal process or enforce judgments against us.

We are incorporated and maintain operations in Canada. In addition, while certain of our directors and officers reside in the United States, many of them reside outside of the United States. Accordingly, service of process upon us may be difficult to obtain within the United States. Furthermore, because substantially all of our assets are located outside the United States, any judgment obtained in the United States against us, including one predicated on the civil liability provisions of the U.S. federal securities laws, may not be collectible within the United States. Therefore, it may not be possible to enforce those actions against us.

In addition, it may be difficult to assert U.S. securities law claims in original actions instituted in Canada. Canadian courts may refuse to hear a claim based on an alleged violation of U.S. securities laws against us or these persons on the grounds that Canada is not the most appropriate forum in which to bring such a claim. Even if a Canadian court agrees to hear a claim, it may determine that Canadian law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Canadian law. Furthermore, it may not be possible to subject foreign persons or entities to the jurisdiction of the courts in Canada. Similarly, to the extent that our assets are located in Canada, investors may have difficulty collecting from us any judgments obtained in the U.S. courts and predicated on the civil liability provisions of U.S. securities provisions.

If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.

The preparation of financial statements in conformity with generally accepted accounting principles in the United States, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates.” The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common shares.

Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on our reputation, business, financial position, and profit.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.

If we or our non-U.S. subsidiary is a CFC there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our common shares.

Each “Ten Percent Shareholder” (as defined below) in a non-U.S. corporation that is classified as a controlled foreign corporation, or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder’s pro rata share of the CFC’s “Subpart F income,” global intangible low taxed income, and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such Ten Percent Shareholder’s U.S. federal income tax return for the year for which reporting was due from starting.

A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly, indirectly, or constructively, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A “Ten Percent Shareholder” is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation.

The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. In addition, recent changes to the attribution rules relating to the determination of CFC status may make it difficult to determine our CFC status for any taxable year. In addition, those changes to the attribution rules may result in ownership of the stock of our non-U.S. subsidiaries being attributed to our U.S. subsidiaries, which could result in our non-U.S. subsidiaries being treated as CFCs and certain U.S. Holders of our common shares being treated as Ten Percent Shareholders of such non-U.S. subsidiary CFCs. In addition, it is possible that a shareholder treated as a U.S. person for U.S. federal income tax purposes will acquire, directly or indirectly, enough of

our common shares to be treated as a Ten Percent Shareholder. We believe that we and our non-U.S. subsidiaries will not be treated as CFCs in the 2021 taxable year solely by virtue of direct or indirect ownership by Ten Percent Shareholders. However, we believe that our non-U.S. subsidiaries may be treated as CFCs in the 2021 taxable year due to attribution rules that deem constructive ownership by our U.S. subsidiaries. It is unclear whether we would be treated as a CFC in a subsequent taxable year. We cannot provide any assurances that we will assist holders of our common shares in determining whether we or any of our non-U.S. subsidiaries are treated as a CFC or whether any holder of the common shares is treated as a Ten Percent Shareholder with respect to any such CFC or furnish to any Ten Percent Shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations.

U.S. Holders should consult their tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC, including the possibility and consequences of becoming a Ten Percent Shareholder in our non-U.S. subsidiaries that may be treated as CFCs due to the changes to the attribution rules. If we are classified as both a CFC and a PFIC (as defined below), we generally will not be treated as a PFIC with respect to those U.S. Holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC (referred to as the “CFC/PFIC overlap rule”). A “U.S. Holder” is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our common shares and is (i) an individual who is a citizen or resident of the United States, (ii) a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income taxation regardless of its source or (iv) a trust if (1) a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2) the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations. Recent proposed changes to PFIC regulations, if adopted, would expand the definition of “U.S. Holder” for purposes of the CFC/PFIC overlap rule and other PFIC rules, elections, and reporting requirements discussed below. The proposed regulations would require domestic partnerships and S-corporations to be treated as an aggregate of their partners or shareholders rather than as entities, which may result in such partners and shareholders to now be subject to the PFIC rules where they previously were not. It is unclear whether these proposed regulations may be adopted or if they will undergo further modifications before they are finalized. If adopted, it is also unclear when will be the effective date of the final regulations.

Our U.S. shareholders may suffer adverse tax consequences if we are characterized as a PFIC.

The rules governing passive foreign investment companies, or PFICs, can have adverse effects on U.S. Holders for U.S. federal income tax purposes. Generally, if, for any taxable year, at least 75% of our gross income is passive income (such as interest income), or at least 50% of the gross value of our assets (determined on the basis of a weighted quarterly average) is attributable to assets that produce passive income or are held for the production of passive income (including cash), we would be characterized as a PFIC for U.S. federal income tax purposes. The determination of whether we are a PFIC, which must be made annually after the close of each taxable year, depends on the particular facts and circumstances and may also be affected by the application of the PFIC rules, which are subject to differing interpretations. Our status as a PFIC will depend on the composition of our income and the composition and value of our assets (including goodwill and other intangible assets), which will be affected by how, and how quickly, we utilize any cash that was raised in any of our financing transactions. If we were a publicly traded CFC or not a CFC for any part of such year, the value of our assets generally may be determined by reference to the fair market value of our common shares, which may be volatile. Moreover, our ability to earn specific types of income that will be treated as non-passive for purposes of the PFIC rules is uncertain with respect to future years. We believe we were not classified as a PFIC during the taxable year ended December 31, 2021. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Accordingly, we cannot provide any assurances regarding our PFIC status for any current or future taxable years.

If we are classified as a PFIC, a U.S. Holder would be subject to adverse U.S. federal income tax consequences, such as ineligibility for certain preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements under U.S. federal income tax laws and regulations. A U.S. Holder may in certain circumstances mitigate adverse tax consequences of the PFIC rules by filing an election to treat the PFIC as a qualified electing fund, or QEF, or, if shares of the PFIC are “marketable stock” for purposes of the PFIC rules, by making a mark-to-market election with respect to the shares of the PFIC. U.S. Holders are urged to consult their own tax advisors regarding the potential consequences if we were or were to become classified as a PFIC, including the availability, and advisability, of, and procedure for, making QEF or mark-to-market elections.

Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.

A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including

amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a “permanent establishment” under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.

Changes in tax law could adversely affect our business and financial condition.

The rules dealing with U.S. federal, state, and local and non-U.S. taxation are constantly under review by persons involved in the legislative process, the Internal Revenue Service, the U.S. Treasury Department and other taxing authorities. Changes to tax laws or tax rulings, or changes in interpretations of existing laws (which changes may have retroactive application), could adversely affect us or holders of our common stock. These changes could subject us to additional income-based taxes and non-income taxes (such as payroll, sales, use, value-added, digital tax, net worth, property, and goods and services taxes), which in turn could materially affect our financial position and results of operations. Additionally, new, changed, modified, or newly interpreted or applied tax laws could increase our customers’ and our compliance, operating and other costs, as well as the costs of our products. In recent years, many such changes have been made, and changes are likely to continue to occur in the future. As we expand the scale of our business activities, any changes in the U.S. and non-U.S. taxation of such activities may increase our effective tax rate and harm our business, financial condition, and results of operations.

General Risk Factors

Our business has been and may continue to be adversely affected by the ongoing COVID-19 pandemic.

In late 2019, a novel strain of coronavirus, SARS-CoV-2, which resulted in the evolving COVID-19 pandemic, surfaced in Wuhan, China. Since then, COVID-19 has spread across the globe and to multiple regions within the United States and Canada, including British Columbia, where our primary office and laboratory space is located. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government imposed shelter-in-place orders, quarantines, travel restrictions and other public health safety measures, as well as reported adverse impacts on healthcare resources, facilities and providers, in Canada, across the United States and in other countries. In the event that government authorities were to further modify current restrictions, our employees conducting research and development or manufacturing activities may not be able to access our laboratory and manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.

As a result of the ongoing COVID-19 pandemic, or similar pandemics and outbreaks, we have experienced and may continue to experience severe delays and disruptions, including, for example:

•

interruption of or delays in receiving products and supplies from third parties;

•

limitations on our business operations by local, state, provincial and/or federal governments that could impact our ability to sell our data packages;

•

delays in negotiations with partners and potential partners;

•

increases in facilities costs to comply with physical distancing guidance;

•

business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working from home, travel limitations, cyber-security and data accessibility, or communication or mass transit disruptions; and

•

limitations on employee resources that would otherwise be focused on the conduct of our activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.

Any of these factors could severely impact our research and development activities, business operations and sales, or delay necessary interactions with local regulators, manufacturing sites and other important contractors and partners. These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19, could continue to spread to additional countries, or could return to countries where the pandemic has been partially contained, and could further adversely impact our ability to conduct our business generally and have a material adverse impact on our operations and financial condition and results.

The extent to which the COVID-19 pandemic may negatively impact our operations and results of operations or those of our stakeholders will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, additional or modified government actions,

new information that will emerge concerning the severity and impact of the COVID-19 pandemic and actions to contain the outbreak or treat its impact, such as social distancing, quarantines, lock-downs or business closures.

The ongoing military action between Russia and Ukraine and related sanctions could adversely affect our business, financial condition, and patent administration.

In February of 2022, Russian military forces invaded Ukraine, and sustained conflict and disruption in the region is likely. Although the length, impact and outcome of the ongoing military conflict in Ukraine is highly unpredictable, this conflict could lead to significant market disruptions, including significant volatility in commodity prices and supply of energy resources, instability in financial markets, higher inflation, supply chain interruptions, political and social instability, cyber attacks and cybersecurity threats, and could also aggravate the other risk factors that we identify herein.

In addition, the impact of sanctions against Russia and the potential retaliatory acts from Russia, could have a material adverse effect on our business and intellectual property rights. For example, we may be unable to obtain patent rights to our Trianni and microfluidic platforms as well as bamlanivimab which are protected in other jurisdictions around the world.

Our employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the applicable laws and regulations in the United States, Canada and abroad, report financial information or data accurately or disclose unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting and other business arrangements. Such misconduct could result in legal or regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and any other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations.

The market price of our common shares may be volatile, and you could lose all or part of your investment.

The trading price of our common shares is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume These factors include:

•

actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results;

•

the introduction of new technologies or enhancements to existing technology by us or others in our industry;

•

our inability to establish additional collaborations;

•

departures of key scientific or management personnel;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

•

our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

•

publication of research reports about us or our industry, or antibody discovery in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•

changes in the market valuations of similar companies;

•

overall performance of the equity markets;

•

sales of our common shares by us or our shareholders in the future;

•

trading volume of our common shares;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

significant lawsuits, including patent or shareholder litigation;

•

the impact of the ongoing COVID-19 pandemic on our business;

•

general political and economic conditions, including those resulting from the conflict between Russia and Ukraine and the attendant sanctions; and

•

other events or factors, many of which are beyond our control.

In addition, the stock market in general, and The Nasdaq Global Select Market and technology and life sciences companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common shares, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would harm our business, financial condition and results of operations.

Requirements associated with being a public company will increase our costs significantly, as well as divert significant company resources and management attention.

As of this report, we are subject to the reporting requirements of the Exchange Act or the other rules and regulations of the SEC and any securities exchange relating to public companies. Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market LLC, or Nasdaq, to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory ‘‘say on pay’’ voting requirements that apply to us since we ceased to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.

We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business. In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.

The trading market for our common shares will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Sale of Unregistered Securities

There were no unregistered sales of the Company’s equity securities during the three months ended June 30, 2022.

Use of Proceeds from our Initial Public Offering

On December 15, 2020, we completed the initial public offering, or IPO, of our common shares pursuant to which we issued and sold 27,772,500 common shares at a price to the public of $20.00 per share, which included the exercise in full of the underwriters’ option to purchase additional common shares.

The offer and sale of all of the common shares in our IPO was registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-250838), which was declared effective by the SEC on December 10, 2020. Credit Suisse Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Berenberg Capital Markets LLC, SVB Leerink LLC and BMO Capital Markets Corp. acted as the underwriters of our IPO.

We received aggregate gross proceeds from our IPO of $555.5 million, or aggregate net proceeds of $522.8 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common shares or to any of our affiliates.

Cash used since the IPO is described elsewhere in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our periodic reports filed with the SEC. There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus for our IPO.

Item 5. Other Information.

As previously reported in our Current Report on Form 8-K filed with the SEC on June 21, 2022, in a non-binding advisory vote held at the 2022 Annual Meeting of Shareholders on the frequency of future say-on-pay votes regarding the compensation of our named executive officers, our shareholders expressed their preference for a say-on-pay vote to be conducted every one year. After taking into consideration the voting results and the prior recommendation of our board of directors in favor of an annual shareholder advisory vote on the compensation of our named executive officers, our board of directors intends to hold future advisory votes on the compensation of our named executive officers every year. Our board of directors will re-evaluate this determination after the next shareholder advisory vote on the frequency of say-on-pay votes (which will be at the 2028 Annual Meeting of Shareholders, unless presented earlier).

Item 6. Exhibits.

The following exhibits are filed with this Quarterly Report on Form 10-Q:

Exhibit Number		Description

3.1		Articles of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 30, 2021).
4.1		Amended and Restated Investors Rights Agreement among the Registrant and certain of its shareholders, dated March 23, 2020 (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-250838) filed on November 20, 2020).
4.2		Form of Specimen Common Share Certificate (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-250838) filed on December 7, 2020).
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*	Filed herewith.

The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AbCellera Biologics Inc.

Date: August 9, 2022	By:	/s/ Carl L.G. Hansen
		Carl L.G. Hansen, Ph.D. Chief Executive Officer (Principal Executive Officer)

Date: August 9, 2022	By:	/s/ Andrew Booth
		Andrew Booth Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 abcl-ex311_8.htm EX-31.1 abcl-ex311_8.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Carl L. G. Hansen certify that:

1.	I have reviewed this quarterly report of AbCellera Biologics Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2022

By:

/s/ Carl L. G. Hansen

Carl L. G. Hansen, Ph.D.

Chief Executive Officer and Director

(Principal Executive Officer)

EX-31.2 3 abcl-ex312_7.htm EX-31.2 abcl-ex312_7.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew Booth, certify that:

1.	I have reviewed this quarterly report of AbCellera Biologics Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2022

By:

/s/ Andrew Booth

Andrew Booth

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 abcl-ex321_6.htm EX-32.1 abcl-ex321_6.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AbCellera Biologics Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 9, 2022

By:

/s/ Carl L. G. Hansen

Carl L. G. Hansen

Chief Executive Officer and Director

(Principal Executive Officer)

EX-32.2 5 abcl-ex322_9.htm EX-32.2 abcl-ex322_9.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 9, 2022

By:

/s/ Andrew Booth

Andrew Booth

Chief Financial Officer

(Principal Financial Officer)

GRAPHIC 6 gflfxvhuhguz000001.jpg GRAPHIC begin 644 gflfxvhuhguz000001.jpg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abcl-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Operations link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Net Earnings (Loss) Per Share link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Property and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Investments in and Loans to Equity Accounted Investees link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Accounts Payable and Other Liabilities link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Revenue link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Commitment and Contingencies link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Related Party Transaction link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Net Earnings (Loss) Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Property and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Accounts Payable and Other Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Shareholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Revenue (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Net Earnings (Loss) Per Share - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Investments in and Loans to Equity Accounted Investees - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Shareholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Shareholders' Equity - Summary of Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Shareholders' Equity - Summary of Restricted Share Units Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Revenue - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Revenue - Additional Information (Details1) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Revenue - Additional Information (Details1) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Related Party Transaction - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 abcl-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 abcl-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 abcl-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Period End Date Document Period End Date Current Fiscal Year End Date Current Fiscal Year End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Cash cash Equivalents and marketable securities. Accounts and accrued receivable, current. Deferred revenue and grant funding noncurrent. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Available For Sale Securities Debt Securities Total cash, cash equivalents, and marketable securities Cash Cash Equivalents And Marketable Securities Accounts and accrued receivable Accounts And Accrued Receivable Current Restricted cash Restricted Cash Other current assets Other Assets Current Total current assets Assets Current Long-term assets: Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Intangible assets, net Intangible Assets Net Excluding Goodwill Goodwill Goodwill Investments in and loans to equity accounted investees Investments In Affiliates Subsidiaries Associates And Joint Ventures Other long-term assets Other Assets Noncurrent Total long-term assets Assets Noncurrent Total assets Assets Liabilities and shareholders' equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable and other liabilities Accounts Payable And Other Accrued Liabilities Current portion of contingent consideration payable Business Combination Contingent Consideration Liability Current Income taxes payable Accrued Income Taxes Current Accrued royalties payable Accrued Royalties Current Deferred revenue Contract With Customer Liability Current Total current liabilities Liabilities Current Long-term liabilities: Liabilities Noncurrent [Abstract] Operating lease liability Operating Lease Liability Noncurrent Deferred revenue and grant funding Deferred Revenue And Grant Funding Noncurrent Contingent consideration payable Business Combination Contingent Consideration Liability Noncurrent Deferred tax liability Deferred Income Tax Liabilities Net Other long-term liabilities Other Liabilities Noncurrent Total long-term liabilities Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Shareholders' equity: Stockholders Equity [Abstract] Common shares: no par value, unlimited authorized shares at December 31, 2021 and June 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at December 31, 2021 and June 30, 2022, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated earnings Retained Earnings Accumulated Deficit Total shareholders' equity Stockholders Equity Total liabilities and shareholders' equity Liabilities And Stockholders Equity Common stock, no par value Common Stock No Par Value Common stock, shares authorized Common Stock Shares Authorized Unlimited Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Grants and Incentives. Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Research fees. Research Fees Research Fees [Member] Licensing Revenue License [Member] Milestone payments. Milestone Payments Milestone Payments [Member] Royalty Revenue Royalty [Member] Statement [Line Items] Statement [Line Items] Revenue: Revenues [Abstract] Total revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Royalty fees Royalty Expense Research and development Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Depreciation and amortization Depreciation And Amortization Total operating expenses Operating Expenses Income (loss) from operations Operating Income Loss Other (income) expense Nonoperating Income Expense [Abstract] Other (income) expense Other Nonoperating Income Expense Grants and incentives Grants And Incentives Total other (income) Nonoperating Income Expense Net earnings (loss) before income tax Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax (recovery) expense Income Tax Expense Benefit Net earnings (loss) Net Income Loss Foreign currency translation adjustment Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent Comprehensive income (loss) Comprehensive Income Net Of Tax Net earnings (loss) per share attributable to common shareholders Earnings Per Share [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Weighted-average common shares outstanding Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Stock issued and Restricted Stock Units vested during period shares stock options exercised. Stock issued and Restricted Stock Units vested during period value stock options exercised. Adjustments to additional paid in capital, reclassification of liability classified options. Statement Of Stockholders Equity [Abstract] Accumulated Earnings Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Shares Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Earnings Retained Earnings [Member] Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income [Member] Beginning balances Beginning balances, Shares Shares Outstanding Shares issued under stock option plan Stock Issued During Period Value Stock Options Exercised Shares issued under stock option plan, Shares Stock Issued During Period Shares Stock Options Exercised Shares issued and restricted stock units ("RSUs") vested under stock option plan Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised Shares issued and restricted stock units ("RSUs") vested under stock option plan, Shares Stock Issued And Restricted Stock Units Vested During Period Shares Stock Options Exercised Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Reclassification of liability classified options Adjustments To Additional Paid In Capital Reclassification Of Liability Classified Options Net earnings (loss) Ending balances Ending balances, Shares Increase (decrease) in accrued royalties receivable. Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable. Increase decrease in deferred grant income. Proceeds from receipt of grant funding. Payments to acquire long-term investments and other assets. Repayment of long-term debt and contingent consideration. Proceeds from debt and exercise of stock options. Payment of liability for in-licensing agreement. Non cash or part non cash acquisition property and equipment purchases in accounts payable. Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net income Profit Loss Cash flows from operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation of property and equipment Depreciation Amortization of intangible assets Amortization Of Intangible Assets Amortization of operating lease right-of-use assets Operating Lease Right Of Use Asset Amortization Expense Stock-based compensation Share Based Compensation Other Other Noncash Income Expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts and accrued research fees receivable Increase Decrease In Receivables Accrued royalties receivable Increase Decrease In Accrued Royalties Receivable Income taxes payable Increase Decrease In Accrued Income Taxes Payable Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable Deferred revenue Increase Decrease In Deferred Revenue Accrued royalties payable Increase Decrease In Royalties Payable Deferred grant revenue Increase Decrease In Deferred Grant Income Other assets Increase Decrease In Other Operating Assets Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchase of marketable securities Payments To Acquire Marketable Securities Proceeds from marketable securities Proceeds From Sale And Maturity Of Marketable Securities Receipt of grant funding Proceeds From Receipt Of Grant Funding Long-term investments and other assets Payments To Acquire Long Term Investments And Other Assets Investment in and loans to equity accounted investees Payments To Acquire Equity Method Investments Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Repayment of long-term debt and contingent consideration Repayment Of Long Term Debt And Contingent Consideration Proceeds from debt and exercise of stock options Proceeds From Debt And Exercise Of Stock Options Payment of liability for in-licensing agreement Payment Of Liability For In Licensing Agreement Net cash used in financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents and restricted cash, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents and restricted cash, end of period Restricted cash included in other assets Restricted Cash And Cash Equivalents Noncurrent Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Supplemental disclosure of non-cash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Property plant and equipment in accounts payable Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable Right-of-use assets obtained in exchange for operating lease obligation Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Operations Nature Of Operations Basis of presentation Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Net earnings (loss) per share Earnings Per Share [Text Block] Property Plant And Equipment [Abstract] Property and equipment, net Property Plant And Equipment Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Equity Method Investments And Joint Ventures [Abstract] Investments in and loans to equity accounted investees Equity Method Investments Disclosure [Text Block] Payables And Accruals [Abstract] Accounts Payable and Other Liabilities Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Shareholders' Equity Shareholders Equity And Share Based Payments [Text Block] Revenue From Contract With Customer [Abstract] Revenue Revenue From Contract With Customer [Text Block] Investments All Other Investments [Abstract] Financial instruments Financial Instruments Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transaction Related Party Transactions Disclosure [Text Block] Basis of presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Disclosure of accounting policy for unusual or infrequent items. COVID-19 Pandemic Unusual Or Infrequent Items Policy [Text Block] Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements Policy Policy [Text Block] Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Intangible Assets Schedule Of Finite Lived Intangible Assets Table [Text Block] Schedule of Estimated Amortization Expense on Intangible Assets Finite Lived Intangible Assets Amortization Expense Table [Text Block] Schedule of Accounts Payable and Other Liabilities Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Pre-initial public offering plan. Pre-IPO Plan Pre Initial Public Offering Plan [Member] 2020 Share option and incentive plan. 2020 Share Option and Incentive Plan Two Thousand Twenty Share Option And Incentive Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Share Units Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Summary of Stock-Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Deferred Revenue Outstanding Contract With Customer Asset And Liability Table [Text Block] Changes in Fair Value of Liability for Contingent Consideration Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Financial Assets Measured at Fair Value on Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Basic earnings (loss) per share Earnings Per Share Basic [Abstract] Net earnings (loss) attributable to common shareholders - basic Net Income Loss Available To Common Stockholders Basic Weighted-average common shares outstanding - basic Net earnings (loss) per share attributable to common shareholders - basic Diluted earnings (loss) per share Earnings Per Share Diluted [Abstract] Net earnings (loss) attributable to common shareholders - diluted Net Income Loss Available To Common Stockholders Diluted Stock options and RSUs Incremental Common Shares Attributable To Share Based Payment Arrangements Weighted-average common shares outstanding - diluted Net earnings (loss) per share attributable to common shareholders - diluted Total potential common shares excluded Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Computers Computer Equipment [Member] Land Land [Member] Laboratory equipment. Laboratory Equipment Laboratory Equipment [Member] Leasehold Improvements Leasehold Improvements [Member] Operating lease right-of-use assets. Operating Lease Right-of-use Assets Operating Lease Right Of Use Assets [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment Property Plant And Equipment Gross Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Leasehold improvements include tenant improvements Leasehold Improvements Gross Depreciation expense on property and equipment Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] License based intangible assets. License License Based Intangible Assets [Member] Technology Technology Based Intangible Assets [Member] IPR&D In Process Research And Development [Member] Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Gross carrying amount Finite Lived Intangible Assets Gross Accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Net book value 2023 Finite Lived Intangible Assets Amortization Expense Next Twelve Months 2024 Finite Lived Intangible Assets Amortization Expense Year Two 2025 Finite Lived Intangible Assets Amortization Expense Year Three 2026 Finite Lived Intangible Assets Amortization Expense Year Four 2027 Finite Lived Intangible Assets Amortization Expense Year Five Finite lived intangible assets amortization expense Finite Lived Intangible Assets Net Number of joint ventures. Schedule Of Equity Method Investments [Table] Schedule Of Equity Method Investments [Table] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Dayhu joint venture. Dayhu JV Dayhu Joint Venture [Member] Beedie joint venture. Beedie JV Beedie Joint Venture [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum [Member] Minimum [Member] Schedule Of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Number Of Joint Ventures Number Of Joint Ventures Equity investment balance, contributions made in joint venture Payments To Acquire Interest In Subsidiaries And Affiliates Equity method investment, commitment amount. Equity method investment, outstanding related party loan. Percentage of construction loan. Equity method investment, commitment amount Equity Method Investment Commitment Amount Commitment amount, repayment term Debt Instrument Term Commitment amount, maturity date Debt Instrument Maturity Date Debt instrument, repayment description Debt Instrument Payment Terms Equity method investment, outstanding related party loan Equity Method Investment Outstanding Related Party Loan Percentage of construction loan Percentage Of Construction Loan Liability for in-licensing agreement current. Deferred grant funding current. Accounts payable and accrued liabilities Accounts Payable And Accrued Liabilities Current Liability for in-licensing agreement Liability For In Licensing Agreement Current Operating lease liability Operating Lease Liability Current Payroll liabilities Employee Related Liabilities Current Current portion of deferred grant funding Deferred Grant Funding Current Total accounts payable and other liabilities Accounts Payable And Other Accrued Liabilities Current Number of shares available for issuance Common Stock Capital Shares Reserved For Future Issuance Number of Shares Outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of Shares, Exercised Number of Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number of Shares Outstanding, Ending Balance Number of Options exercisable as of March 31, 2022 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted-Average Exercise Price, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Ending Balance Weighted-Average Exercise Price, Options exercisable as of March 31, 2022 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted Share Units (RSUs) Restricted Stock Units R S U [Member] Number of Shares Outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Number of Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Number of Shares, Vested and settled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Number of Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Number of Shares Outstanding, Ending Balance Weighted-Average Grant Date Fair Value, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Vested and settled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Ending Balance Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Sales and Marketing Selling And Marketing Expense [Member] Stock-based compensation expense Allocated Share Based Compensation Expense Deferred revenue Contract With Customer Liability Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Research, collaboration and license agreement. Research, Collaboration and License Agreement Research Collaboration And License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Eli Lilly. Eli Lilly Eli Lilly [Member] Various other agreements. Various Other Agreements Various Other Agreements [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Contract with customer liability, revenue recognized Contract With Customer Liability Revenue Recognized Milestone payment threshold amount. Low to mid-teens royalty threshold sales amount. Mid-teens to mid-twenties royalty threshold sales amount. Milestone payment threshold amount Milestone Payment Threshold Amount Low to mid-teens royalty threshold sales amount Low To Mid Teens Royalty Threshold Sales Amount Mid-teens to mid-twenties royalty threshold sales amount Mid Teens To Mid Twenties Royalty Threshold Sales Amount Upfront payment received. Upfront payment received Upfront Payment Received Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Revenue, remaining performance obligation Revenue Remaining Performance Obligation Revenue, remaining performance obligation, expected timing of satisfaction period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Contingent consideration. Contingent Consideration Contingent Consideration [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 3 Fair Value Inputs Level3 [Member] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Trianni. Trianni Trianni [Member] TetraGenetics. TetraGenetics Inc Tetra Genetic [Member] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Liability at beginning of the period Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Increase (decrease) in fair value of liability for contingent consideration Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Liability at end of the period Measurement Input Type Measurement Input Type [Axis] Measurement Input Type Measurement Input Type [Domain] Measurement Input, Discount Rate Measurement Input Discount Rate [Member] Discount rate Alternative Investment Measurement Input Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Corporate Bonds Corporate Bond Securities [Member] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] US Government Agencies U S Government Agencies Debt Securities [Member] Certificate of Deposit Certificates Of Deposit [Member] Commercial Paper Commercial Paper [Member] Asset Backed Securities Asset Backed Securities [Member] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value Measurements on Recurring Basis Fair Value Measurements Recurring [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Marketable securities. Marketable Securities Marketable Securities [Member] Assets Assets Fair Value Disclosure Lessee Lease Description [Table] Lessee Lease Description [Table] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Current liabilities. Current Liabilities Current Liabilities [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Phase 1. Phase 1 Phase One [Member] Phase 2. Phase 2 Phase Two [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Royalty expensed Strategic innovation fund eligible expenditure. Strategic innovation fund eligible expenditure Strategic Innovation Fund Eligible Expenditure Accrued liabilities, current Accrued Liabilities Current Related party transaction advisory services. Related party transaction adviser fee paid. Advisory services Related Party Transaction Advisory Services Adviser fee paid Related Party Transaction Adviser Fee Paid EX-101.PRE 11 abcl-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2022

Aug. 04, 2022

Cover [Abstract]

Document Type 10-Q

Amendment Flag false

Document Fiscal Year Focus 2022

Document Fiscal Period Focus Q2

Document Period End Date Jun. 30, 2022

Current Fiscal Year End Date --12-31

Entity Registrant Name AbCellera Biologics Inc.

Entity Central Index Key 0001703057

Entity Tax Identification Number 00-0000000

Entity File Number 001-39781

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Large Accelerated Filer

Entity Small Business false

Entity Emerging Growth Company false

Entity Shell Company false

Entity Incorporation, State or Country Code A1

Entity Address, Address Line One 2215 Yukon Street

Entity Address, City or Town Vancouver

Entity Address, State or Province BC

Entity Address, Postal Zip Code V5Y 0A1

City Area Code 604

Local Phone Number 559-9005

Title of 12(b) Security Common shares, no par value per share

Trading Symbol ABCL

Security Exchange Name NASDAQ

Document Quarterly Report true

Document Transition Report false

Entity Common Stock, Shares Outstanding 285,138,643

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 308
-Subsection a
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Current assets:

Cash and cash equivalents $ 790,615 $ 476,142

Marketable securities 231,652 246,835

Total cash, cash equivalents, and marketable securities 1,022,267 722,977

Accounts and accrued receivable 52,797 160,576

Restricted cash 25,000 25,000

Other current assets 43,891 21,247

Total current assets 1,143,955 929,800

Long-term assets:

Property and equipment, net 149,178 111,616

Intangible assets, net 143,179 148,392

Goodwill 47,806 47,806

Investments in and loans to equity accounted investees 65,824 50,313

Other long-term assets 43,842 30,642

Total long-term assets 449,829 388,769

Total assets 1,593,784 1,318,569

Current liabilities:

Accounts payable and other liabilities 24,390 32,017

Current portion of contingent consideration payable 34,252 22,934

Income taxes payable 107,322 35,683

Accrued royalties payable 50,555 22,506

Deferred revenue 4,621 7,536

Total current liabilities 221,140 120,676

Long-term liabilities:

Operating lease liability 32,759 36,413

Deferred revenue and grant funding 64,800 60,758

Contingent consideration payable 24,629 35,886

Deferred tax liability 34,616 37,370

Other long-term liabilities 2,984 1,733

Total long-term liabilities 159,788 172,160

Total liabilities 380,928 292,836

Commitments and contingencies

Shareholders' equity:

Common shares: no par value, unlimited authorized shares at December 31, 2021 and June 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at December 31, 2021 and June 30, 2022, respectively 726,825 722,430

Additional paid-in capital 56,001 35,357

Accumulated other comprehensive income 576 280

Accumulated earnings 429,454 267,666

Total shareholders' equity 1,212,856 1,025,733

Total liabilities and shareholders' equity $ 1,593,784 $ 1,318,569

X

- Definition
Accounts and accrued receivable, current.
+ References
No definition available.
+ Details

Name: abcl_AccountsAndAccruedReceivableCurrent

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash cash Equivalents and marketable securities.
+ References
No definition available.
+ Details

Name: abcl_CashCashEquivalentsAndMarketableSecurities

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Deferred revenue and grant funding noncurrent.
+ References
No definition available.
+ Details

Name: abcl_DeferredRevenueAndGrantFundingNoncurrent

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedRoyaltiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in equity method investee and investment in and advance to affiliate.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
+ Details

Name: us-gaap_RestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
6 Months Ended 12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Statement Of Financial Position [Abstract]

Common stock, no par value

Common stock, shares authorized Unlimited Unlimited

Common stock, shares issued 285,052,302 283,257,104

Common stock, shares outstanding 285,052,302 283,257,104

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorizedUnlimited

Namespace Prefix: us-gaap_

Data Type: us-types:authorizedUnlimitedItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Revenue:

Total revenue $ 45,917 $ 27,643 $ 362,497 $ 230,384

Operating expenses:

Royalty fees 5,210 3,610 49,847 23,622

Research and development ^[1] 26,685 15,046 53,052 27,403

Sales and marketing ^[1] 3,120 1,295 5,490 3,869

General and administrative ^[1] 14,412 11,203 28,680 17,688

Depreciation and amortization 4,886 3,522 8,875 6,827

Total operating expenses 54,313 34,676 145,944 79,409

Income (loss) from operations (8,396) (7,033) 216,553 150,975

Other (income) expense

Other (income) expense 25 (314) (641) (645)

Grants and incentives (1,535) (4,646) (6,730) (7,794)

Total other (income) (1,510) (4,960) (7,371) (8,439)

Net earnings (loss) before income tax (6,886) (2,073) 223,924 159,414

Income tax (recovery) expense (101) 250 62,136 44,516

Net earnings (loss) (6,785) (2,323) 161,788 114,898

Foreign currency translation adjustment (211) 2,152 296 2,152

Comprehensive income (loss) $ (6,996) $ (171) $ 162,084 $ 117,050

Net earnings (loss) per share attributable to common shareholders

Basic $ (0.02) $ (0.01) $ 0.57 $ 0.42

Diluted $ (0.02) $ (0.01) $ 0.52 $ 0.36

Weighted-average common shares outstanding

Basic 284,686,542 272,196,107 284,292,312 270,953,541

Diluted 284,686,542 272,196,107 313,361,183 321,555,443

Research Fees

Revenue:

Total revenue $ 12,538 $ 5,215 $ 21,871 $ 9,201

Licensing Revenue

Revenue:

Total revenue 147 263 377 20,522

Milestone Payments

Revenue:

Total revenue 1,000 8,000

Royalty Revenue

Revenue:

Total revenue $ 33,232 $ 21,165 $ 340,249 $ 192,661

[1] Exclusive of depreciation and amortization

X

- Definition
Grants and Incentives.
+ References
No definition available.
+ Details

Name: abcl_GrantsAndIncentives

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=abcl_ResearchFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=abcl_MilestonePaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands

Total

Common Shares

Additional Paid-in Capital

Accumulated Earnings

Accumulated Other Comprehensive Income

Beginning balances at Dec. 31, 2020 $ 830,508 $ 710,387 $ 5,919 $ 114,202

Beginning balances, Shares at Dec. 31, 2020 269,497,768

Shares issued under stock option plan 173 $ 752 (579)

Shares issued under stock option plan, Shares 1,428,162

Stock-based compensation expense 4,021 4,021

Reclassification of liability classified options 5,201 5,201

Net earnings (loss) 117,221 117,221

Ending balances at Mar. 31, 2021 957,124 $ 711,139 14,562 231,423

Ending balances, Shares at Mar. 31, 2021 270,925,930

Beginning balances at Dec. 31, 2020 830,508 $ 710,387 5,919 114,202

Beginning balances, Shares at Dec. 31, 2020 269,497,768

Foreign currency translation adjustment 2,152

Net earnings (loss) 114,898

Ending balances at Jun. 30, 2021 967,679 $ 714,758 21,669 229,100 $ 2,152

Ending balances, Shares at Jun. 30, 2021 276,982,678

Beginning balances at Mar. 31, 2021 957,124 $ 711,139 14,562 231,423

Beginning balances, Shares at Mar. 31, 2021 270,925,930

Shares issued under stock option plan 1,779 $ 3,619 (1,840)

Shares issued under stock option plan, Shares 6,056,748

Stock-based compensation expense 8,473 8,473

Reclassification of liability classified options 474 474

Foreign currency translation adjustment 2,152 2,152

Net earnings (loss) (2,323) (2,323)

Ending balances at Jun. 30, 2021 967,679 $ 714,758 21,669 229,100 2,152

Ending balances, Shares at Jun. 30, 2021 276,982,678

Beginning balances at Dec. 31, 2021 1,025,733 $ 722,430 35,357 267,666 280

Beginning balances, Shares at Dec. 31, 2021 283,257,104

Shares issued and restricted stock units ("RSUs") vested under stock option plan 403 $ 3,325 (2,922)

Shares issued and restricted stock units ("RSUs") vested under stock option plan, Shares 1,264,077

Stock-based compensation expense 12,291 12,291

Foreign currency translation adjustment 507 507

Net earnings (loss) 168,573 168,573

Ending balances at Mar. 31, 2022 1,207,507 $ 725,755 44,726 436,239 787

Ending balances, Shares at Mar. 31, 2022 284,521,181

Beginning balances at Dec. 31, 2021 1,025,733 $ 722,430 35,357 267,666 280

Beginning balances, Shares at Dec. 31, 2021 283,257,104

Foreign currency translation adjustment 296

Net earnings (loss) 161,788

Ending balances at Jun. 30, 2022 1,212,856 $ 726,825 56,001 429,454 576

Ending balances, Shares at Jun. 30, 2022 285,052,302

Beginning balances at Mar. 31, 2022 1,207,507 $ 725,755 44,726 436,239 787

Beginning balances, Shares at Mar. 31, 2022 284,521,181

Shares issued and restricted stock units ("RSUs") vested under stock option plan 232 $ 1,070 (838)

Shares issued and restricted stock units ("RSUs") vested under stock option plan, Shares 531,121

Stock-based compensation expense 12,113 12,113

Foreign currency translation adjustment (211) (211)

Net earnings (loss) (6,785) (6,785)

Ending balances at Jun. 30, 2022 $ 1,212,856 $ 726,825 $ 56,001 $ 429,454 $ 576

Ending balances, Shares at Jun. 30, 2022 285,052,302

X

- Definition
Adjustments to additional paid in capital, reclassification of liability classified options.
+ References
No definition available.
+ Details

Name: abcl_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Stock issued and Restricted Stock Units vested during period shares stock options exercised.
+ References
No definition available.
+ Details

Name: abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: abcl_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock issued and Restricted Stock Units vested during period value stock options exercised.
+ References
No definition available.
+ Details

Name: abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Cash flows from operating activities:

Net income $ 161,788 $ 114,898

Cash flows from operating activities:

Depreciation of property and equipment 3,681 1,897

Amortization of intangible assets 5,213 4,930

Amortization of operating lease right-of-use assets 2,120 1,354

Stock-based compensation 24,404 13,900

Other (298) 337

Changes in operating assets and liabilities:

Accounts and accrued research fees receivable (6,963) (28,339)

Accrued royalties receivable 106,583 172,768

Income taxes payable 52,251 (30,330)

Accounts payable and accrued liabilities (1,882) (3,640)

Deferred revenue (2,979) 4,848

Accrued royalties payable 28,049 (3,623)

Deferred grant revenue 5,406 22,349

Other assets (4,139) (4,121)

Net cash provided by operating activities 373,234 267,228

Cash flows from investing activities:

Purchases of property and equipment (45,817) (40,448)

Purchase of marketable securities (134,306)

Proceeds from marketable securities 145,808

Receipt of grant funding 8,098 4,520

Long-term investments and other assets (11,657) (5,034)

Investment in and loans to equity accounted investees (15,694) (20,510)

Net cash used in investing activities (53,568) (61,472)

Cash flows from financing activities:

Repayment of long-term debt and contingent consideration (73) (4,373)

Proceeds from debt and exercise of stock options 2,175 2,755

Payment of liability for in-licensing agreement (4,060) (5,000)

Net cash used in financing activities (1,958) (6,618)

Effect of exchange rate changes on cash and cash equivalents (1,411) (683)

Increase in cash and cash equivalents 316,297 198,455

Cash and cash equivalents and restricted cash, beginning of period 501,142 594,116

Cash and cash equivalents and restricted cash, end of period 817,439 792,571

Restricted cash included in other assets (1,824)

Total cash, cash equivalents and restricted cash shown in the statement of cash flows 815,615 792,571

Supplemental disclosure of non-cash investing and financing activities

Property plant and equipment in accounts payable 2,146

Right-of-use assets obtained in exchange for operating lease obligation $ (796) $ 29,573

X

- Definition
Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable.
+ References
No definition available.
+ Details

Name: abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase (decrease) in accrued royalties receivable.
+ References
No definition available.
+ Details

Name: abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Increase decrease in deferred grant income.
+ References
No definition available.
+ Details

Name: abcl_IncreaseDecreaseInDeferredGrantIncome

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Non cash or part non cash acquisition property and equipment purchases in accounts payable.
+ References
No definition available.
+ Details

Name: abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation.
+ References
No definition available.
+ Details

Name: abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payment of liability for in-licensing agreement.
+ References
No definition available.
+ Details

Name: abcl_PaymentOfLiabilityForInLicensingAgreement

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Payments to acquire long-term investments and other assets.
+ References
No definition available.
+ Details

Name: abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds from debt and exercise of stock options.
+ References
No definition available.
+ Details

Name: abcl_ProceedsFromDebtAndExerciseOfStockOptions

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from receipt of grant funding.
+ References
No definition available.
+ Details

Name: abcl_ProceedsFromReceiptOfGrantFunding

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Repayment of long-term debt and contingent consideration.
+ References
No definition available.
+ Details

Name: abcl_RepaymentOfLongTermDebtAndContingentConsideration

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInRoyaltiesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense for right-of-use asset from operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2

Nature of Operations
6 Months Ended

Jun. 30, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Operations
1. Nature of operations

AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. The Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI https://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2

Basis of Presentation
6 Months Ended

Jun. 30, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of presentation
2. Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2021.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2021 and 2022 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021.

All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI https://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI https://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI https://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2

Significant Accounting Policies
6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Significant Accounting Policies
3. Significant accounting policies

Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

COVID-19 Pandemic

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the

carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s condensed consolidated financial statements.

Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI https://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2

Net Earnings (Loss) Per Share
6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Net earnings (loss) per share
4. Net earnings (loss) per share

Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:

Three months ended June 30,

Six months ended June 30,

2021

2022

2021

2022

Basic earnings (loss) per share

Net earnings (loss) attributable to common shareholders - basic

$

(2,323

)

$

(6,785

)

$

114,898

$

161,788

Weighted-average common shares outstanding - basic

272,196,107

284,686,542

270,953,541

284,292,312

Net earnings (loss) per share attributable to common shareholders - basic

$

(0.01

)

$

(0.02

)

$

0.42

$

0.57

Diluted earnings (loss) per share

Net earnings (loss) attributable to common shareholders - diluted

$

(2,323

)

$

(6,785

)

$

114,898

$

161,788

Weighted-average common shares outstanding - basic

272,196,107

284,686,542

270,953,541

284,292,312

Stock options and RSUs

-

-

50,601,902

29,068,871

Weighted-average common shares outstanding - diluted

272,196,107

284,686,542

321,555,443

313,361,183

Net earnings (loss) per share attributable to common shareholders - diluted

$

(0.01

)

$

(0.02

)

$

0.36

$

0.52

The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three months ended June 30, 2021 and June 30, 2022, as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended June 30, 2021 and June 30, 2022 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.

The Company excluded 47,221,295 and nil potential common shares for the three and six months ended June 30, 2021, respectively, and 48,678,673 and 11,937,411 potential common shares for the three and six months ended June 30, 2022, respectively, from the computation of diluted net earnings (loss) per share attributable to common shareholders because including them would have had an anti-dilutive effect.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI https://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2

Property and Equipment, Net
6 Months Ended

Jun. 30, 2022

Property Plant And Equipment [Abstract]

Property and equipment, net
5. Property and equipment, net

Property and equipment, net consisted of the following:

December 31, 2021

June 30, 2022

Computers

$

7,843

$

7,961

Land

33,044

53,405

Laboratory equipment

18,805

32,407

Leasehold improvements

23,962

32,160

Operating lease right-of-use assets

37,788

36,464

Property and equipment

121,442

162,397

Less accumulated depreciation

(9,826

)

(13,219

)

Property and equipment, net

$

111,616

$

149,178

As of December 31, 2021 and June 30, 2022, leasehold improvements include tenant improvements in progress that have not commenced depreciation in the amount of $19.8 million and $7.7 million, respectively. Depreciation expense on property and equipment for the three and six months ended June 30, 2021 was $1.1 million and $1.9 million, respectively, and $2.3 million and $3.7 million, for the three and six months ended June 30, 2022, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI https://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2

Intangible Assets
6 Months Ended

Jun. 30, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets
6. Intangible assets

Intangible assets consisted of the following:

June 30, 2022

Gross

carrying

amount

Accumulated

amortization

Net book

value

License

$

35,873

$

13,889

$

21,984

Technology

52,700

3,905

48,795

IPR&D

72,400

-

72,400

$

160,973

$

17,794

$

143,179

Amortization expense on intangible assets is estimated to be as follows for each of the next five years ended June 30:

Amortization

Expense

2023

$

10,425

2024

8,803

2025

4,041

2026

4,041

2027

4,041

$

31,351

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-URI https://asc.fasb.org/subtopic&trid=2144471
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2

Investments in and Loans to Equity Accounted Investees
6 Months Ended

Jun. 30, 2022

Equity Method Investments And Joint Ventures [Abstract]

Investments in and loans to equity accounted investees
7. Investments in and loans to equity accounted investees

The Company has entered into two joint ventures as part of the construction of future office and laboratory headquarters. During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). As of June 30, 2022, the equity investment balance of $19.8 million represents the contributions made since inception. In March, 2021, the Company entered into the Beedie joint venture (Beedie JV). To date, the equity investment balance of $15.2 million represents contributions made since inception into the Beedie JV. To date, the Company has recorded immaterial amounts of its proportionate income or loss with respect to both ventures.

In March, 2021, the Company made a commitment of up to CAD $82.7 million ($61.5 million) to the Dayhu JV to fund the construction at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the joint venture. As of December 31, 2021, and June 30, 2022, the outstanding related party loan balance was $18.0 million and $30.8 million, respectively, to the joint venture.

In June 2022, the Company made a commitment to Beedie for a land loan of up to CAD $7.5 million ($5.8 million) plus a construction loan for up to 80% of Beedie’s share of construction costs. The commitment is at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement of the construction loan and five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the joint venture.

Subsequent to June 30, 2022, the Company entered into an agreement of up to CAD $46.0 million ($35.7 million) with Dayhu to replace the outstanding construction loan balance as at January 1, 2023, at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement. The agreement has a maturity of December 31, 2025, with a call provision, callable by the Company after September 30, 2023, including customary make whole provisions. The loan is secured by the underlying land and existing and future assets of the joint venture.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-URI https://asc.fasb.org/topic&trid=2196965
+ Details

Name: us-gaap_EquityMethodInvestmentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2

Accounts Payable and Other Liabilities
6 Months Ended

Jun. 30, 2022

Payables And Accruals [Abstract]

Accounts Payable and Other Liabilities
8. Accounts payable and other liabilities

Accounts payable and other liabilities consisted of the following:

December 31, 2021

June 30, 2022

Accounts payable and accrued liabilities

$

14,924

$

10,313

Liability for in-licensing agreement

4,933

-

Operating lease liability

3,652

4,023

Payroll liabilities

4,035

4,282

Current portion of deferred grant funding

4,473

5,772

Total accounts payable and other liabilities

$

32,017

$

24,390

X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2

Shareholders' Equity
6 Months Ended

Jun. 30, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Shareholders' Equity
9. Shareholders’ equity

Sixth Amended and Restated Stock Option Plan:

The Company maintains the AbCellera Biologics Inc. Sixth Amended and Restated Stock Option Plan and our Pre-IPO Plan. Any awards granted under the Pre-IPO Plan will remain subject to the terms of our Pre-IPO Plan and applicable award agreements.

2020 Share Option and Incentive Plan:

Our 2020 Share Option and Incentive Plan, or 2020 Plan, was approved by our board of directors on November 18, 2020, and approved by our shareholders on December 1, 2020.

As of June 30, 2022, the number of shares available for issuance under the 2020 Plan was 24,415,404, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.

The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2021:

Number of

Shares

Weighted-

Average Exercise

Price

Outstanding as of December 31, 2021

39,206,307

$

0.86

Granted

-

-

Exercised

(1,734,149

)

0.37

Forfeited

(451,917

)

0.27

Outstanding as of June 30, 2022

37,020,241

$

0.89

Options exercisable as of June 30, 2022

20,705,504

0.61

The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2021:

Number of

Shares

Weighted-

Average Exercise

Price

Outstanding as of December 31, 2021

5,284,347

$

19.19

Granted

3,583,848

10.88

Exercised

-

-

Forfeited

(327,546

)

15.90

Outstanding as of June 30, 2022

8,540,649

$

15.83

Options exercisable as of June 30, 2022

584,306

26.07

As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and are subject to annual vesting. The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2021:

Number of

Shares

Weighted-

Average Grant

Date Fair Value

Outstanding as of December 31, 2021

1,080,413

$

23.62

Granted

2,289,954

10.88

Vested and settled

(61,178

)

45.52

Forfeited

(192,481

)

15.87

Outstanding as of June 30, 2022

3,116,708

$

14.31

Stock-based compensation:

Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:

Three months ended June 30,

Six months ended June 30,

2021

2022

2021

2022

Research and development

$

3,720

$

6,264

$

6,877

$

12,201

Sales and marketing

161

475

1,116

1,469

General and administrative

4,592

5,374

5,907

10,734

$

8,473

$

12,113

$

13,900

$

24,404

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI https://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2

Revenue
6 Months Ended

Jun. 30, 2022

Revenue From Contract With Customer [Abstract]

Revenue
10. Revenue

The disaggregated revenue categories are presented on the face of the condensed consolidated statements of income (loss) and comprehensive income (loss).

Deferred revenue

Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.

Deferred revenue outstanding in each respective period is as follows:

December 31, 2020

June 30, 2021

December 31, 2021

June 30, 2022

Deferred revenue

$

26,321

$

31,232

$

34,954

$

32,004

During the three and six months ended June 30, 2021, the Company recognized $1.8 million and $3.4 million, respectively, and $6.3 million and $7.7 million during the three and six months ended June 30, 2022, respectively, of revenue that had been included in deferred revenue in the previous year.

In March of 2020, the Company entered into a research collaboration and license agreement with Eli Lilly pursuant to which the Company will perform discovery research for several targets for Eli Lilly to develop and commercialize. Under the agreement, the Company is entitled to receive an aggregate of up to $29.0 million of milestone payments as well as royalties in the low single digits based on net sales for non-COVID-19 targets and in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million.

The agreement resulted in an initial upfront payment of $26.7 million, of which $21.9 million was included in deferred revenue at December 31, 2020. In the year ended December 31, 2021, the Company received an additional $1.7 million in payments, for total payments received in respect of this agreement of $28.4 million. In the six months ended June 30, 2022, the Company received $0.6 million in additional payments. The Company recognized $3.8 million and $4.3 million of revenue in the three and six months ended June 30, 2022, respectively. The Company expects to recognize approximately $1.4 million in revenue in the next 12 months related to these payments under the agreement.

Of the remaining deferred revenue balance of $15.2 million, which is related to various other agreements, approximately $3.2 million is expected to be recognized in revenue in the next 12 months.

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2

Financial Instruments
6 Months Ended

Jun. 30, 2022

Investments All Other Investments [Abstract]

Financial instruments
11. Financial instruments

Fair Value Measurements

The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.

The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans to equity accounted investees, accounts payable and accrued liabilities and royalties payable, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, royalties payable, and loans to equity accounted investees approximate their fair values.

Contingent Consideration

Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition.

The following table presents the changes in fair value of the liability for contingent consideration:

Six months ended June 30, 2022

Liability at

beginning of

the period

Increase (decrease) in fair

value of liability for contingent

consideration

Liability at

end of the

period

Trianni (i)

$

22,934

$

574

$

23,508

TetraGenetics (ii)

$

35,886

$

(513

)

$

35,373

i)

The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.

ii)

The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 8%, the rate that measures the risks inherent in the future cash flows.

Marketable Securities

As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations.

Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.

The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:

Fair Value Measurements at June 30, 2022:

Level 1

Level 2

Level 3

Total

Marketable securities

U.S. government agencies

$

17,358

$

-

$

-

$

17,358

Certificate of deposit

-

20,875

-

20,875

Commercial paper

-

34,711

-

34,711

Corporate bonds

-

142,392

-

142,392

Asset backed securities

-

16,316

-

16,316

$

17,358

$

214,294

$

-

$

231,652

X

- Definition
The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.
+ References
No definition available.
+ Details

Name: us-gaap_FinancialInstrumentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2

Commitment and Contingencies
6 Months Ended

Jun. 30, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies
12. Commitments and contingencies

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.

The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.

Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three and six months ended June 30, 2022, the Company has expensed approximately $5.2 million and $49.8 million, respectively, related to such obligations, of which $50.6 million is included in current liabilities.

Since inception, the Company has incurred expenditures of $44.9 million and $26.3 million under phase 1 and 2, respectively, under the Canadian government’s Strategic Innovation Fund, or SIF. Spending under phase 1 of the agreement and such amounts are not repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of June 30, 2022, no amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable as of June 30, 2022.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI https://asc.fasb.org/topic&trid=2144648

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 440
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI https://asc.fasb.org/topic&trid=2127136

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2

Related Party Transaction
6 Months Ended

Jun. 30, 2022

Related Party Transactions [Abstract]

Related Party Transaction
13. Related Party Transaction

In addition to the loans to the equity accounted investees disclosed in Note 7, the Company had the following related party transactions:

During the second quarter, the Company engaged advisory services with a firm co-founded by a director of the Company in the amount of up to $0.3 million, of which $0.1 million was paid and included in other assets at June 30, 2022.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI https://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2

Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Basis of presentation Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2021.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2021 and 2022 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021.

All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

Use of Estimates
Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

COVID-19 Pandemic
COVID-19 Pandemic

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the

carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s condensed consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted
Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.

X

- Definition
Disclosure of accounting policy for unusual or infrequent items.
+ References
No definition available.
+ Details

Name: abcl_UnusualOrInfrequentItemsPolicyTextBlock

Namespace Prefix: abcl_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2

Net Earnings (Loss) Per Share (Tables)
6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders
Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:

Three months ended June 30,

Six months ended June 30,

2021

2022

2021

2022

Basic earnings (loss) per share

Net earnings (loss) attributable to common shareholders - basic

$

(2,323

)

$

(6,785

)

$

114,898

$

161,788

Weighted-average common shares outstanding - basic

272,196,107

284,686,542

270,953,541

284,292,312

Net earnings (loss) per share attributable to common shareholders - basic

$

(0.01

)

$

(0.02

)

$

0.42

$

0.57

Diluted earnings (loss) per share

Net earnings (loss) attributable to common shareholders - diluted

$

(2,323

)

$

(6,785

)

$

114,898

$

161,788

Weighted-average common shares outstanding - basic

272,196,107

284,686,542

270,953,541

284,292,312

Stock options and RSUs

-

-

50,601,902

29,068,871

Weighted-average common shares outstanding - diluted

272,196,107

284,686,542

321,555,443

313,361,183

Net earnings (loss) per share attributable to common shareholders - diluted

$

(0.01

)

$

(0.02

)

$

0.36

$

0.52

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2

Property and Equipment, Net (Tables)
6 Months Ended

Jun. 30, 2022

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment, Net
Property and equipment, net consisted of the following:

December 31, 2021

June 30, 2022

Computers

$

7,843

$

7,961

Land

33,044

53,405

Laboratory equipment

18,805

32,407

Leasehold improvements

23,962

32,160

Operating lease right-of-use assets

37,788

36,464

Property and equipment

121,442

162,397

Less accumulated depreciation

(9,826

)

(13,219

)

Property and equipment, net

$

111,616

$

149,178

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2

Intangible Assets (Tables)
6 Months Ended

Jun. 30, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets
Intangible assets consisted of the following:

June 30, 2022

Gross

carrying

amount

Accumulated

amortization

Net book

value

License

$

35,873

$

13,889

$

21,984

Technology

52,700

3,905

48,795

IPR&D

72,400

-

72,400

$

160,973

$

17,794

$

143,179

Schedule of Estimated Amortization Expense on Intangible Assets
Amortization expense on intangible assets is estimated to be as follows for each of the next five years ended June 30:

Amortization

Expense

2023

$

10,425

2024

8,803

2025

4,041

2026

4,041

2027

4,041

$

31,351

X

- Definition
Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2

Accounts Payable and Other Liabilities (Tables)
6 Months Ended

Jun. 30, 2022

Payables And Accruals [Abstract]

Schedule of Accounts Payable and Other Liabilities
Accounts payable and other liabilities consisted of the following:

December 31, 2021

June 30, 2022

Accounts payable and accrued liabilities

$

14,924

$

10,313

Liability for in-licensing agreement

4,933

-

Operating lease liability

3,652

4,023

Payroll liabilities

4,035

4,282

Current portion of deferred grant funding

4,473

5,772

Total accounts payable and other liabilities

$

32,017

$

24,390

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2

Shareholders' Equity (Tables)
6 Months Ended

Jun. 30, 2022

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Restricted Share Units Activity The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2021:

Number of

Shares

Weighted-

Average Grant

Date Fair Value

Outstanding as of December 31, 2021

1,080,413

$

23.62

Granted

2,289,954

10.88

Vested and settled

(61,178

)

45.52

Forfeited

(192,481

)

15.87

Outstanding as of June 30, 2022

3,116,708

$

14.31

Summary of Stock-Based Compensation Expense
Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:

Three months ended June 30,

Six months ended June 30,

2021

2022

2021

2022

Research and development

$

3,720

$

6,264

$

6,877

$

12,201

Sales and marketing

161

475

1,116

1,469

General and administrative

4,592

5,374

5,907

10,734

$

8,473

$

12,113

$

13,900

$

24,404

Pre-IPO Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Stock Option Activity
The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2021:

Number of

Shares

Weighted-

Average Exercise

Price

Outstanding as of December 31, 2021

39,206,307

$

0.86

Granted

-

-

Exercised

(1,734,149

)

0.37

Forfeited

(451,917

)

0.27

Outstanding as of June 30, 2022

37,020,241

$

0.89

Options exercisable as of June 30, 2022

20,705,504

0.61

2020 Share Option and Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Stock Option Activity
The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2021:

Number of

Shares

Weighted-

Average Exercise

Price

Outstanding as of December 31, 2021

5,284,347

$

19.19

Granted

3,583,848

10.88

Exercised

-

-

Forfeited

(327,546

)

15.90

Outstanding as of June 30, 2022

8,540,649

$

15.83

Options exercisable as of June 30, 2022

584,306

26.07

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=abcl_PreInitialPublicOfferingPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2

Revenue (Tables)
6 Months Ended

Jun. 30, 2022

Revenue From Contract With Customer [Abstract]

Summary of Deferred Revenue Outstanding
Deferred revenue outstanding in each respective period is as follows:

December 31, 2020

June 30, 2021

December 31, 2021

June 30, 2022

Deferred revenue

$

26,321

$

31,232

$

34,954

$

32,004

X

- Definition
Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2

Financial Instruments (Tables)
6 Months Ended

Jun. 30, 2022

Investments All Other Investments [Abstract]

Changes in Fair Value of Liability for Contingent Consideration
The following table presents the changes in fair value of the liability for contingent consideration:

Six months ended June 30, 2022

Liability at

beginning of

the period

Increase (decrease) in fair

value of liability for contingent

consideration

Liability at

end of the

period

Trianni (i)

$

22,934

$

574

$

23,508

TetraGenetics (ii)

$

35,886

$

(513

)

$

35,373

Summary of Financial Assets Measured at Fair Value on Recurring Basis
The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:

Fair Value Measurements at June 30, 2022:

Level 1

Level 2

Level 3

Total

Marketable securities

U.S. government agencies

$

17,358

$

-

$

-

$

17,358

Certificate of deposit

-

20,875

-

20,875

Commercial paper

-

34,711

-

34,711

Corporate bonds

-

142,392

-

142,392

Asset backed securities

-

16,316

-

16,316

$

17,358

$

214,294

$

-

$

231,652

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2

Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Basic earnings (loss) per share

Net earnings (loss) attributable to common shareholders - basic $ (6,785) $ (2,323) $ 161,788 $ 114,898

Weighted-average common shares outstanding - basic 284,686,542 272,196,107 284,292,312 270,953,541

Net earnings (loss) per share attributable to common shareholders - basic $ (0.02) $ (0.01) $ 0.57 $ 0.42

Diluted earnings (loss) per share

Net earnings (loss) attributable to common shareholders - diluted $ (6,785) $ (2,323) $ 161,788 $ 114,898

Weighted-average common shares outstanding - basic 284,686,542 272,196,107 284,292,312 270,953,541

Stock options and RSUs 29,068,871 50,601,902

Weighted-average common shares outstanding - diluted 284,686,542 272,196,107 313,361,183 321,555,443

Net earnings (loss) per share attributable to common shareholders - diluted $ (0.02) $ (0.01) $ 0.52 $ 0.36

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2

Net Earnings (Loss) Per Share - Additional Information (Details) - shares
3 Months Ended 6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Earnings Per Share [Abstract]

Total potential common shares excluded 48,678,673 47,221,295 11,937,411 0

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Property Plant And Equipment [Line Items]

Property and equipment $ 162,397 $ 121,442

Less accumulated depreciation (13,219) (9,826)

Property and equipment, net 149,178 111,616

Computers

Property Plant And Equipment [Line Items]

Property and equipment 7,961 7,843

Land

Property Plant And Equipment [Line Items]

Property and equipment 53,405 33,044

Laboratory Equipment

Property Plant And Equipment [Line Items]

Property and equipment 32,407 18,805

Leasehold Improvements

Property Plant And Equipment [Line Items]

Property and equipment 32,160 23,962

Operating Lease Right-of-use Assets

Property Plant And Equipment [Line Items]

Property and equipment $ 36,464 $ 37,788

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_LaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_OperatingLeaseRightOfUseAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2

Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Leasehold improvements include tenant improvements $ 7,700 $ 7,700 $ 19,800

Depreciation expense on property and equipment $ 2,300 $ 1,100 $ 3,681 $ 1,897

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_LeaseholdImprovementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Finite Lived Intangible Assets [Line Items]

Gross carrying amount $ 160,973

Accumulated amortization 17,794

Net book value 143,179 $ 148,392

License

Finite Lived Intangible Assets [Line Items]

Gross carrying amount 35,873

Accumulated amortization 13,889

Net book value 21,984

Technology

Finite Lived Intangible Assets [Line Items]

Gross carrying amount 52,700

Accumulated amortization 3,905

Net book value 48,795

IPR&D

Finite Lived Intangible Assets [Line Items]

Gross carrying amount 72,400

Net book value $ 72,400

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abcl_LicenseBasedIntangibleAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2

Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)
$ in Thousands

Jun. 30, 2022

USD ($)

Goodwill And Intangible Assets Disclosure [Abstract]

2023 $ 10,425

2024 8,803

2025 4,041

2026 4,041

2027 4,041

Finite lived intangible assets amortization expense $ 31,351

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2

Investments in and Loans to Equity Accounted Investees - Additional Information (Details)
1 Months Ended 6 Months Ended 16 Months Ended

Jun. 30, 2022

USD ($)

Jun. 30, 2022

CAD ($)

Mar. 31, 2021

USD ($)

Mar. 31, 2021

CAD ($)

Jun. 30, 2022

USD ($)

JointVenture

Jun. 30, 2022

USD ($)

Jun. 30, 2022

CAD ($)

Mar. 31, 2022

USD ($)

Dec. 31, 2021

USD ($)

Schedule Of Equity Method Investments [Line Items]

Number Of Joint Ventures | JointVenture 2

Equity method investment, outstanding related party loan $ 46,000,000.0

Dayhu JV

Schedule Of Equity Method Investments [Line Items]

Equity investment balance, contributions made in joint venture $ 19,800,000

Commitment amount, repayment term 30 months 30 months

Commitment amount, maturity date Dec. 31, 2025 Dec. 31, 2025 Sep. 01, 2023 Sep. 01, 2023

Debt instrument, repayment description repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement.

Equity method investment, outstanding related party loan $ 35,700,000 $ 35,700,000 $ 35,700,000 $ 30,800,000 $ 18,000,000.0

Dayhu JV | Maximum

Schedule Of Equity Method Investments [Line Items]

Equity method investment, commitment amount $ 61,500,000 $ 82,700,000

Beedie JV

Schedule Of Equity Method Investments [Line Items]

Equity investment balance, contributions made in joint venture $ 15,200,000

Commitment amount, repayment term 30 months 30 months

Debt instrument, repayment description repayment on the earlier of thirty months from the date of initial advancement of the construction loan and five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement

Beedie JV | Maximum

Schedule Of Equity Method Investments [Line Items]

Equity method investment, commitment amount $ 5,800,000 $ 7,500,000

Percentage of construction loan 80.00% 80.00%

X

- Definition
Equity method investment, commitment amount.
+ References
No definition available.
+ Details

Name: abcl_EquityMethodInvestmentCommitmentAmount

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Equity method investment, outstanding related party loan.
+ References
No definition available.
+ Details

Name: abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of joint ventures.
+ References
No definition available.
+ Details

Name: abcl_NumberOfJointVentures

Namespace Prefix: abcl_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of construction loan.
+ References
No definition available.
+ Details

Name: abcl_PercentageOfConstructionLoan

Namespace Prefix: abcl_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(3))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_BeedieJointVentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2

Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Payables And Accruals [Abstract]

Accounts payable and accrued liabilities $ 10,313 $ 14,924

Liability for in-licensing agreement 4,933

Operating lease liability 4,023 3,652

Payroll liabilities 4,282 4,035

Current portion of deferred grant funding 5,772 4,473

Total accounts payable and other liabilities $ 24,390 $ 32,017

X

- Definition
Deferred grant funding current.
+ References
No definition available.
+ Details

Name: abcl_DeferredGrantFundingCurrent

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Liability for in-licensing agreement current.
+ References
No definition available.
+ Details

Name: abcl_LiabilityForInLicensingAgreementCurrent

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2

Shareholders' Equity - Additional Information (Details)

Jun. 30, 2022

shares

2020 Share Option and Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of shares available for issuance 24,415,404

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2

Shareholders' Equity - Summary of Stock Option Activity (Details)
6 Months Ended

Jun. 30, 2022

$ / shares

shares

Pre-IPO Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of Shares Outstanding, Beginning Balance | shares 39,206,307

Number of Shares, Exercised | shares (1,734,149)

Number of Shares, Forfeited | shares (451,917)

Number of Shares Outstanding, Ending Balance | shares 37,020,241

Number of Options exercisable as of March 31, 2022 | shares 20,705,504

Weighted-Average Exercise Price, Beginning Balance | $ / shares $ 0.86

Weighted-Average Exercise Price, Exercised | $ / shares 0.37

Weighted-Average Exercise Price, Forfeited | $ / shares 0.27

Weighted-Average Exercise Price, Ending Balance | $ / shares 0.89

Weighted-Average Exercise Price, Options exercisable as of March 31, 2022 | $ / shares $ 0.61

2020 Share Option and Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of Shares Outstanding, Beginning Balance | shares 5,284,347

Number of Shares, Granted | shares 3,583,848

Number of Shares, Forfeited | shares (327,546)

Number of Shares Outstanding, Ending Balance | shares 8,540,649

Number of Options exercisable as of March 31, 2022 | shares 584,306

Weighted-Average Exercise Price, Beginning Balance | $ / shares $ 19.19

Weighted-Average Exercise Price, Granted | $ / shares 10.88

Weighted-Average Exercise Price, Forfeited | $ / shares 15.90

Weighted-Average Exercise Price, Ending Balance | $ / shares 15.83

Weighted-Average Exercise Price, Options exercisable as of March 31, 2022 | $ / shares $ 26.07

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=abcl_PreInitialPublicOfferingPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2

Shareholders' Equity - Summary of Restricted Share Units Activity (Details) - 2020 Share Option and Incentive Plan - Restricted Share Units (RSUs)
6 Months Ended

Jun. 30, 2022

$ / shares

shares

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of Shares Outstanding, Beginning Balance | shares 1,080,413

Number of Shares, Granted | shares 2,289,954

Number of Shares, Vested and settled | shares (61,178)

Number of Shares, Forfeited | shares (192,481)

Number of Shares Outstanding, Ending Balance | shares 3,116,708

Weighted-Average Grant Date Fair Value, Beginning Balance | $ / shares $ 23.62

Weighted-Average Grant Date Fair Value, Granted | $ / shares 10.88

Weighted-Average Grant Date Fair Value, Vested and settled | $ / shares 45.52

Weighted-Average Grant Date Fair Value, Forfeited | $ / shares 15.87

Weighted-Average Grant Date Fair Value, Ending Balance | $ / shares $ 14.31

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2

Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense $ 12,113 $ 8,473 $ 24,404 $ 13,900

Research and Development

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense 6,264 3,720 12,201 6,877

General and Administrative

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense 5,374 4,592 10,734 5,907

Sales and Marketing

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense $ 475 $ 161 $ 1,469 $ 1,116

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2

Revenue - Summary of Deferred Revenue Outstanding (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Jun. 30, 2021

Dec. 31, 2020

Revenue From Contract With Customer [Abstract]

Deferred revenue $ 32,004 $ 34,954 $ 31,232 $ 26,321

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2

Revenue - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2021

Mar. 31, 2020

Disaggregation Of Revenue [Line Items]

Contract with customer liability, revenue recognized $ 6,300,000 $ 1,800,000 $ 7,700,000 $ 3,400,000

Deferred revenue 32,004,000 $ 31,232,000 32,004,000 $ 31,232,000 $ 34,954,000 $ 26,321,000 $ 34,954,000

Research, Collaboration and License Agreement | Eli Lilly

Disaggregation Of Revenue [Line Items]

Contract with customer liability, revenue recognized 3,800,000 4,300,000

Upfront payment received 0.6 $ 1,700,000 26,700,000 $ 28,400,000

Deferred revenue $ 21,900,000

Research, Collaboration and License Agreement | Maximum | Eli Lilly

Disaggregation Of Revenue [Line Items]

Milestone payment threshold amount $ 29,000,000.0

Low to mid-teens royalty threshold sales amount 125,000,000.0

Research, Collaboration and License Agreement | Minimum [Member] | Eli Lilly

Disaggregation Of Revenue [Line Items]

Mid-teens to mid-twenties royalty threshold sales amount $ 125,000,000.0

Various Other Agreements

Disaggregation Of Revenue [Line Items]

Deferred revenue $ 15,200,000 $ 15,200,000

X

- Definition
Low to mid-teens royalty threshold sales amount.
+ References
No definition available.
+ Details

Name: abcl_LowToMidTeensRoyaltyThresholdSalesAmount

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Mid-teens to mid-twenties royalty threshold sales amount.
+ References
No definition available.
+ Details

Name: abcl_MidTeensToMidTwentiesRoyaltyThresholdSalesAmount

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Milestone payment threshold amount.
+ References
No definition available.
+ Details

Name: abcl_MilestonePaymentThresholdAmount

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Upfront payment received.
+ References
No definition available.
+ Details

Name: abcl_UpfrontPaymentReceived

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=abcl_ResearchCollaborationAndLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=abcl_EliLillyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=abcl_VariousOtherAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
$ in Millions

Jun. 30, 2022

USD ($)

Research, Collaboration and License Agreement | Eli Lilly

Disaggregation Of Revenue [Line Items]

Revenue, remaining performance obligation $ 1.4

Revenue, remaining performance obligation, expected timing of satisfaction period 12 months

Various Other Agreements

Disaggregation Of Revenue [Line Items]

Revenue, remaining performance obligation $ 3.2

Revenue, remaining performance obligation, expected timing of satisfaction period 12 months

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_TypeOfArrangementAxis=abcl_ResearchCollaborationAndLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=abcl_EliLillyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=abcl_VariousOtherAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2

Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) - Contingent Consideration - Level 3
$ in Thousands
6 Months Ended

Jun. 30, 2022

USD ($)

Trianni

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Liability at beginning of the period $ 22,934 ^[1]

Increase (decrease) in fair value of liability for contingent consideration 574 ^[1]

Liability at end of the period 23,508 ^[1]

TetraGenetics Inc

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Liability at beginning of the period 35,886 ^[2]

Increase (decrease) in fair value of liability for contingent consideration (513) ^[2]

Liability at end of the period $ 35,373 ^[2]

[1]
The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.

[2]
The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 8%, the rate that measures the risks inherent in the future cash flows.

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=abcl_ContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abcl_TrianniMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abcl_TetraGeneticMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2

Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical) - Measurement Input, Discount Rate

Jun. 30, 2022

Trianni

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Discount rate 22

TetraGenetics Inc

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Discount rate 8

X

- Definition
Value of input used to measure alternative investment.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_AlternativeInvestmentMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abcl_TrianniMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abcl_TetraGeneticMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2

Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements on Recurring Basis - Marketable Securities
$ in Thousands

Jun. 30, 2022

USD ($)

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets $ 231,652

US Government Agencies

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 17,358

Certificate of Deposit

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 20,875

Commercial Paper

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 34,711

Asset Backed Securities

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 16,316

Level 1

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 17,358

Level 1 | US Government Agencies

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 17,358

Level 2

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 214,294

Level 2 | Certificate of Deposit

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 20,875

Level 2 | Commercial Paper

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 34,711

Level 2 | Asset Backed Securities

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 16,316

Corporate Bonds

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets 142,392

Corporate Bonds | Level 2

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Assets $ 142,392

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=abcl_MarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2

Commitments and Contingencies - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Lessee Lease Description [Line Items]

Royalty expensed $ 5,210,000 $ 3,610,000 $ 49,847,000 $ 23,622,000

Accrued liabilities, current $ 0 0

Phase 1

Lessee Lease Description [Line Items]

Strategic innovation fund eligible expenditure 44,900,000

Phase 2

Lessee Lease Description [Line Items]

Strategic innovation fund eligible expenditure 26,300,000

Current Liabilities

Lessee Lease Description [Line Items]

Royalty expensed $ 50,600,000

X

- Definition
Strategic innovation fund eligible expenditure.
+ References
No definition available.
+ Details

Name: abcl_StrategicInnovationFundEligibleExpenditure

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=abcl_CurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2

Related Party Transaction - Additional Information (Details)
$ in Millions
6 Months Ended

Jun. 30, 2022

USD ($)

Related Party Transactions [Abstract]

Advisory services $ 0.3

Adviser fee paid $ 0.1

X

- Definition
Related party transaction adviser fee paid.
+ References
No definition available.
+ Details

Name: abcl_RelatedPartyTransactionAdviserFeePaid

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Related party transaction advisory services.
+ References
No definition available.
+ Details

Name: abcl_RelatedPartyTransactionAdvisoryServices

Namespace Prefix: abcl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 abcl-10q_20220630_htm.xml IDEA: XBRL DOCUMENT 0001703057 2022-01-01 2022-06-30 0001703057 2022-08-04 0001703057 2021-12-31 0001703057 2022-06-30 0001703057 2021-01-01 2021-12-31 0001703057 abcl:ResearchFeesMember 2021-04-01 2021-06-30 0001703057 abcl:ResearchFeesMember 2022-04-01 2022-06-30 0001703057 abcl:ResearchFeesMember 2021-01-01 2021-06-30 0001703057 abcl:ResearchFeesMember 2022-01-01 2022-06-30 0001703057 us-gaap:LicenseMember 2021-04-01 2021-06-30 0001703057 us-gaap:LicenseMember 2022-04-01 2022-06-30 0001703057 us-gaap:LicenseMember 2021-01-01 2021-06-30 0001703057 us-gaap:LicenseMember 2022-01-01 2022-06-30 0001703057 abcl:MilestonePaymentsMember 2021-04-01 2021-06-30 0001703057 abcl:MilestonePaymentsMember 2021-01-01 2021-06-30 0001703057 us-gaap:RoyaltyMember 2021-04-01 2021-06-30 0001703057 us-gaap:RoyaltyMember 2022-04-01 2022-06-30 0001703057 us-gaap:RoyaltyMember 2021-01-01 2021-06-30 0001703057 us-gaap:RoyaltyMember 2022-01-01 2022-06-30 0001703057 2021-04-01 2021-06-30 0001703057 2022-04-01 2022-06-30 0001703057 2021-01-01 2021-06-30 0001703057 us-gaap:CommonStockMember 2021-12-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001703057 us-gaap:RetainedEarningsMember 2021-12-31 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001703057 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001703057 2022-01-01 2022-03-31 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001703057 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001703057 us-gaap:CommonStockMember 2022-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001703057 us-gaap:RetainedEarningsMember 2022-03-31 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001703057 2022-03-31 0001703057 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001703057 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001703057 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001703057 us-gaap:CommonStockMember 2022-06-30 0001703057 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001703057 us-gaap:RetainedEarningsMember 2022-06-30 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001703057 us-gaap:CommonStockMember 2020-12-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001703057 us-gaap:RetainedEarningsMember 2020-12-31 0001703057 2020-12-31 0001703057 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001703057 2021-01-01 2021-03-31 0001703057 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001703057 us-gaap:CommonStockMember 2021-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001703057 us-gaap:RetainedEarningsMember 2021-03-31 0001703057 2021-03-31 0001703057 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001703057 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001703057 us-gaap:CommonStockMember 2021-06-30 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001703057 us-gaap:RetainedEarningsMember 2021-06-30 0001703057 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001703057 2021-06-30 0001703057 abcl:PreInitialPublicOfferingPlanMember 2022-01-01 2022-06-30 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2022-01-01 2022-06-30 0001703057 us-gaap:ComputerEquipmentMember 2021-12-31 0001703057 us-gaap:ComputerEquipmentMember 2022-06-30 0001703057 us-gaap:LandMember 2021-12-31 0001703057 us-gaap:LandMember 2022-06-30 0001703057 abcl:LaboratoryEquipmentMember 2021-12-31 0001703057 abcl:LaboratoryEquipmentMember 2022-06-30 0001703057 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001703057 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001703057 abcl:OperatingLeaseRightOfUseAssetsMember 2021-12-31 0001703057 abcl:OperatingLeaseRightOfUseAssetsMember 2022-06-30 0001703057 abcl:LicenseBasedIntangibleAssetsMember 2022-06-30 0001703057 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-06-30 0001703057 us-gaap:InProcessResearchAndDevelopmentMember 2022-06-30 0001703057 abcl:DayhuJointVentureMember 2022-01-01 2022-06-30 0001703057 abcl:BeedieJointVentureMember 2021-03-01 2022-06-30 0001703057 srt:MaximumMember abcl:DayhuJointVentureMember 2021-03-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2021-03-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2022-06-01 2022-06-30 0001703057 abcl:DayhuJointVentureMember 2021-12-31 0001703057 abcl:DayhuJointVentureMember 2022-03-31 0001703057 abcl:DayhuJointVentureMember 2022-06-30 0001703057 srt:MaximumMember abcl:BeedieJointVentureMember 2022-06-01 2022-06-30 0001703057 abcl:BeedieJointVentureMember 2022-06-01 2022-06-30 0001703057 abcl:BeedieJointVentureMember 2022-01-01 2022-06-30 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2022-06-30 0001703057 abcl:PreInitialPublicOfferingPlanMember 2021-12-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2022-06-30 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-12-31 0001703057 us-gaap:RestrictedStockUnitsRSUMember abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-12-31 0001703057 us-gaap:RestrictedStockUnitsRSUMember abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2022-01-01 2022-06-30 0001703057 us-gaap:RestrictedStockUnitsRSUMember abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2022-06-30 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001703057 us-gaap:SellingAndMarketingExpenseMember 2021-04-01 2021-06-30 0001703057 us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001703057 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-06-30 0001703057 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001703057 abcl:EliLillyMember srt:MaximumMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-03-31 0001703057 abcl:EliLillyMember srt:MinimumMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-03-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-01-01 2020-12-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2021-01-01 2021-12-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-01-01 2021-12-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2022-01-01 2022-06-30 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-12-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2022-04-01 2022-06-30 0001703057 abcl:EliLillyMember 2022-01-01 abcl:ResearchCollaborationAndLicenseAgreementMember 2022-06-30 0001703057 abcl:VariousOtherAgreementsMember 2022-06-30 0001703057 2022-01-01 abcl:VariousOtherAgreementsMember 2022-06-30 0001703057 abcl:TrianniMember us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2021-12-31 0001703057 abcl:TetraGeneticMember us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2021-12-31 0001703057 abcl:TrianniMember us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2022-01-01 2022-06-30 0001703057 abcl:TetraGeneticMember us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2022-01-01 2022-06-30 0001703057 abcl:TrianniMember us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2022-06-30 0001703057 abcl:TetraGeneticMember us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2022-06-30 0001703057 abcl:TrianniMember us-gaap:MeasurementInputDiscountRateMember 2022-06-30 0001703057 abcl:TetraGeneticMember us-gaap:MeasurementInputDiscountRateMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:MarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001703057 abcl:CurrentLiabilitiesMember 2022-01-01 2022-06-30 0001703057 abcl:PhaseOneMember 2022-01-01 2022-06-30 0001703057 abcl:PhaseTwoMember 2022-01-01 2022-06-30 shares iso4217:USD iso4217:USD shares abcl:JointVenture iso4217:CAD pure false Q2 --12-31 0001703057 00-0000000 Unlimited Unlimited 0 0 10-Q true 2022-06-30 2022 false 001-39781 AbCellera Biologics Inc. A1 2215 Yukon Street Vancouver BC V5Y 0A1 604 559-9005 Common shares, no par value per share ABCL NASDAQ Yes Yes Large Accelerated Filer false false false 285138643 476142000 790615000 246835000 231652000 722977000 1022267000 160576000 52797000 25000000 25000000 21247000 43891000 929800000 1143955000 111616000 149178000 148392000 143179000 47806000 47806000 50313000 65824000 30642000 43842000 388769000 449829000 1318569000 1593784000 32017000 24390000 22934000 34252000 35683000 107322000 22506000 50555000 7536000 4621000 120676000 221140000 36413000 32759000 60758000 64800000 35886000 24629000 37370000 34616000 1733000 2984000 172160000 159788000 292836000 380928000 283257104 283257104 285052302 285052302 722430000 726825000 35357000 56001000 280000 576000 267666000 429454000 1025733000 1212856000 1318569000 1593784000 5215000 12538000 9201000 21871000 263000 147000 20522000 377000 1000000 8000000 21165000 33232000 192661000 340249000 27643000 45917000 230384000 362497000 3610000 5210000 23622000 49847000 15046000 26685000 27403000 53052000 1295000 3120000 3869000 5490000 11203000 14412000 17688000 28680000 3522000 4886000 6827000 8875000 34676000 54313000 79409000 145944000 -7033000 -8396000 150975000 216553000 314000 -25000 645000 641000 4646000 1535000 7794000 6730000 4960000 1510000 8439000 7371000 -2073000 -6886000 159414000 223924000 250000 -101000 44516000 62136000 -2323000 -6785000 114898000 161788000 2152000 -211000 2152000 296000 -171000 -6996000 117050000 162084000 -0.01 -0.02 0.42 0.57 -0.01 -0.02 0.36 0.52 272196107 284686542 270953541 284292312 272196107 284686542 321555443 313361183 283257104 722430000 35357000 267666000 280000 1025733000 1264077 3325000 -2922000 403000 12291000 12291000 507000 507000 168573000 168573000 284521181 725755000 44726000 436239000 787000 1207507000 531121 1070000 -838000 232000 12113000 12113000 -211000 -211000 -6785000 -6785000 285052302 726825000 56001000 429454000 576000 1212856000 269497768 710387000 5919000 114202000 830508000 1428162 752000 -579000 173000 4021000 4021000 5201000 5201000 117221000 117221000 270925930 711139000 14562000 231423000 957124000 6056748 3619000 -1840000 1779000 8473000 8473000 474000 474000 2152000 2152000 -2323000 -2323000 276982678 714758000 21669000 229100000 2152000 967679000 114898000 161788000 1897000 3681000 4930000 5213000 1354000 2120000 13900000 24404000 -337000 298000 28339000 6963000 -172768000 -106583000 -30330000 52251000 -3640000 -1882000 4848000 -2979000 -3623000 28049000 -22349000 -5406000 4121000 4139000 267228000 373234000 40448000 45817000 134306000 145808000 4520000 8098000 5034000 11657000 20510000 15694000 -61472000 -53568000 4373000 73000 2755000 2175000 5000000 4060000 -6618000 -1958000 -683000 -1411000 198455000 316297000 594116000 501142000 792571000 817439000 1824000 792571000 815615000 2146000 29573000 -796000 1. Nature of operations AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. The Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. 2. Basis of presentation <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2021. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2021 and 2022 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars. Basis of presentation <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2021. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2021 and 2022 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars. 3. Significant accounting policies <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates. <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s condensed consolidated financial statements. <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements not yet adopted <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption. <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates. <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s condensed consolidated financial statements. <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements not yet adopted <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption. 4. Net earnings (loss) per share Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic earnings (loss) per share</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,323</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,785</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,898</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,788</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,196,107</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,686,542</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,953,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,292,312</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.02</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.42</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.57</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Diluted earnings (loss) per share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,323</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,785</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,898</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,788</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,196,107</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,686,542</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,953,541</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,292,312</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options and RSUs</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,601,902</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,068,871</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - diluted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,196,107</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,686,542</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,555,443</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,361,183</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.02</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.52</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three months ended June 30, 2021 and June 30, 2022, as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended June 30, 2021 and June 30, 2022 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded 47,221,295 and nil potential common shares for the three and six months ended June 30, 2021, respectively, and 48,678,673 and 11,937,411 potential common shares for the three and six months ended June 30, 2022, respectively, from the computation of diluted net earnings (loss) per share attributable to common shareholders because including them would have had an anti-dilutive effect. Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic earnings (loss) per share</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,323</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,785</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,898</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,788</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,196,107</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,686,542</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,953,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,292,312</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.02</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.42</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.57</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Diluted earnings (loss) per share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,323</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,785</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,898</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,788</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,196,107</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,686,542</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,953,541</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,292,312</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options and RSUs</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,601,902</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,068,871</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - diluted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,196,107</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,686,542</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,555,443</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,361,183</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.02</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.52</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> -2323000 -6785000 114898000 161788000 272196107 284686542 270953541 284292312 -0.01 -0.02 0.42 0.57 -2323000 -6785000 114898000 161788000 272196107 284686542 270953541 284292312 50601902 29068871 272196107 284686542 321555443 313361183 -0.01 -0.02 0.36 0.52 47221295 48678673 11937411 5. Property and equipment, net Property and equipment, net consisted of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,843</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,961</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,405</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,805</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,407</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,962</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,160</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,788</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,464</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,442</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,397</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,826</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,219</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,616</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,178</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> As of December 31, 2021 and June 30, 2022, leasehold improvements include tenant improvements in progress that have not commenced depreciation in the amount of $19.8 million and $7.7 million, respectively. Depreciation expense on property and equipment for the three and six months ended June 30, 2021 was $1.1 million and $1.9 million, respectively, and $2.3 million and $3.7 million, for the three and six months ended June 30, 2022, respectively. Property and equipment, net consisted of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,843</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,961</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,405</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,805</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,407</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,962</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,160</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,788</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,464</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,442</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,397</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,826</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,219</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,616</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,178</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 7843000 7961000 33044000 53405000 18805000 32407000 23962000 32160000 37788000 36464000 121442000 162397000 9826000 13219000 111616000 149178000 19800000 7700000 1100000 1900000 2300000 3700000 6. Intangible assets Intangible assets consisted of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">carrying <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amount</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net book <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,873</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,889</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,984</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,700</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,905</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,795</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&D</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,400</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,400</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,973</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,794</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,179</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense on intangible assets is estimated to be as follows for each of the next five years ended June 30: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,425</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,803</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,351</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Intangible assets consisted of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">carrying <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amount</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net book <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,873</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,889</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,984</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,700</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,905</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,795</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&D</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,400</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,400</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,973</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,794</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,179</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 35873000 13889000 21984000 52700000 3905000 48795000 72400000 72400000 160973000 17794000 143179000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense on intangible assets is estimated to be as follows for each of the next five years ended June 30: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,425</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,803</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,351</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 10425000 8803000 4041000 4041000 4041000 31351000 7. Investments in and loans to equity accounted investees The Company has entered into two joint ventures as part of the construction of future office and laboratory headquarters. During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). As of June 30, 2022, the equity investment balance of $19.8 million represents the contributions made since inception. In March, 2021, the Company entered into the Beedie joint venture (Beedie JV). To date, the equity investment balance of $15.2 million represents contributions made since inception into the Beedie JV. To date, the Company has recorded immaterial amounts of its proportionate income or loss with respect to both ventures. In March, 2021, the Company made a commitment of up to CAD $82.7 million ($61.5 million) to the Dayhu JV to fund the construction at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the joint venture. As of December 31, 2021, and June 30, 2022, the outstanding related party loan balance was $18.0 million and $30.8 million, respectively, to the joint venture. In June 2022, the Company made a commitment to Beedie for a land loan of up to CAD $7.5 million ($5.8 million) plus a construction loan for up to 80% of Beedie’s share of construction costs. The commitment is at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement of the construction loan and five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the joint venture. Subsequent to June 30, 2022, the Company entered into an agreement of up to CAD $46.0 million ($35.7 million) with Dayhu to replace the outstanding construction loan balance as at January 1, 2023, at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement. The agreement has a maturity of December 31, 2025, with a call provision, callable by the Company after September 30, 2023, including customary make whole provisions. The loan is secured by the underlying land and existing and future assets of the joint venture. 2 19800000 15200000 82700000 61500000 repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. P30M 2023-09-01 18000000.0 30800000 7500000 5800000 0.80 repayment on the earlier of thirty months from the date of initial advancement of the construction loan and five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement P30M 46000000.0 35700000 2025-12-31 8. Accounts payable and other liabilities Accounts payable and other liabilities consisted of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,924</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability for in-licensing agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,933</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,652</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,035</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,282</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred grant funding</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,473</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,772</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and other liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,017</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,390</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Accounts payable and other liabilities consisted of the following: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,924</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability for in-licensing agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,933</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,652</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,035</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,282</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred grant funding</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,473</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,772</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and other liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,017</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,390</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 14924000 10313000 4933000 3652000 4023000 4035000 4282000 4473000 5772000 32017000 24390000 9. Shareholders’ equity <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sixth Amended and Restated Stock Option Plan: <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains the AbCellera Biologics Inc. Sixth Amended and Restated Stock Option Plan and our Pre-IPO Plan. Any awards granted under the Pre-IPO Plan will remain subject to the terms of our Pre-IPO Plan and applicable award agreements. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2020 Share Option and Incentive Plan: <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our 2020 Share Option and Incentive Plan, or 2020 Plan, was approved by our board of directors on November 18, 2020, and approved by our shareholders on December 1, 2020. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2022, the number of shares available for issuance under the 2020 Plan was 24,415,404, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2021: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,206,307</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.86</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,734,149</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.37</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(451,917</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,020,241</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.89</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,705,504</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2021: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,284,347</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.19</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583,848</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.88</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(327,546</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.90</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,540,649</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.83</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584,306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.07</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and are subject to annual vesting. The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2021: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080,413</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.62</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,289,954</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.88</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and settled</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,178</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.52</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(192,481</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.87</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,116,708</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.31</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation: <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,720</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,264</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,877</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,201</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,116</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,592</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,374</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,907</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,734</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,473</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,113</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,900</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,404</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 24415404 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2021: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,206,307</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.86</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,734,149</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.37</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(451,917</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,020,241</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.89</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,705,504</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 39206307 0.86 1734149 0.37 451917 0.27 37020241 0.89 20705504 0.61 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2021: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,284,347</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.19</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583,848</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.88</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(327,546</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.90</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,540,649</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.83</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584,306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.07</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 5284347 19.19 3583848 10.88 327546 15.90 8540649 15.83 584306 26.07 The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2021: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080,413</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.62</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,289,954</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.88</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and settled</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,178</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.52</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(192,481</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.87</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,116,708</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.31</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 1080413 23.62 2289954 10.88 61178 45.52 192481 15.87 3116708 14.31 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,720</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,264</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,877</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,201</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,116</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,592</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,374</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,907</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,734</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,473</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,113</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,900</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,404</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 3720000 6264000 6877000 12201000 161000 475000 1116000 1469000 4592000 5374000 5907000 10734000 8473000 12113000 13900000 24404000 10. Revenue <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disaggregated revenue categories are presented on the face of the condensed consolidated statements of income (loss) and comprehensive income (loss). <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred revenue <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue outstanding in each respective period is as follows: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,321</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,232</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,954</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,004</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June 30, 2021, the Company recognized $1.8 million and $3.4 million, respectively, and $6.3 million and $7.7 million during the three and six months ended June 30, 2022, respectively, of revenue that had been included in deferred revenue in the previous year. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March of 2020, the Company entered into a research collaboration and license agreement with Eli Lilly pursuant to which the Company will perform discovery research for several targets for Eli Lilly to develop and commercialize. Under the agreement, the Company is entitled to receive an aggregate of up to $29.0 million of milestone payments as well as royalties in the low single digits based on net sales for non-COVID-19 targets and in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement resulted in an initial upfront payment of $26.7 million, of which $21.9 million was included in deferred revenue at December 31, 2020. In the year ended December 31, 2021, the Company received an additional $1.7 million in payments, for total payments received in respect of this agreement of $28.4 million. In the six months ended June 30, 2022, the Company received $0.6 million in additional payments. The Company recognized $3.8 million and $4.3 million of revenue in the three and six months ended June 30, 2022, respectively. The Company expects to recognize approximately $1.4 million in revenue in the next 12 months related to these payments under the agreement. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the remaining deferred revenue balance of $15.2 million, which is related to various other agreements, approximately $3.2 million is expected to be recognized in revenue in the next 12 months. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue outstanding in each respective period is as follows: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,321</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,232</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,954</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,004</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 26321000 31232000 34954000 32004000 1800000 3400000 6300000 7700000 29000000.0 125000000.0 125000000.0 26700000 21900000 1700000 28400000 0.6 3800000 4300000 1400000 P12M 15200000 3200000 P12M 11. Financial instruments <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans to equity accounted investees, accounts payable and accrued liabilities and royalties payable, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, royalties payable, and loans to equity accounted investees approximate their fair values. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Consideration <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition. The following table presents the changes in fair value of the liability for contingent consideration: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">beginning of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the period</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) in fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value of liability for contingent <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">consideration</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">end of the <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trianni (i)</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,934</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,508</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TetraGenetics (ii)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,886</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(513</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,373</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.65%;"/> <td style="width:96.35%;"/> </tr> <tr> <td valign="top"> i)</td> <td valign="top"> The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.</td> </tr> <tr> <td valign="top"> ii)</td> <td valign="top"> The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 8%, the rate that measures the risks inherent in the future cash flows.</td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Marketable Securities <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at June 30, 2022:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agencies</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,358</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,358</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,875</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,875</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,711</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,711</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,392</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,392</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset backed securities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,316</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,316</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,358</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,294</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,652</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following table presents the changes in fair value of the liability for contingent consideration: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30, 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">beginning of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the period</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) in fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value of liability for contingent <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">consideration</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">end of the <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trianni (i)</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,934</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,508</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TetraGenetics (ii)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,886</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(513</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,373</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 22934000 574000 23508000 35886000 -513000 35373000 22 8 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at June 30, 2022:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agencies</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,358</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,358</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,875</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,875</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,711</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,711</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,392</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,392</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset backed securities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,316</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,316</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.06%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,358</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,294</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,652</td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 17358000 17358000 20875000 20875000 34711000 34711000 142392000 142392000 16316000 16316000 17358000 214294000 231652000 <p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15%;text-indent:-5.15%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Commitments and contingencies <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three and six months ended June 30, 2022, the Company has expensed approximately $5.2 million and $49.8 million, respectively, related to such obligations, of which $50.6 million is included in current liabilities. Since inception, the Company has incurred expenditures of $44.9 million and $26.3 million under phase 1 and 2, respectively, under the Canadian government’s Strategic Innovation Fund, or SIF. Spending under phase 1 of the agreement and such amounts are not repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of June 30, 2022, no amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable as of June 30, 2022. 5200000 49800000 50600000 44900000 26300000 0 13. Related Party Transaction In addition to the loans to the equity accounted investees disclosed in Note 7, the Company had the following related party transactions: During the second quarter, the Company engaged advisory services with a firm co-founded by a director of the Company in the amount of up to $0.3 million, of which $0.1 million was paid and included in other assets at June 30, 2022. 300000 100000 Exclusive of depreciation and amortization The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows. The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 8%, the rate that measures the risks inherent in the future cash flows. EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 145 219 1 true 47 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) Sheet http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Nature of Operations Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureNatureOfOperations Nature of Operations Notes 7 false false R8.htm 100070 - Disclosure - Basis of Presentation Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Significant Accounting Policies Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Net Earnings (Loss) Per Share Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShare Net Earnings (Loss) Per Share Notes 10 false false R11.htm 100100 - Disclosure - Property and Equipment, Net Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 100110 - Disclosure - Intangible Assets Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssets Intangible Assets Notes 12 false false R13.htm 100120 - Disclosure - Investments in and Loans to Equity Accounted Investees Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvestees Investments in and Loans to Equity Accounted Investees Notes 13 false false R14.htm 100130 - Disclosure - Accounts Payable and Other Liabilities Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities Accounts Payable and Other Liabilities Notes 14 false false R15.htm 100140 - Disclosure - Shareholders' Equity Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquity Shareholders' Equity Notes 15 false false R16.htm 100150 - Disclosure - Revenue Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenue Revenue Notes 16 false false R17.htm 100160 - Disclosure - Financial Instruments Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstruments Financial Instruments Notes 17 false false R18.htm 100170 - Disclosure - Commitment and Contingencies Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentAndContingencies Commitment and Contingencies Notes 18 false false R19.htm 100180 - Disclosure - Related Party Transaction Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransaction Related Party Transaction Notes 19 false false R20.htm 100190 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Net Earnings (Loss) Per Share (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareTables Net Earnings (Loss) Per Share (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShare 21 false false R22.htm 100210 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNet 22 false false R23.htm 100220 - Disclosure - Intangible Assets (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssets 23 false false R24.htm 100230 - Disclosure - Accounts Payable and Other Liabilities (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesTables Accounts Payable and Other Liabilities (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities 24 false false R25.htm 100240 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquity 25 false false R26.htm 100250 - Disclosure - Revenue (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenue 26 false false R27.htm 100260 - Disclosure - Financial Instruments (Tables) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstruments 27 false false R28.htm 100270 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details) Details http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareTables 28 false false R29.htm 100280 - Disclosure - Net Earnings (Loss) Per Share - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareAdditionalInformationDetails Net Earnings (Loss) Per Share - Additional Information (Details) Details http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareTables 29 false false R30.htm 100290 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 30 false false R31.htm 100300 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 32 false false R33.htm 100320 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) Details 33 false false R34.htm 100330 - Disclosure - Investments in and Loans to Equity Accounted Investees - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails Investments in and Loans to Equity Accounted Investees - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) Details 35 false false R36.htm 100350 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Shareholders' Equity - Summary of Stock Option Activity (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails Shareholders' Equity - Summary of Stock Option Activity (Details) Details 37 false false R38.htm 100370 - Disclosure - Shareholders' Equity - Summary of Restricted Share Units Activity (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails Shareholders' Equity - Summary of Restricted Share Units Activity (Details) Details 38 false false R39.htm 100380 - Disclosure - Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) Details 39 false false R40.htm 100390 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueSummaryOfDeferredRevenueOutstandingDetails Revenue - Summary of Deferred Revenue Outstanding (Details) Details 40 false false R41.htm 100400 - Disclosure - Revenue - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails Revenue - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Revenue - Additional Information (Details1) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1 Revenue - Additional Information (Details1) Details 42 false false R43.htm 100420 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) Details 43 false false R44.htm 100430 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical) Details 44 false false R45.htm 100440 - Disclosure - Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) Details 45 false false R46.htm 100450 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Related Party Transaction - Additional Information (Details) Sheet http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails Related Party Transaction - Additional Information (Details) Details 47 false false All Reports Book All Reports abcl-10q_20220630.htm abcl-20220630.xsd abcl-20220630_cal.xml abcl-20220630_def.xml abcl-20220630_lab.xml abcl-20220630_pre.xml abcl-ex311_8.htm abcl-ex312_7.htm abcl-ex321_6.htm abcl-ex322_9.htm gflfxvhuhguz000001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abcl-10q_20220630.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 145, "dts": { "calculationLink": { "local": [ "abcl-20220630_cal.xml" ] }, "definitionLink": { "local": [ "abcl-20220630_def.xml" ] }, "inline": { "local": [ "abcl-10q_20220630.htm" ] }, "labelLink": { "local": [ "abcl-20220630_lab.xml" ] }, "presentationLink": { "local": [ "abcl-20220630_pre.xml" ] }, "schema": { "local": [ "abcl-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 361, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 8, "http://xbrl.sec.gov/dei/2022": 5, "total": 13 }, "keyCustom": 31, "keyStandard": 188, "memberCustom": 19, "memberStandard": 28, "nsprefix": "abcl", "nsuri": "http://www.abcellera.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Net Earnings (Loss) Per Share", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShare", "shortName": "Net Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Property and Equipment, Net", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Intangible Assets", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Investments in and Loans to Equity Accounted Investees", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvestees", "shortName": "Investments in and Loans to Equity Accounted Investees", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Accounts Payable and Other Liabilities", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities", "shortName": "Accounts Payable and Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Shareholders' Equity", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Revenue", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Financial Instruments", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Commitment and Contingencies", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentAndContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Related Party Transaction", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransaction", "shortName": "Related Party Transaction", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Net Earnings (Loss) Per Share (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareTables", "shortName": "Net Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Intangible Assets (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Accounts Payable and Other Liabilities (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesTables", "shortName": "Accounts Payable and Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Revenue (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Financial Instruments (Tables)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails", "shortName": "Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Net Earnings (Loss) Per Share - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareAdditionalInformationDetails", "shortName": "Net Earnings (Loss) Per Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20211231", "decimals": "-5", "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": "INF", "first": true, "lang": null, "name": "abcl:NumberOfJointVentures", "reportCount": 1, "unique": true, "unitRef": "U_abclJointVenture", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Investments in and Loans to Equity Accounted Investees - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "shortName": "Investments in and Loans to Equity Accounted Investees - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": "INF", "first": true, "lang": null, "name": "abcl:NumberOfJointVentures", "reportCount": 1, "unique": true, "unitRef": "U_abclJointVenture", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails", "shortName": "Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapPlanNameAxis_abclTwoThousandTwentyShareOptionAndIncentivePlanMember_20220630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Shareholders' Equity - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "shortName": "Shareholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapPlanNameAxis_abclTwoThousandTwentyShareOptionAndIncentivePlanMember_20220630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapPlanNameAxis_abclPreInitialPublicOfferingPlanMember_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Shareholders' Equity - Summary of Stock Option Activity (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "shortName": "Shareholders' Equity - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapPlanNameAxis_abclPreInitialPublicOfferingPlanMember_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_abclTwoThousandTwentyShareOptionAndIncentivePlanMember_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Shareholders' Equity - Summary of Restricted Share Units Activity (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails", "shortName": "Shareholders' Equity - Summary of Restricted Share Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_abclTwoThousandTwentyShareOptionAndIncentivePlanMember_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails", "shortName": "Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited)", "role": "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueSummaryOfDeferredRevenueOutstandingDetails", "shortName": "Revenue - Summary of Deferred Revenue Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Revenue - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "shortName": "Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_srtCounterpartyNameAxis_abclEliLillyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_abclResearchCollaborationAndLicenseAgreementMember_20220630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Revenue - Additional Information (Details1)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1", "shortName": "Revenue - Additional Information (Details1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_srtCounterpartyNameAxis_abclEliLillyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_abclResearchCollaborationAndLicenseAgreementMember_20220630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapBusinessAcquisitionAxis_abclTrianniMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_abclContingentConsiderationMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "shortName": "Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapBusinessAcquisitionAxis_abclTrianniMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_abclContingentConsiderationMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "link:footnote", "td", "tr", "table", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapBusinessAcquisitionAxis_abclTrianniMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AlternativeInvestmentMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical", "shortName": "Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "link:footnote", "td", "tr", "table", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapBusinessAcquisitionAxis_abclTrianniMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AlternativeInvestmentMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapCashAndCashEquivalentsAxis_abclMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapCashAndCashEquivalentsAxis_abclMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220401_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abclPhaseOneMember_20220101_20220630", "decimals": "-5", "lang": null, "name": "abcl:StrategicInnovationFundEligibleExpenditure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-5", "first": true, "lang": null, "name": "abcl:RelatedPartyTransactionAdvisoryServices", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Related Party Transaction - Additional Information (Details)", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails", "shortName": "Related Party Transaction - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220630", "decimals": "-5", "first": true, "lang": null, "name": "abcl:RelatedPartyTransactionAdvisoryServices", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Nature of Operations", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNatureOfOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Basis of Presentation", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Significant Accounting Policies", "role": "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20220630.htm", "contextRef": "C_0001703057_20220101_20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "abcl_AccountsAndAccruedReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts and accrued receivable, current.", "label": "Accounts And Accrued Receivable Current", "terseLabel": "Accounts and accrued receivable" } } }, "localname": "AccountsAndAccruedReceivableCurrent", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital, reclassification of liability classified options.", "label": "Adjustments To Additional Paid In Capital Reclassification Of Liability Classified Options", "terseLabel": "Reclassification of liability classified options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_BeedieJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beedie joint venture.", "label": "Beedie Joint Venture [Member]", "terseLabel": "Beedie JV" } } }, "localname": "BeedieJointVentureMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_CashCashEquivalentsAndMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash cash Equivalents and marketable securities.", "label": "Cash Cash Equivalents And Marketable Securities", "totalLabel": "Total cash, cash equivalents, and marketable securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecurities", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "abcl_CurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current liabilities.", "label": "Current Liabilities [Member]", "terseLabel": "Current Liabilities" } } }, "localname": "CurrentLiabilitiesMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_DayhuJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dayhu joint venture.", "label": "Dayhu Joint Venture [Member]", "terseLabel": "Dayhu JV" } } }, "localname": "DayhuJointVentureMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_DeferredGrantFundingCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred grant funding current.", "label": "Deferred Grant Funding Current", "terseLabel": "Current portion of deferred grant funding" } } }, "localname": "DeferredGrantFundingCurrent", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abcl_DeferredRevenueAndGrantFundingNoncurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue and grant funding noncurrent.", "label": "Deferred Revenue And Grant Funding Noncurrent", "terseLabel": "Deferred revenue and grant funding" } } }, "localname": "DeferredRevenueAndGrantFundingNoncurrent", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_EliLillyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eli Lilly.", "label": "Eli Lilly [Member]", "terseLabel": "Eli Lilly" } } }, "localname": "EliLillyMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "abcl_EquityMethodInvestmentCommitmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, commitment amount.", "label": "Equity Method Investment Commitment Amount", "terseLabel": "Equity method investment, commitment amount" } } }, "localname": "EquityMethodInvestmentCommitmentAmount", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, outstanding related party loan.", "label": "Equity Method Investment Outstanding Related Party Loan", "terseLabel": "Equity method investment, outstanding related party loan" } } }, "localname": "EquityMethodInvestmentOutstandingRelatedPartyLoan", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_GrantsAndIncentives": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Grants and Incentives.", "label": "Grants And Incentives", "negatedLabel": "Grants and incentives" } } }, "localname": "GrantsAndIncentives", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued royalties receivable.", "label": "Increase Decrease In Accrued Royalties Receivable", "negatedLabel": "Accrued royalties receivable" } } }, "localname": "IncreaseDecreaseInAccruedRoyaltiesReceivable", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_IncreaseDecreaseInDeferredGrantIncome": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in deferred grant income.", "label": "Increase Decrease In Deferred Grant Income", "negatedLabel": "Deferred grant revenue" } } }, "localname": "IncreaseDecreaseInDeferredGrantIncome", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "abcl_LiabilityForInLicensingAgreementCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for in-licensing agreement current.", "label": "Liability For In Licensing Agreement Current", "terseLabel": "Liability for in-licensing agreement" } } }, "localname": "LiabilityForInLicensingAgreementCurrent", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abcl_LicenseBasedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License based intangible assets.", "label": "License Based Intangible Assets [Member]", "terseLabel": "License" } } }, "localname": "LicenseBasedIntangibleAssetsMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abcl_LowToMidTeensRoyaltyThresholdSalesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Low to mid-teens royalty threshold sales amount.", "label": "Low To Mid Teens Royalty Threshold Sales Amount", "terseLabel": "Low to mid-teens royalty threshold sales amount" } } }, "localname": "LowToMidTeensRoyaltyThresholdSalesAmount", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities.", "label": "Marketable Securities [Member]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "abcl_MidTeensToMidTwentiesRoyaltyThresholdSalesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mid-teens to mid-twenties royalty threshold sales amount.", "label": "Mid Teens To Mid Twenties Royalty Threshold Sales Amount", "terseLabel": "Mid-teens to mid-twenties royalty threshold sales amount" } } }, "localname": "MidTeensToMidTwentiesRoyaltyThresholdSalesAmount", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MilestonePaymentThresholdAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment threshold amount.", "label": "Milestone Payment Threshold Amount", "terseLabel": "Milestone payment threshold amount" } } }, "localname": "MilestonePaymentThresholdAmount", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MilestonePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments [Member]", "terseLabel": "Milestone Payments" } } }, "localname": "MilestonePaymentsMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash or part non cash acquisition property and equipment purchases in accounts payable.", "label": "Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable", "terseLabel": "Property plant and equipment in accounts payable" } } }, "localname": "NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation.", "label": "Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation" } } }, "localname": "NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_NumberOfJointVentures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of joint ventures.", "label": "Number Of Joint Ventures", "terseLabel": "Number Of Joint Ventures" } } }, "localname": "NumberOfJointVentures", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "abcl_OperatingLeaseRightOfUseAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease right-of-use assets.", "label": "Operating Lease Right Of Use Assets [Member]", "terseLabel": "Operating Lease Right-of-use Assets" } } }, "localname": "OperatingLeaseRightOfUseAssetsMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "abcl_PaymentOfLiabilityForInLicensingAgreement": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of liability for in-licensing agreement.", "label": "Payment Of Liability For In Licensing Agreement", "negatedLabel": "Payment of liability for in-licensing agreement" } } }, "localname": "PaymentOfLiabilityForInLicensingAgreement", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to acquire long-term investments and other assets.", "label": "Payments To Acquire Long Term Investments And Other Assets", "negatedLabel": "Long-term investments and other assets" } } }, "localname": "PaymentsToAcquireLongTermInvestmentsAndOtherAssets", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_PercentageOfConstructionLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of construction loan.", "label": "Percentage Of Construction Loan", "terseLabel": "Percentage of construction loan" } } }, "localname": "PercentageOfConstructionLoan", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "abcl_PhaseOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 1.", "label": "Phase One [Member]", "terseLabel": "Phase 1" } } }, "localname": "PhaseOneMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_PhaseTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 2.", "label": "Phase Two [Member]", "terseLabel": "Phase 2" } } }, "localname": "PhaseTwoMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_PreInitialPublicOfferingPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-initial public offering plan.", "label": "Pre Initial Public Offering Plan [Member]", "terseLabel": "Pre-IPO Plan" } } }, "localname": "PreInitialPublicOfferingPlanMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "abcl_ProceedsFromDebtAndExerciseOfStockOptions": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from debt and exercise of stock options.", "label": "Proceeds From Debt And Exercise Of Stock Options", "terseLabel": "Proceeds from debt and exercise of stock options" } } }, "localname": "ProceedsFromDebtAndExerciseOfStockOptions", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_ProceedsFromReceiptOfGrantFunding": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from receipt of grant funding.", "label": "Proceeds From Receipt Of Grant Funding", "terseLabel": "Receipt of grant funding" } } }, "localname": "ProceedsFromReceiptOfGrantFunding", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_RelatedPartyTransactionAdviserFeePaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party transaction adviser fee paid.", "label": "Related Party Transaction Adviser Fee Paid", "terseLabel": "Adviser fee paid" } } }, "localname": "RelatedPartyTransactionAdviserFeePaid", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_RelatedPartyTransactionAdvisoryServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related party transaction advisory services.", "label": "Related Party Transaction Advisory Services", "terseLabel": "Advisory services" } } }, "localname": "RelatedPartyTransactionAdvisoryServices", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_RepaymentOfLongTermDebtAndContingentConsideration": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of long-term debt and contingent consideration.", "label": "Repayment Of Long Term Debt And Contingent Consideration", "negatedLabel": "Repayment of long-term debt and contingent consideration" } } }, "localname": "RepaymentOfLongTermDebtAndContingentConsideration", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_ResearchCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research, collaboration and license agreement.", "label": "Research Collaboration And License Agreement [Member]", "terseLabel": "Research, Collaboration and License Agreement" } } }, "localname": "ResearchCollaborationAndLicenseAgreementMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "abcl_ResearchFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research fees.", "label": "Research Fees [Member]", "terseLabel": "Research Fees" } } }, "localname": "ResearchFeesMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued and Restricted Stock Units vested during period shares stock options exercised.", "label": "Stock Issued And Restricted Stock Units Vested During Period Shares Stock Options Exercised", "terseLabel": "Shares issued and restricted stock units (\"RSUs\") vested under stock option plan, Shares" } } }, "localname": "StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued and Restricted Stock Units vested during period value stock options exercised.", "label": "Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised", "terseLabel": "Shares issued and restricted stock units (\"RSUs\") vested under stock option plan" } } }, "localname": "StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_StrategicInnovationFundEligibleExpenditure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Strategic innovation fund eligible expenditure.", "label": "Strategic Innovation Fund Eligible Expenditure", "terseLabel": "Strategic innovation fund eligible expenditure" } } }, "localname": "StrategicInnovationFundEligibleExpenditure", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_TetraGeneticMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TetraGenetics.", "label": "Tetra Genetic [Member]", "terseLabel": "TetraGenetics Inc" } } }, "localname": "TetraGeneticMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "domainItemType" }, "abcl_TrianniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trianni.", "label": "Trianni [Member]", "terseLabel": "Trianni" } } }, "localname": "TrianniMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "domainItemType" }, "abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Share option and incentive plan.", "label": "Two Thousand Twenty Share Option And Incentive Plan [Member]", "terseLabel": "2020 Share Option and Incentive Plan" } } }, "localname": "TwoThousandTwentyShareOptionAndIncentivePlanMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "abcl_UnusualOrInfrequentItemsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for unusual or infrequent items.", "label": "Unusual Or Infrequent Items Policy [Text Block]", "terseLabel": "COVID-19 Pandemic" } } }, "localname": "UnusualOrInfrequentItemsPolicyTextBlock", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "abcl_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_VariousOtherAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various other agreements.", "label": "Various Other Agreements [Member]", "terseLabel": "Various Other Agreements" } } }, "localname": "VariousOtherAgreementsMember", "nsuri": "http://www.abcellera.com/20220630", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r42", "r78", "r79", "r198", "r203" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r180", "r181", "r182", "r183", "r197", "r202", "r242", "r244", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r393", "r395", "r422", "r423" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r180", "r181", "r182", "r183", "r197", "r202", "r242", "r244", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r393", "r395", "r422", "r423" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r140", "r181", "r182", "r220", "r224", "r359", "r392", "r394" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r140", "r181", "r182", "r220", "r224", "r359", "r392", "r394" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r175", "r180", "r181", "r182", "r183", "r197", "r202", "r232", "r242", "r244", "r274", "r275", "r276", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r393", "r395", "r422", "r423" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r175", "r180", "r181", "r182", "r183", "r197", "r202", "r232", "r242", "r244", "r274", "r275", "r276", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r393", "r395", "r422", "r423" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r41", "r42", "r78", "r79", "r198", "r203" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]", "terseLabel": "Accounts Payable and Other Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable And Accrued Liabilities Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable And Other Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable And Other Accrued Liabilities Current", "totalLabel": "Total accounts payable and other liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r366", "r380" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities, current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r6", "r32" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties Current", "terseLabel": "Accrued royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r171" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r44", "r45", "r46", "r382", "r400", "r401" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r43", "r46", "r52", "r53", "r54", "r81", "r82", "r83", "r310", "r339", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r22" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r81", "r82", "r83", "r280", "r281", "r282", "r317" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r246", "r283", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestmentMeasurementInput": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure alternative investment.", "label": "Alternative Investment Measurement Input", "terseLabel": "Discount rate" } } }, "localname": "AlternativeInvestmentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "decimalItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r70", "r159", "r165" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Total potential common shares excluded" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r147", "r233" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset Backed Securities [Member]", "terseLabel": "Asset Backed Securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r16", "r75", "r129", "r132", "r138", "r150", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r305", "r311", "r329", "r345", "r347", "r365", "r379" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r29", "r75", "r150", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r305", "r311", "r329", "r345", "r347" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r75", "r150", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r305", "r311", "r329", "r345" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets Noncurrent", "totalLabel": "Total long-term assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Noncurrent [Abstract]", "terseLabel": "Long-term assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r144", "r146", "r153", "r368" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10320.0, "parentTag": "abcl_CashCashEquivalentsAndMarketableSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r241", "r243", "r298" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r241", "r243", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r300", "r301" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination Contingent Consideration Liability Current", "terseLabel": "Current portion of contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r300", "r301" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination Contingent Consideration Liability Noncurrent", "terseLabel": "Contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r80", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r10", "r72" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10310.0, "parentTag": "abcl_CashCashEquivalentsAndMarketableSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r67", "r72", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "terseLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r67", "r72", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r67", "r330" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificate of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r37", "r369", "r386" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r177", "r178", "r179", "r184", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Number of shares available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r81", "r82", "r317" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock No Par Value", "terseLabel": "Common stock, no par value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".", "label": "Common Stock Shares Authorized Unlimited", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorizedUnlimited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "authorizedUnlimitedItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r204" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r347" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common shares: no par value, unlimited authorized shares at December 31, 2021 and June 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at December 31, 2021 and June 30, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r57", "r372", "r388" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Summary of Deferred Revenue Outstanding" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r207", "r208", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueSummaryOfDeferredRevenueOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r207", "r208", "r221" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Contract with customer liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r34", "r197", "r324" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "verboseLabel": "Commitment amount, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r35", "r378" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument Payment Terms", "verboseLabel": "Debt instrument, repayment description" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument Term", "verboseLabel": "Commitment amount, repayment term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r289", "r290" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r70", "r169" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation of property and equipment", "verboseLabel": "Depreciation expense on property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r70", "r169" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10150.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r220", "r224", "r225", "r226", "r227", "r228", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net earnings (loss) per share attributable to common shareholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r58", "r86", "r87", "r88", "r89", "r90", "r94", "r97", "r107", "r108", "r109", "r113", "r114", "r318", "r319", "r373", "r389" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic", "verboseLabel": "Net earnings (loss) per share attributable to common shareholders - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic [Abstract]", "terseLabel": "Basic earnings (loss) per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r58", "r86", "r87", "r88", "r89", "r90", "r97", "r107", "r108", "r109", "r113", "r114", "r318", "r319", "r373", "r389" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted", "verboseLabel": "Net earnings (loss) per share attributable to common shareholders - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Diluted [Abstract]", "terseLabel": "Diluted earnings (loss) per share" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r110", "r111", "r112", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net earnings (loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r330" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Payroll liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r52", "r53", "r54", "r81", "r82", "r83", "r85", "r91", "r93", "r116", "r152", "r204", "r205", "r280", "r281", "r282", "r292", "r293", "r317", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments And Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments Disclosure [Text Block]", "terseLabel": "Investments in and loans to equity accounted investees" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvestees" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r320", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r199", "r200", "r201", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r321", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Fair Value By Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r320", "r321", "r323", "r324", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r199", "r233", "r234", "r239", "r240", "r321", "r348" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r199", "r200", "r201", "r233", "r234", "r239", "r240", "r321", "r349" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r199", "r200", "r201", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r321", "r350" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Changes in Fair Value of Liability for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease", "terseLabel": "Increase (decrease) in fair value of liability for contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Liability at end of the period", "periodStartLabel": "Liability at beginning of the period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r199", "r200", "r201", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r326", "r328" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements on Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r14", "r164" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r166" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite Lived Intangible Assets Amortization Expense Table [Text Block]", "terseLabel": "Schedule of Estimated Amortization Expense on Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r166" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r166" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r166" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r166" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r160", "r161", "r164", "r167", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r164", "r361" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r160", "r163" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r164", "r360" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "totalLabel": "Finite lived intangible assets amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10140.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r13", "r154", "r155", "r156", "r157", "r347", "r364" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research And Development [Member]", "terseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r129", "r131", "r134", "r137", "r139", "r362", "r370", "r374", "r390" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Net earnings (loss) before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r173", "r176" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r92", "r93", "r128", "r291", "r294", "r295", "r391" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Income tax (recovery) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r69" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase Decrease In Accrued Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r69" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r69" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase Decrease In Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r69" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Receivables", "negatedLabel": "Accounts and accrued research fees receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRoyaltiesPayable": { "auth_ref": [ "r69" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.", "label": "Increase Decrease In Royalties Payable", "terseLabel": "Accrued royalties payable" } } }, "localname": "IncreaseDecreaseInRoyaltiesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r98", "r99", "r100", "r109", "r248" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable To Share Based Payment Arrangements", "terseLabel": "Stock options and RSUs" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r158", "r162" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net", "totalLabel": "Net book value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r16" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments In Affiliates Subsidiaries Associates And Joint Ventures", "terseLabel": "Investments in and loans to equity accounted investees" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements Gross", "terseLabel": "Leasehold improvements include tenant improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r75", "r133", "r150", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r306", "r311", "r312", "r329", "r345", "r346" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r75", "r150", "r329", "r347", "r367", "r384" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r33", "r75", "r150", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r306", "r311", "r312", "r329", "r345", "r346", "r347" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r7", "r8", "r9", "r18", "r19", "r75", "r150", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r306", "r311", "r312", "r329", "r345", "r346" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "Licensing Revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r117", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r67", "r68", "r71" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r47", "r49", "r54", "r56", "r71", "r75", "r84", "r86", "r87", "r88", "r89", "r92", "r93", "r105", "r129", "r131", "r134", "r137", "r139", "r150", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r319", "r329", "r371", "r387" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net earnings (loss)", "totalLabel": "Net earnings (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r86", "r87", "r88", "r89", "r94", "r95", "r106", "r109", "r129", "r131", "r134", "r137", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Basic", "terseLabel": "Net earnings (loss) attributable to common shareholders - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r96", "r101", "r102", "r103", "r104", "r106", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Diluted", "terseLabel": "Net earnings (loss) attributable to common shareholders - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "negatedTotalLabel": "Total other (income)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other (income) expense" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10100.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r129", "r131", "r134", "r137", "r139" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r337" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r337" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r28", "r347" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10300.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r303", "r304", "r309" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income Expense", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "negatedLabel": "Other (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r64" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments To Acquire Equity Method Investments", "negatedLabel": "Investment in and loans to equity accounted investees" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments To Acquire Interest In Subsidiaries And Affiliates", "terseLabel": "Equity investment balance, contributions made in joint venture" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r145" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Proceeds from marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r47", "r49", "r54", "r66", "r75", "r84", "r92", "r93", "r129", "r131", "r134", "r137", "r139", "r150", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r303", "r307", "r308", "r313", "r314", "r319", "r329", "r374" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r174", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r11", "r170" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r172", "r347", "r376", "r385" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRelatedPartyTransaction" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r286", "r358", "r424" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10120.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r10", "r73", "r363", "r381" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10290.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r72", "r73", "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Noncurrent", "negatedLabel": "Restricted cash included in other assets" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Share Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r205", "r347", "r383", "r399", "r401" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r81", "r82", "r83", "r85", "r91", "r93", "r152", "r280", "r281", "r282", "r292", "r293", "r317", "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r126", "r127", "r130", "r135", "r136", "r140", "r141", "r142", "r219", "r220", "r359" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r218", "r223", "r231" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Revenue, remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty fees", "verboseLabel": "Royalty expensed" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty Revenue" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accounts Payable and Other Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r1", "r75", "r149", "r150", "r329" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule Of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r160", "r163", "r360" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r160", "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r245", "r247", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Restricted Share Units Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r252", "r267", "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10130.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Number of Shares Outstanding, Ending Balance", "periodStartLabel": "Number of Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Number of Shares, Vested and settled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Vested and settled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of Options exercisable as of March 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of March 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Shares Outstanding, Ending Balance", "periodStartLabel": "Number of Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r206", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders Equity And Share Based Payments [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balances, Shares", "periodStartLabel": "Beginning balances, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r74", "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r39", "r52", "r53", "r54", "r81", "r82", "r83", "r85", "r91", "r93", "r116", "r152", "r204", "r205", "r280", "r281", "r282", "r292", "r293", "r317", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Accumulated Earnings" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r81", "r82", "r83", "r116", "r359" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r204", "r205", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of Shares, Exercised", "terseLabel": "Shares issued under stock option plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r39", "r204", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Shares issued under stock option plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r75", "r143", "r150", "r329", "r347" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balances", "periodStartLabel": "Beginning balances", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20220630/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r77", "r233", "r375" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "US Government Agencies" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r96", "r109" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Diluted", "totalLabel": "Weighted-average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Weighted-average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r94", "r109" ], "calculation": { "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Basic", "verboseLabel": "Weighted-average common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abcellera.com/20220630/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r425": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r428": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r429": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r430": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r431": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" } }, "version": "2.1" } ZIP 67 0001564590-22-028784-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-028784-xbrl.zip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�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�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
~~:LT_/?HVA#^W,F356\]C6U+L+1F#8+ZW5,W4JC"S+B[(6Y MD$[G)/L5ZZ>$7[$93F!]U<5NC_ SA+~~
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�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end

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2022	Aug. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Period End Date	Jun. 30, 2022
Current Fiscal Year End Date	--12-31
Entity Registrant Name	AbCellera Biologics Inc.
Entity Central Index Key	0001703057
Entity Tax Identification Number	00-0000000
Entity File Number	001-39781
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	2215 Yukon Street
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V5Y 0A1
City Area Code	604
Local Phone Number	559-9005
Title of 12(b) Security	Common shares, no par value per share
Trading Symbol	ABCL
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		285,138,643

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 790,615	$ 476,142
Marketable securities	231,652	246,835
Total cash, cash equivalents, and marketable securities	1,022,267	722,977
Accounts and accrued receivable	52,797	160,576
Restricted cash	25,000	25,000
Other current assets	43,891	21,247
Total current assets	1,143,955	929,800
Long-term assets:
Property and equipment, net	149,178	111,616
Intangible assets, net	143,179	148,392
Goodwill	47,806	47,806
Investments in and loans to equity accounted investees	65,824	50,313
Other long-term assets	43,842	30,642
Total long-term assets	449,829	388,769
Total assets	1,593,784	1,318,569
Current liabilities:
Accounts payable and other liabilities	24,390	32,017
Current portion of contingent consideration payable	34,252	22,934
Income taxes payable	107,322	35,683
Accrued royalties payable	50,555	22,506
Deferred revenue	4,621	7,536
Total current liabilities	221,140	120,676
Long-term liabilities:
Operating lease liability	32,759	36,413
Deferred revenue and grant funding	64,800	60,758
Contingent consideration payable	24,629	35,886
Deferred tax liability	34,616	37,370
Other long-term liabilities	2,984	1,733
Total long-term liabilities	159,788	172,160
Total liabilities	380,928	292,836
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2021 and June 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at December 31, 2021 and June 30, 2022, respectively	726,825	722,430
Additional paid-in capital	56,001	35,357
Accumulated other comprehensive income	576	280
Accumulated earnings	429,454	267,666
Total shareholders' equity	1,212,856	1,025,733
Total liabilities and shareholders' equity	$ 1,593,784	$ 1,318,569

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Common stock, no par value
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	285,052,302	283,257,104
Common stock, shares outstanding	285,052,302	283,257,104

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-in Capital	Accumulated Earnings	Accumulated Other Comprehensive Income
Beginning balances at Dec. 31, 2020	$ 830,508	$ 710,387	$ 5,919	$ 114,202
Beginning balances, Shares at Dec. 31, 2020		269,497,768
Shares issued under stock option plan	173	$ 752	(579)
Shares issued under stock option plan, Shares		1,428,162
Stock-based compensation expense	4,021		4,021
Reclassification of liability classified options	5,201		5,201
Net earnings (loss)	117,221			117,221
Ending balances at Mar. 31, 2021	957,124	$ 711,139	14,562	231,423
Ending balances, Shares at Mar. 31, 2021		270,925,930
Beginning balances at Dec. 31, 2020	830,508	$ 710,387	5,919	114,202
Beginning balances, Shares at Dec. 31, 2020		269,497,768
Foreign currency translation adjustment	2,152
Net earnings (loss)	114,898
Ending balances at Jun. 30, 2021	967,679	$ 714,758	21,669	229,100	$ 2,152
Ending balances, Shares at Jun. 30, 2021		276,982,678
Beginning balances at Mar. 31, 2021	957,124	$ 711,139	14,562	231,423
Beginning balances, Shares at Mar. 31, 2021		270,925,930
Shares issued under stock option plan	1,779	$ 3,619	(1,840)
Shares issued under stock option plan, Shares		6,056,748
Stock-based compensation expense	8,473		8,473
Reclassification of liability classified options	474		474
Foreign currency translation adjustment	2,152				2,152
Net earnings (loss)	(2,323)			(2,323)
Ending balances at Jun. 30, 2021	967,679	$ 714,758	21,669	229,100	2,152
Ending balances, Shares at Jun. 30, 2021		276,982,678
Beginning balances at Dec. 31, 2021	1,025,733	$ 722,430	35,357	267,666	280
Beginning balances, Shares at Dec. 31, 2021		283,257,104
Shares issued and restricted stock units ("RSUs") vested under stock option plan	403	$ 3,325	(2,922)
Shares issued and restricted stock units ("RSUs") vested under stock option plan, Shares		1,264,077
Stock-based compensation expense	12,291		12,291
Foreign currency translation adjustment	507				507
Net earnings (loss)	168,573			168,573
Ending balances at Mar. 31, 2022	1,207,507	$ 725,755	44,726	436,239	787
Ending balances, Shares at Mar. 31, 2022		284,521,181
Beginning balances at Dec. 31, 2021	1,025,733	$ 722,430	35,357	267,666	280
Beginning balances, Shares at Dec. 31, 2021		283,257,104
Foreign currency translation adjustment	296
Net earnings (loss)	161,788
Ending balances at Jun. 30, 2022	1,212,856	$ 726,825	56,001	429,454	576
Ending balances, Shares at Jun. 30, 2022		285,052,302
Beginning balances at Mar. 31, 2022	1,207,507	$ 725,755	44,726	436,239	787
Beginning balances, Shares at Mar. 31, 2022		284,521,181
Shares issued and restricted stock units ("RSUs") vested under stock option plan	232	$ 1,070	(838)
Shares issued and restricted stock units ("RSUs") vested under stock option plan, Shares		531,121
Stock-based compensation expense	12,113		12,113
Foreign currency translation adjustment	(211)				(211)
Net earnings (loss)	(6,785)			(6,785)
Ending balances at Jun. 30, 2022	$ 1,212,856	$ 726,825	$ 56,001	$ 429,454	$ 576
Ending balances, Shares at Jun. 30, 2022		285,052,302

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income	$ 161,788	$ 114,898
Cash flows from operating activities:
Depreciation of property and equipment	3,681	1,897
Amortization of intangible assets	5,213	4,930
Amortization of operating lease right-of-use assets	2,120	1,354
Stock-based compensation	24,404	13,900
Other	(298)	337
Changes in operating assets and liabilities:
Accounts and accrued research fees receivable	(6,963)	(28,339)
Accrued royalties receivable	106,583	172,768
Income taxes payable	52,251	(30,330)
Accounts payable and accrued liabilities	(1,882)	(3,640)
Deferred revenue	(2,979)	4,848
Accrued royalties payable	28,049	(3,623)
Deferred grant revenue	5,406	22,349
Other assets	(4,139)	(4,121)
Net cash provided by operating activities	373,234	267,228
Cash flows from investing activities:
Purchases of property and equipment	(45,817)	(40,448)
Purchase of marketable securities	(134,306)
Proceeds from marketable securities	145,808
Receipt of grant funding	8,098	4,520
Long-term investments and other assets	(11,657)	(5,034)
Investment in and loans to equity accounted investees	(15,694)	(20,510)
Net cash used in investing activities	(53,568)	(61,472)
Cash flows from financing activities:
Repayment of long-term debt and contingent consideration	(73)	(4,373)
Proceeds from debt and exercise of stock options	2,175	2,755
Payment of liability for in-licensing agreement	(4,060)	(5,000)
Net cash used in financing activities	(1,958)	(6,618)
Effect of exchange rate changes on cash and cash equivalents	(1,411)	(683)
Increase in cash and cash equivalents	316,297	198,455
Cash and cash equivalents and restricted cash, beginning of period	501,142	594,116
Cash and cash equivalents and restricted cash, end of period	817,439	792,571
Restricted cash included in other assets	(1,824)
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	815,615	792,571
Supplemental disclosure of non-cash investing and financing activities
Property plant and equipment in accounts payable	2,146
Right-of-use assets obtained in exchange for operating lease obligation	$ (796)	$ 29,573

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2021. These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2021 and 2022 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021. All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.
Use of Estimates	Use of estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
COVID-19 Pandemic	COVID-19 Pandemic With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s condensed consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted	Recent accounting pronouncements not yet adopted The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment	$ 162,397	$ 121,442
Less accumulated depreciation	(13,219)	(9,826)
Property and equipment, net	149,178	111,616
Computers
Property Plant And Equipment [Line Items]
Property and equipment	7,961	7,843
Land
Property Plant And Equipment [Line Items]
Property and equipment	53,405	33,044
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment	32,407	18,805
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	32,160	23,962
Operating Lease Right-of-use Assets
Property Plant And Equipment [Line Items]
Property and equipment	$ 36,464	$ 37,788

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	$ 160,973
Accumulated amortization	17,794
Net book value	143,179	$ 148,392
License
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	35,873
Accumulated amortization	13,889
Net book value	21,984
Technology
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	52,700
Accumulated amortization	3,905
Net book value	48,795
IPR&D
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	72,400
Net book value	$ 72,400

Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2023	$ 10,425
2024	8,803
2025	4,041
2026	4,041
2027	4,041
Finite lived intangible assets amortization expense	$ 31,351

Investments in and Loans to Equity Accounted Investees - Additional Information (Details)	1 Months Ended				6 Months Ended	16 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CAD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 CAD ($)	Jun. 30, 2022 USD ($) JointVenture	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CAD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Schedule Of Equity Method Investments [Line Items]
Number Of Joint Ventures \| JointVenture					2
Equity method investment, outstanding related party loan							$ 46,000,000.0
Dayhu JV
Schedule Of Equity Method Investments [Line Items]
Equity investment balance, contributions made in joint venture					$ 19,800,000
Commitment amount, repayment term			30 months	30 months
Commitment amount, maturity date	Dec. 31, 2025	Dec. 31, 2025	Sep. 01, 2023	Sep. 01, 2023
Debt instrument, repayment description					repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement.
Equity method investment, outstanding related party loan	$ 35,700,000				$ 35,700,000	$ 35,700,000		$ 30,800,000	$ 18,000,000.0
Dayhu JV \| Maximum
Schedule Of Equity Method Investments [Line Items]
Equity method investment, commitment amount			$ 61,500,000	$ 82,700,000
Beedie JV
Schedule Of Equity Method Investments [Line Items]
Equity investment balance, contributions made in joint venture						$ 15,200,000
Commitment amount, repayment term	30 months	30 months
Debt instrument, repayment description					repayment on the earlier of thirty months from the date of initial advancement of the construction loan and five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement
Beedie JV \| Maximum
Schedule Of Equity Method Investments [Line Items]
Equity method investment, commitment amount	$ 5,800,000	$ 7,500,000
Percentage of construction loan	80.00%	80.00%

Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accounts payable and accrued liabilities	$ 10,313	$ 14,924
Liability for in-licensing agreement		4,933
Operating lease liability	4,023	3,652
Payroll liabilities	4,282	4,035
Current portion of deferred grant funding	5,772	4,473
Total accounts payable and other liabilities	$ 24,390	$ 32,017

Shareholders' Equity - Additional Information (Details)	Jun. 30, 2022 shares
2020 Share Option and Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for issuance	24,415,404

Shareholders' Equity - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Pre-IPO Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance \| shares	39,206,307
Number of Shares, Exercised \| shares	(1,734,149)
Number of Shares, Forfeited \| shares	(451,917)
Number of Shares Outstanding, Ending Balance \| shares	37,020,241
Number of Options exercisable as of March 31, 2022 \| shares	20,705,504
Weighted-Average Exercise Price, Beginning Balance \| $ / shares	$ 0.86
Weighted-Average Exercise Price, Exercised \| $ / shares	0.37
Weighted-Average Exercise Price, Forfeited \| $ / shares	0.27
Weighted-Average Exercise Price, Ending Balance \| $ / shares	0.89
Weighted-Average Exercise Price, Options exercisable as of March 31, 2022 \| $ / shares	$ 0.61
2020 Share Option and Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance \| shares	5,284,347
Number of Shares, Granted \| shares	3,583,848
Number of Shares, Forfeited \| shares	(327,546)
Number of Shares Outstanding, Ending Balance \| shares	8,540,649
Number of Options exercisable as of March 31, 2022 \| shares	584,306
Weighted-Average Exercise Price, Beginning Balance \| $ / shares	$ 19.19
Weighted-Average Exercise Price, Granted \| $ / shares	10.88
Weighted-Average Exercise Price, Forfeited \| $ / shares	15.90
Weighted-Average Exercise Price, Ending Balance \| $ / shares	15.83
Weighted-Average Exercise Price, Options exercisable as of March 31, 2022 \| $ / shares	$ 26.07

Revenue - Summary of Deferred Revenue Outstanding (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Deferred revenue	$ 32,004	$ 34,954	$ 31,232	$ 26,321

Revenue - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended		24 Months Ended
Revenue - Additional Information (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Contract with customer liability, revenue recognized	$ 6,300,000	$ 1,800,000	$ 7,700,000	$ 3,400,000
Deferred revenue	32,004,000	$ 31,232,000	32,004,000	$ 31,232,000	$ 34,954,000	$ 26,321,000	$ 34,954,000
Research, Collaboration and License Agreement \| Eli Lilly
Disaggregation Of Revenue [Line Items]
Contract with customer liability, revenue recognized	3,800,000		4,300,000
Upfront payment received			0.6		$ 1,700,000	26,700,000	$ 28,400,000
Deferred revenue						$ 21,900,000
Research, Collaboration and License Agreement \| Maximum \| Eli Lilly
Disaggregation Of Revenue [Line Items]
Milestone payment threshold amount								$ 29,000,000.0
Low to mid-teens royalty threshold sales amount								125,000,000.0
Research, Collaboration and License Agreement \| Minimum [Member] \| Eli Lilly
Disaggregation Of Revenue [Line Items]
Mid-teens to mid-twenties royalty threshold sales amount								$ 125,000,000.0
Various Other Agreements
Disaggregation Of Revenue [Line Items]
Deferred revenue	$ 15,200,000		$ 15,200,000

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01 $ in Millions	Jun. 30, 2022 USD ($)
Research, Collaboration and License Agreement \| Eli Lilly
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation	$ 1.4
Revenue, remaining performance obligation, expected timing of satisfaction period	12 months
Various Other Agreements
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation	$ 3.2
Revenue, remaining performance obligation, expected timing of satisfaction period	12 months

Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) (Parenthetical) - Measurement Input, Discount Rate	Jun. 30, 2022
Trianni
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Discount rate	22
TetraGenetics Inc
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Discount rate	8

Financial Instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements on Recurring Basis - Marketable Securities $ in Thousands	Jun. 30, 2022 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	$ 231,652
US Government Agencies
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	17,358
Certificate of Deposit
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	20,875
Commercial Paper
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	34,711
Asset Backed Securities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	16,316
Level 1
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	17,358
Level 1 \| US Government Agencies
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	17,358
Level 2
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	214,294
Level 2 \| Certificate of Deposit
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	20,875
Level 2 \| Commercial Paper
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	34,711
Level 2 \| Asset Backed Securities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	16,316
Corporate Bonds
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	142,392
Corporate Bonds \| Level 2
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Assets	$ 142,392

Related Party Transaction - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Related Party Transactions [Abstract]
Advisory services	$ 0.3
Adviser fee paid	$ 0.1